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Abstract   
Aneuploidy (extra or missing individual chromosomes) is the leading cause of miscarriage, 
embryo wastage and in-vitro fertilization (IVF) failure.  Aneuploidy increases with 
maternal age and is widespread in human preimplantation embryos.  Thus, aneuploidy 
screening before implantation during an IVF cycle (preimplantation genetic screening or 
PGS), to increase pregnancy rates and decreasing miscarriage rates, is also widespread.  
Despite this, PGS faces challenges in terms of both biological and technical limitations that 
may impede its full potential.  Biologically, the phenomenon of chromosomal mosaicism 
(the presence of two or more cell lines - typically, one aneuploid and one euploid) may 
lead to false positives or false negatives, and the discard or transfer of euploid or 
aneuploid embryos, respectively.  Technically, it is uncertain whether diagnosis on the 
biopsied piece is representative of the remaining embryo.  Because these dilemmas it is 
unknown if PGS will only benefit a few selected groups of patients or potentially the entire 
IVF patient population.  In a series of published works, this thesis demonstrates a 
significant contribution to field of preimplantation genetics, provides insight into 
technical and biological limitations of PGS, and into the etiology of aneuploidy and 
mosaicism. 
 
^ƉĞĐŝĨŝĐĂůůǇ ? / ŝŶƚƌŽĚƵĐĞ Ă ŶŽǀĞů ƚĞĐŚŶŝƋƵĞ ƚŽ  “ŵĂƉ ? ĐŚƌŽŵŽƐŽŵĂů ŵŽƐĂŝĐŝƐŵ ? ďǇ
reconstructing a virtual image of the blastocyst with the approximate location of 
individual cells and their corresponding chromosomal makeup.  I also demonstrate the 
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ability of PGS to be performed on blastocysts that were previously frozen; thus, 
blastocysts have to be thawed/warmed, biopsied, vitrified and rewarmed prior to use.  
From a clinical standpoint, I present evidence of the differences in PGS outcomes between 
day 5 and day 6 blastocysts:  The data suggests that day 6 blastocysts are less likely to be 
euploid than day 5 blastocysts.  Furthermore, day 6 euploid blastocysts exhibit similar 
pregnancy and implantation rates when compared to their day 5 counterparts.  I also 
published on a study examining differences in PGS outcomes in those patients that are 
ĚĞĨŝŶĞĚĂƐ  “ƉƌĞƐƵŵĞĚĨĞƌƚŝůĞ ?ĂƐŽƉƉŽƐĞĚƚŽƚŚŽƐĞ ƚŚĂƚĂƌĞ  “ŝŶĨĞƌƚŝůĞ ? ? ŶŽƚŚĞr study 
examined pregnancy and implantation rates between two competing platforms, 
quantitative polymerase chain reaction (qPCR) and array comparative genomic 
hybridization (aCGH).  I also examined the pregnancy rates of poor quality embryos on 
day 6 that would have been discarded.   
From a biological standpoint, I examined the mechanisms through which embryos 
diagnosed as aneuploid on day 3 could develop to a euploid blastocyst, demonstrating 
that euploid blastocysts can develop from aneuploid cleavage stage embryos.  I also 
demonstrated differences in aneuploidy rates between polar, mural, and a piece defined 
ĂƐ  “ŵŝĚ ? ƚƌŽƉŚĞĐƚŽĚĞƌŵ ? ĂŶĚ ďůĂƐƚŽĐǇƐƚƐ ĚŝĂŐŶŽƐĞĚ ĂƐ ĂŶĞƵƉůŽŝĚ ŵĂǇ ŶŽƚ ƌĞĨůĞĐƚ ƚŚĞ
chromosomal constitution of the whole embryo proper.   
This work herein presented provides a deeper understanding of the technical limitations 
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Table 15: Cycle characteristics of the patient populations undergoing frozen embryo 
transfers Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? ? ? ? ? 
Table 16: IVF cycle characteristics and aneuploidy rates between qPCR and aCGH tested 
blastocysts Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? ?
 
Table 17: Pregnancy and implantation rates per cycle when euploid blastocysts diagnosed 
by qPCR, aCGH, and untested embryos are transferred during a frozen embryo 
cycle Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ?168 
 
Table 18: SNP results of the same embryo at the cleavage and blastocysts stage.  (0) 
denotes no chromosomes present (i.e., (0)3, indicates no chromosome 3).  Sex 
chromosomes are disomic unless noted. ^ denotes <85% confidence in diagnosis 
(dx) Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? ? 
 
Table 19: A comparison of aneuploidy rates between the polar, mid, and mural 
trophectoderm Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? ? ?
 
Table 20: A comparison of aneuploidy rates between polar and mural 
trophectoderm Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? ? ?
 
Table 21: Trophectoderm samples and their corresponding whole embryo aCGH 
analysis Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? ? ? 
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1.0 General Introduction 
1.1 Chronology/Timing 
1.1.1 8-20 Week Gestation 
Fetal oogenesis begins around the 8th week gestation with the migration of primordial 
germ cells (PGC) into the germ layer, specifically the gonadal primordi (De Felici, 2010).  
Between weeks 8 to 11 of gestation, the PGCs multiply and are now referred to as oogonia 
(Garcia et al. ? ? ? ? ? ) ?ǇǁĞĞŬ ? ? ?ĐůƵƐƚĞƌƐŽĨŽŽŐŽŶŝĂŚĂǀĞĨŽƌŵĞĚǁŝƚŚŝŶƚŚĞĨĞƚƵƐ ?ŽǀĂƌǇ ?
Oogonia within the ovary have to undergo DNA replication followed by two reduction 
divisions referred to as meiosis I and meiosis II in order to produce a haploid gamete(s) 
necessary for reproduction.   
Meiosis I is divided into five stages: interphase, prophase, metaphase, anaphase, and 
telophase.  Unlike mitosis, which is explained later and can take only a few hours, meiosis 
can take anywhere from 10-40 years to complete.  All these processes involve the 
replication and division and chromosomes.  Chromosomes will be explained in more 
detail later but they carry the traits and genes from each parent and enable the passing 
of genetic information from generation to generation. 
The first stage of meiosis, or interphase, is a simple replication of the parental 
chromosomes.  Thus, the chromosomes are replicated from 46 to 92.   
The oogonium becomes a primary oocyte consisting of 46 pairs of chromosomes.  At this 
stage the oocyte contains four chromatids of each chromosome: 1. a chromatid from the 
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ŵŽƚŚĞƌ ? ? ?ĂĚƵƉůŝĐĂƚŝŽŶŽĨŵŽƚŚĞƌ ?ƐĐŚƌŽŵĂƚŝĚ ?ƐŝƐƚĞƌĐŚƌŽŵĂƚŝĚ ) ? ? ?ĂĐŚƌŽŵĂƚŝĚĨƌŽŵ
ƚŚĞĨĂƚŚĞƌ ? ? ?ĂĚƵƉůŝĐĂƚŝŽŶŽĨƚŚĞĨĂƚŚĞƌ ?ƐĐŚƌŽŵĂƚŝĚ ?ƐŝƐƚĞƌĐŚƌŽŵĂƚŝĚ ?&ŝŐure 1).   
All of this occurs approximately at 20 weeks gestation.  Once DNA is replicated and 
interphase is completed, the primary oocyte progresses to the diplotene stage of 
prophase of meiosis I where it will remain with all duplicated 46 chromosomes until 
puberty. 
Figure 1: An arrested germinal vesicle with the chromosomes and their complement.  
 
1.1.2 Puberty 
Upon puberty, monthly hormonal signals in the form of luteinizing hormone (LH) and 
follicular stimulating hormone (FSH) are produced by the pituitary gland and act on the 
follicles where the oocyte is arrested.  The combinations of these hormones stimulate the 
primordial follicle to undergo changes leading to the simultaneous maturation of the 
follicle and oocyte and the resumption of meiosis I (Figure 2). 
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During this time, the oocyte within the follicle are undergoing changes that increase the 
ribosomal and messenger ribonucleic acid that will be used in the development of the 
embryo.  The zona pellucida (ZP) and gap junctions between the oocyte and granulosa 
cells also start to form in response to FSH and LH.  The oocyte is still arrested at the 
diplotene stage of prophase at meiosis I.  
Figure 2:  Illustration of the events involved in oocyte maturation.  A) Release of various 
hormones leading to oocyte maturation within the follicle.  B) Resting stage of an oocyte 
at the onset of maturation.  C) Chromosome configuration of each chromosome within 
the oocyte at the onset of maturation. 
 
With a surge of LH, the GV oocyte will begin a process known as haploidization, reducing 
the total number of chromatids from 92 or 4 pairs of 23 chromatids (present in the GV) 
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to 46 or 2 pairs of 23 chromatids present in the mature oocyte.  The maturation of the 
oocyte and reduction division of chromosomes needed for haploidization can only occur 
properly with aid from the spindle apparatus. 
In response to the LH surge, numerous factors are activated by the oocyte aiding in the 
process of maturation and the reduction division of chromosomes.  Maturation 
promotion factor (MPF) activity increases and in turn, activates mitogen activated protein 
kinase (MAPK).  MAPK is needed in conjunction with cytostatic factor (CSF) for spindle 
stability and chromosome alignment during the meiotic divisions (Masui and Markert, 
1971).  The increase in MPF is the signal to begin the construction of the first meiotic 
spindle (Sobajima et al., 1993).  As the GV progresses, the nuclear envelope begins to 
break down (GVBD), allowing the microtubules access to the condensed chromosomes.  
Although still at prophase I, the oocyte now becomes known as a MI oocyte. 
As previously discussed, during meiosis I chromosomes are arranged as a bivalent.  In this 
configuration, genetic recombination can occur at places where two chromosomes cross, 
referred to as a chiasma.  The molecule referred to as cohesin holds the sister chromatids 
together while the chiasmata and synaptical complex hold the homologous chromosomes 
together allowing for the formation of the bivalent.  This process assures the genetic 
variation amongst offspring, but also helps control the process of chromosome 
segregation.  During the MI division, not only do chiasmata serve as crossing over points, 
they also supply a force that opposes the pull on the chromosomes by the spindle.  A 
decrease in number of chiasmata would decrease the force opposing the pull of the 
25 
spindle.  In the case of no force opposing the pulling of the spindle, chromosome 
segregation may occur prior to the attachment of microtubules at the kinetochore, 
leading to premature separation of the chromosomes (Lamb et al., 1996).   
 
1.2 The Spindle Apparatus 
Centrioles are organelles within the oocyte that define the poles of the spindle apparatus 
and begin the production of microtubules used to capture chromosomes.  Research 
however, suggests that centrioles are non-existent in human oocytes (Szollosi et al., 
1972).  Instead, in mammals, including humans, the microtubules project from MTOCs 
(microtubule organization centers) referred to as centrosomes (Carabatsos et al., 2000).  
Microtubules consist of alpha and beta monomers bundled together to form a dimer 
(Compton, 2000; Meng et al., 2004).  These microtubules randomly attach to the 
chromosomes on the centromere at a site called the kinetochore (Figure 3). 
The kinetochore complex on the centromere of the chromosomes is composed of 
multiple proteins that are involved in the capture and movement of chromosomes along 
ƚŚĞŵŝĐƌŽƚƵďƵůĞƐ ?ĞŶƚƌŽŵĞƌĞƉƌŽƚĞŝŶƐ ?EW ?Ɛ )ĂƌĞĂĐůĂƐƐŽĨƉƌŽƚĞŝŶƐƚŚĂƚĂƌĞƉƌĞƐĞŶƚ
on the centromere (more specifically the kinetochore of chromosomes) and are involved 
in chromosome capture and chromosome segregation (Ma et al. ? ? ? ? ? ) ?EW ?ƐŝŶĐůƵĚĞ
mitotic arrest-deficient (Mad) 1, Mad2, and benzimidazole (Bub; all present at the 
kinetochore) that act as signals for chromosome division. 
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When microtubules are not attached to the kinetochore, the kinetochore is 
ƉŚŽƐƉŚŽƌǇůĂƚĞĚĂŶĚĐŽŶƚĂŝŶƐůĂƌŐĞĂŵŽƵŶƚƐŽĨEW ?Ɛ  ?ŚĞŶet al., 1996; Burke, 2000; 
Gardner and Burke, 2000).  These proteins inhibit the premature division of chromosomes 
and sustain the spindle at the metaphase stage.  During the MI stage, microtubules 
ŽƌŝŐŝŶĂƚŝŶŐĨƌŽŵƚŚĞDdK ?ƐďĞŐŝŶƚŽƉŽůǇŵĞƌŝǌĞ ?dƵď ůŝŶŝƐĂĚĚĞĚĨƌŽŵƚŚĞŶĞŐĂƚŝǀĞĞŶĚ
at the spindle pole to the positive end that will extend into the cytoplasm (Eichenlaub-
Ritter et al., 2003).  When deploymerization (removal of alpha/beta dimer) occurs, tubulin 
is removed from the negative end, effectively shortening the tubulin and pulling the 
ĐŚƌŽŵŽƐŽŵĞƐĨƌŽŵĞĂĐŚŽƚŚĞƌƚŽǁĂƌĚƐƚŚĞDdK ?Ɛ ? 
Figure 3.  Composite picture of the spindle, chromosomes, and microtubules. 
 
To extend into the cytoplasm, the addition of tubulin to microtubules is facilitated by 
GDP/GTP hydrolysis (Palacios et al., 1993; Combelles and Albertini, 2001).  The 
microtubules extend in all directions from thĞ DdK ?Ɛ ?  Ǉ ƌĂŶĚŽŵ ĐŚĂŶĐĞ ? ƚŚĞ
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microtubules come in contact and attach to the chromosomes at the kinetochore.  Once 
ďŽƚŚDdK ?ƐŚĂǀĞĐĂƉƚƵƌĞĚƚŚĞĐŚƌŽŵŽƐŽŵĞ ?ƚĞŶƐŝŽŶŝƐĐƌĞĂƚĞĚďǇŽŶĞDdKƉƵůůŝŶŐŝŶ
one direction and the other MTOC pulling in the other.  The bivalents are held together 
by chiasmata, creating a force opposing the pull of the microtubules (Smith and Nicolas, 
1998).  Tension created by the pulling of the chromosomes in opposite directions causes 
a loss of CENPs from the kinetochore, effectively dephosphorylating the chromosome 
(Nicklas et al., 1997).  
 
1.2.1 Spindle and Meiosis 
As previously mentioned, the oocyte is arrested at the diplotene stage of prophase I of 
meiosis I.  As oocyte maturation resumes, the GV envelope breaks down, the spindle 
condenses, and chromosomes migrate to periphery of the MI oocyte, thus signaling the 
end of the prophase I and the beginning of metaphase I.  At metaphase I all chromosomes 
align on the metaphase plate and microtubules are attached to the kinetochore, the 
spindle apparatus and chromosomes rotate 900.  Once rotation is complete, the oocyte 
leaves metaphase I and proceeds to anaphase I.  At anaphase I, MPF activity decreases 
thereby allowing separation of the bivalents to occur and the chromosomes to proceed 
to the opposite poles.  The arrival of the chromosomes to the opposite poles is referred 
to a telophase I and signals the end of the meiosis I (Figure 4).  With the extrusion of the 
first polar body, the oocyte reduces its chromosome number by half thereby progressing 
to a MII oocyte (Figure 4).  
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At the end of telophase, the MII oocyte has completed meiosis I and contains one polar 
body with 46 chromatids and one oocyte with 46 chromatids.  From here, the oocyte 
enters meiosis II.  Immediately, the oocyte enters prophase II and the spindle begins 
formation again by increasing MPF, thereby activating MAPK that in turn activates CSF.  
With the activation of these factors, the spindle reforms and oocyte enters metaphase II 
as sister chromatids migrate to the MII plate where they remain arrested by CSF and 
MAPK until fertilization.  These two are responsible for holding the chromosomes on the 
MII plate (Masui and Markert, 1971).   
The oocyte will remain arrested at the metaphase II phase until penetration of the oocyte 
by the sperm causes a rise in calcium levels.  The increase in calcium ions inactivates CSF 
and MAPK, allowing the MII oocyte to undergo its second meiotic division.  The loss of the 
CENPs activates cyclin B, which degrades the cohesin between the sister chromatids, 
allowing for chromosome separation and enter anaphase II (Evans et al., 1983; Figure 5).  
As the second meiotic division starts, microtubules begin to depolymerize.  Starting at the 
negative end (spindle pole), the microtubules are depolymerized and actively shortened, 
effectively pulling the chromosomes towards the spindle poles.  As the chromosomes 
arrive at opposite poles (23 in the second polar body and 23 in the oocyte), the oocyte 
has entered telophase II and completed both meiosis I and meiosis II.  The meiosis II 
reduction separates the sister chromatids and reduces the total chromosome content of 
the oocyte from 23 pairs of chromatids to 23 individual chromosomes.  
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Figure 4.  Meiosis I in the human oocyte.  A) An oogonium prior to DNA replication 
containing a chromosome from the mother and father.  B) Primary oocyte (germinal 
vesicle) containing a copy of both of the mother (black) and father (white) chromosomes.  
C) The metaphase I oocyte with the alignment of all chromosomes along the metaphase 
plate.  The chromosomes are rotating and being captured by microtubules for expulsion 
into the first polar body.  D) A metaphase II oocyte immediately after the expulsion of the 
first polar body.  E) A metaphase II oocyte with chromosomes aligned on the metaphase 
plate, with microtubule attachment, and awaiting fertilization. 
 
Figure 5.  Meiosis II in the human oocyte.  A) The mature metaphase II oocyte upon 
completion of meiosis I. B) Entry of a single sperm into the mature oocyte triggers meiosis 





1.2.2 Spindle Checkpoint 
In some mammals and invertebrates, research suggests that a spindle checkpoint exists 
to protect the cell from dividing its chromosomes unequally (Li and Nicklas 1995; Stern 
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and Murray 2001; Homer et al., 2005; Brunet et al., 2003; Wassmann et al., 2003).  If a 
chromosome(s) is not attached to the microtubules, the cell will prevent itself from 
dividing until the chromosome(s) is captured by the microtubules.  This mechanism 
assures proper segregation of chromosomes; however, in human oocytes this mechanism 
seems non-existent.  Advanced maternal age may be a reason for the lack of a spindle 
checkpoint, as evidenced by the increase incidence of aneuploidy in women of advanced 
maternal age.  Or, it may be that other, age independent, factors are the cause (Liu and 
Keefe, 2002).  LeMaire-Adkins et al. (1997) bred mice with Turner syndrome (45, XO) with 
euploid mice.  If a checkpoint exists in the mouse, then no offspring with the karyotype 
45, XO should be produced.  Since multiple mice with the karyotype 45, XO were 
conceived, these data suggests that there is no spindle checkpoint.  Yin et al. (1998) 
conducted a study where mouse oocytes were subjected to low levels trichlorfon.  This 
drug disrupted spindle formation and prevented chromosome alignment, however the 
oocyte continued to progress to the MII stage.  Hassold and Hunt (2001) estimate that 10-
30% of fertilized human oocytes contain an unequal amount of chromosomes.  Although 
this may not seem very high, but when compared to rates in yeast (0.01%) and in the fruit 
fly (0.02% - 0.06%), an apparent lack of a meiotic spindle checkpoint seems probable 
(Sears et al., 1992; Koehler et al., 1996). 
The lack of a spindle checkpoint could allow chromosomes to divide unequally, therefore 
creating extra or missing chromosomes in the oocyte and subsequent embryo.  This might 
explain why the majority of aneuploidy in humans originates in the oocyte during the 
meiotic reduction divisions (Hassold and Hunt, 2001).  Furthermore, research suggests 
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that abnormalities in spindle structure of human oocytes can lead to an increase 
incidence of aneuploidy.  Battaglia et al. (1996) found an increased rate of abnormally 
shaped spindles, microtubules, and chromosome misalignment in older women 
compared to the spindles of younger women, which appeared to have normal 
configurations. 
Reproductive age plays a significant role in the production of aneuploidy due to the fact 
that the oocytes of older women have been arrested since prenatal development.  An 
increase in reproductive age correlates to a loss in cohesin, which binds sister 
chromosomes together.  Moreover, research has indicated that the loss of cohesin leads 
to frequent aneuploidy (Guacci et al., 1997; Michaelis et al., 1997; Losada et al., 1998).  
Steffensen and colleagues (2001) demonstrated severe chromosome segregation in 
Drospholia when cohesin is not present.  In mice with a mutated cohesin gene that 62% 
of oocytes had unpaired chromosomes (Hodges et al., 2005).  This percent increased with 
the age of the mouse; at 6 months of age, >80% of chromosomes were unpaired.  If 
cohesion is decreased, there would be no force to oppose the pulling of the microtubules 
causing unequal separation of chromosomes at the MII phase.  Furthermore, an increase 
in reproductive age also correlates with a decrease in chiasmata (Henderson and 
Edwards, 1968).  A decrease in chiasmata would also decrease the force opposing the 
pulling of the microtubules and therefore would increase the rate of chromosomal 
malsegregation and subsequent aneuploidy.  The spindle not only plays a role in the 
reduction divisions of meiosis but also in chromosome segregation of mitosis. 
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1.2.3 Spindle and Mitosis 
In order to propagate, the fertilized oocyte must replicate the entire genome and equally 
divide into multiple blastomeres, a process referred to as mitosis.  Similar to meiosis, 
mitosis equally divides chromosomes with the aid of the spindle apparatus.  Mitosis is 
divided into five distinct processes: interphase, prophase, metaphase, anaphase, and 
telophase or cytokinesis. 
Interphase is the first step of mitosis and is subdivided into three phases Gap 1 (G1), 
Synthesis (S), and Gap (G2).  During interphase, specifically G1, the cell is preparing itself 
for mitosis by producing the necessary proteins and energy stores needed for division.  
During the S phase, chromosomes are replicated.  After replication, the cell enters G2 and 
awaits for prophase.  During preimplantation development, interphase occurs shortly 
after the male and female pronucelus are joined in the zygote.  The migration of the male 
and female pronucleus to the middle of the oocyte is aided by a network of actin 
microfilaments referred to as the sperm aster.  Along these microfilaments, protein 
motors referred to as dynein, enable the movement of the pronucleus within the 
cytoplasm (Deng et al., 2007; Wuhr et al., 2009; Kimura and Onami, 2005; Kimura and 
Kimura, 2011; Schatten et al., 1986; Kim et al., 1996).  The maternal and paternal DNA 
join together in syngamy producing a two pronuecli (2PN) embryo, now referred to as a 
zygote.  At syngamy, DNA from every chromosome is replicated forming a sister 
chromatid (S phase; Figure 6B). 
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Prophase is the second step during mitosis and involves the degradation of the nucleus, 
ĐŽŶĚĞŶƐĂƚŝŽŶŽĨĐŚƌŽŵŽƐŽŵĞƐ ?ĂŶĚƚŚĞĨŽƌŵĂƚŝŽŶŽĨƚŚĞƐƉŝŶĚůĞĂƉƉĂƌĂƚƵƐďǇDdK ?Ɛ ?
As the chromosomes condense, proteins referred to as cohesins keep the sister 
chromatids connected (Tachibana-Konwalksi et al., 2010).  Simultaneously, the nuclear 
envelope starts to degrade, exposing the condensed chromosomes to the cell (Figure 6C).   
Metaphase refers to the migration of the condensed chromosomes to the middle of the 
cell to an area referred to as the metaphase plate.  While the chromosomes are in the 
metaphase plate, the MTOCs eject microtubules randomly into the cell.  Once attached, 
tension occurs between the sisters chromatids by the pull of the microtubules.  Due to 
proteins and phosphorylation, the separation of the chromosomes typically does not 
ĐŽŵŵĞŶĐĞƵŶůĞƐƐďŽƚŚDdK ?ƐĂƌĞĐŽŶŶĞĐƚĞĚƚŚĞŬŝŶĞƚŽĐŚŽƌĞ ?ŚĞŶet al., 1996; Burke, 
2000; Gardner and Burke, 2000).  Once all microtubules are attached, tension is created 
between sister chromatids by the pull of the microtubules (Figure 6D).   
At anaphase, tension is created by the pulling at the kinetochore in opposite directions 
ďǇƚŚĞDdK ?Ɛ ?dŚŝƐƚĞŶƐŝŽŶƐŝŐŶĂůƐĂƉƌŽƚĞŝŶƌĞĨĞƌƌĞĚƚŽĂƐƐĞƉĂƌĂƐĞƚŽĐůĞĂǀĞĐŽŚĞƐŝŽŶ ?
consequently, the sister chromatids separate and are pulled to opposite ends of the cell 
ďǇ ƚŚĞDdK ?Ɛ  ?EĂƐŵǇƚŚĂŶĚ,ĂĞƌŝŶŐ ?  ? ? ? ? ) ? dŚĞŵŝĐƌŽƚƵďƵůĞƐĂƌĞ ƐŚŽƌƚĞŶĞĚďǇ ƚŚĞ
removal of the alpha and beta monomers at the MTOC.  Thus, the chromosomes do not 
actually migrate to the opposite poles but are rather pulled by the shortening 
microtubules (Figure 6E).  Once at opposing poles, the nuclear envelope begins to form 
around both sets of chromosomes and the chromosomes begin to decondense.   
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Figure 6: Zygote undergoing the first mitotic cleavage division.  A) The zygote showing the 
1st and second polar body and maternal and paternal chromosomes.  B) The zygote with 
duplicated chromosomes (S phase of Interphase).  C) Zygote with the formation of 
microtubules and decondensed nucleus, chromosomes are free floating (Prophase).  D) 
Zygote with chromosomes that are captured by microtubules and aligned on the 
metaphase plate (Metaphase).  E) Chromosomes being pulled to opposite poles 
(Anaphase).  F) Chromosomes at opposite poles.  G) The chromosomes decondense and 
form a nucleus and the cell splits into two; thus, the completion of mitosis (cytokinesis). 
   
ƵƌŝŶŐƚŚŝƐƚŝŵĞ ?ƚŚĞĐĞůůƐƚĂƌƚƐƚŽ “ƉŝŶĐŚ ?ŝƚƐĞůĨĂůŽŶŐƚŚĞŵĞƚĂƉŚĂƐĞƉůĂƚĞ ?dŚŝƐ “ƉŝŶĐŚ ?
creates a cell membrane and separates the one cell into two daughter cells (Figure 6G).  
Once cleaved, the chromosomes are pulled to opposite ends of the cell and the cell is 
ĚŝǀŝĚĞĚŝŶƚŽƚǁŽĞƋƵĂůƐ ?/ŶƐƚĞĂĚŽĨ “ƌĞƐƚŝŶŐ ? ?ƚŚĞĐĞůůƐĞŶƚĞƌĚŝƌĞĐƚůǇŝŶƚŽĂŶŽƚŚĞƌE
replication and mitotic event (Boulding and Kimelman, 2014).  Thus, the first cleavage 
stage divisions occur as fast as DNA can be replicated. 
 
1.3 Preimplantation Embryonic Development 
Preimplantation embryonic development constitutes a multitude of processes that start 
at the joining of the female (oocyte) and male (sperm) gametes in a process known as 
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fertilization.  Once fertilization occurs, preimplantation embryonic development 
commences followed by implantation and live birth of a hopefully healthy individual.   
Fertilization occurs in the fallopian tubes when the oocyte and sperm join together 
forming the zygote, the first cell of the new individual (Figure 7).  The zygote is encased 
in a protein thick layer referred to as the ZP and compromised of two pronuclei, one from 
each parent (Figure 7).  Each pronuclei contains 22 non-sex determining chromosomes 
referred to as autosomes and one of two sex determine chromosomes, either X (female) 
or Y (male).  Thus, the zygote contains 44 autosomes and two sex chromosomes for a total 
of 46 chromosomes.   
While traveling down the fallopian tube, the zygote undergoes multiple mitotic divisions, 
replicating the chromosomes (2N Æ 4N) and then dividing the chromosomes equally (4N 
Æ 2N) into two daughter cells (Figure 7).  By the third day, the zygote has undergone four 
mitotic divisions and contains a total of six to eight cells referred to as blastomeres (Figure 
7).  The junctions between the blastomeres breaks down and they begin to form a tight 
ball of cells referred to as a morula (Figure 7).  On day 4 the morula, while still undergoing 
mitotic divisions, starts to form a fluid filled cavity referred to as a blastocoel.  The 
blastomeres start to differentiate into two different cell lines, the trophectoderm cells, 
which will become the placenta are located on the outside of the embryo, and the inner 
cell mass (ICM) ,which will become the fetus, form on the inside of the embryo (Barlow 
et al., 1972; Figure 7, Figure 8).  With the differentiation of the two cells lines, the embryo 
has progressed from the morula stage to the blastocyst stage (day 5; Figure 7).   
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Figure 7: Developmental stages of a human preimplantation embryo.  
 
As the blastocyst exits the fallopian tubes and heads into the uterus, the blastocoel cavity 
continues to expand, thinning out the ZP.  Ultimately, the blastocyst hatches out of the 
ZP and attaches itself to the uterine wall in a process known as implantation.  Once 
attached, the blastocyst continues to increase in cell number while the trophectoderm 
invades the uterine wall in an attempt to attach itself to the motŚĞƌ ?ƐďůŽŽĚƐƵƉƉůǇ ?KŶĐĞ
implanted, the blastocyst continues to expand and develop into both the placenta and 
fetus.   
 
1.4 Developmental Biology 
The placenta is responsible for supplying nourishment and oxygen to the fetus.  All of the 
cells and the derivatives from the trophoblast are considered extra embryonic tissue and 
do not constitute the embryo proper.  The internal cells of the morula are destined to 
become the ICM (Pedersen et al., 1986; Fleming, 1987).  These cells will make up what 
will become the fetus proper.  However, not all these cells are destined to become the 
fetus and thus, from the ICM, both extraembryonic and embryonic tissue persists.  From 
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the ICM multiple cell lines deviate to form the fetus proper, yolk sac, and amnion (Figure 
8).  A recent study by De Paepe and colleagues (2013) demonstrated that isolated human 
trophectoderm cells can integrate into the ICM and express markers associated with ICM 
cells, indicating that they are not yet committed to becoming extraembryonic tissue.  
Hogan and Tilly (1978) dissected mouse ICM from the trophectoderm and left the ICM in 
ĐƵůƚƵƌĞ ?tŝƚŚŝŶ ?ĚĂǇƐ ?ƐŽŵĞŽĨƚŚĞŝŶĚŝǀŝĚƵĂů/D ?ƐŚĂĚƚŚĞĂƉƉĞĂƌĂŶĐĞŽĨĂďůĂƐƚŽĐǇƐƚ ?
DŽƌĞŽǀĞƌ ?ƚŚĞŝŶĚŝǀŝĚƵĂů/D ?ƐĚĞƌŝǀĞĚƚƌŽƉŚŽďůĂƐƚŐŝĂŶƚĐĞůůƐ ?dŚĞƐĞƐƚƵĚŝĞƐ suggest that 
cells from the ICM feed the trophectoderm.  Ultimately, the majority of the cells from the 
ICM will become the epiblast with further differentiation to extraembryonic mesoderm, 
extraembryonic ectoderm, and amnion, all of which are extraembryonic tissue (Figure 8; 
Crane and Cheung, 1988; Delhozizer-Blanchet, 1991).  All of the above can only happen 
with the proper division of chromosomes. 
Figure 8: Cell lineage from zygote (1 cell) stage to the fetus, including extraembryonic 
materials of the extraembryonic mesoderm and cytotrophoblast (adapted from Crane 





Chromosomes were first discovered by Flemming (1882) and are molecular structures 
that contain genetic information in the form of deoxyribose nucleic acid (DNA) needed to 
create an individual, in essence they are the blueprint for life.  DNA is a combination of 
four molecules: adenine, thymine, guanine, and cytosine.  DNA forms a ladder like 
structure with adenine only connecting to thymine and guanine only connecting to 
cytosine; this ladder folds in on itself creating a double helix.  DNA and the chromosomes 
reside in the nucleus of the cell.  The complete DNA genome of the human is much longer 
than a single cell and thus the DNA must condense around molecules known as histones 
(Margueron and Reinberg 2010; Zhou et al., 2011). 
The condensed DNA forms a chromosome.  The chromosome is composed of three 
different pieces: the centromere, telomere, and origin of replication.  The centromere 
serves two major functions: allowing the sister chromatids to join together and to act as 
a site for the kinetochore to capture the microtubules during chromosome segregation 
(Yunis and Yasmineh 1971; Willard 1990; Schueler et al., 2001).  Centromeres can be 
located anywhere along the chromosome.  In fact, where the centromeres are located 
dictates whether the chromosome is referred to as metacentric, submetacentric, or 
acrocentric.  Metacentric refers to a chromosome where the centromere is in the middle 
giving the appearance of two chromosomes arms that are equal in length (i.e. = 
chromosomes 1, 3, 16, 19, and 20).  Submetacentric refers to a chromosome that has two 
arms of unequal length (i.e. = chromosomes 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 17, 18, X, Y).  
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Lastly, acrocentric refers to chromosomes where the centromere is located towards the 
very end of the chromosome (i.e. = chromosomes 13, 14, 15, 21, 22). 
Telomeres are located at the ends of the chromosomes and consist of repeat sequences 
of DNA (Zakian, 1989).  These repeat sequences of DNA protect the end of the 
chromosome from degradation during mitosis (Greider and Blackburn, 1985; Greider and 
Blackburn, 1989).  Each round of cell division shortens the telomeres.  So, as the cell ages, 
chromosomes become more susceptible to degradation via shortening of telomeres 
(Harley et al., 1990).  To combat this, chromosomes use an enzyme called telomerase that 
continually extends the telomeres to appropriate lengths (de Lange, 2005). 
The origin of replication are all the areas outside of the telomeres and centromeres.  
These areas contain all of our genes and functional genetic makeup that make us who we 
are.  These are areas within the chromosomes that are actively undergoing transcription 
and translation, allowing for the development of proteins that serve for cell functions. 
The human genome contains a total of 46 chromosomes; 22 pairs of autosomes and two 
sex determining chromosomes.  An individual with 22 pairs of autosomes and two sex 
determining chromosomes is considered euploid.  Chromosomes are paramount during 




1.6 Aneuploidy during Reproduction 
The majority of preimplantation embryo wastage and miscarriages are caused by 
aneuploidy (Hassold and Hunt, 2001).  These errors can occur at all stages and involve any 
chromosome (Fragouli and Wells, 2011).  It is believed that the low success rates of IVF 
could be attributed to aneuploidy as the older a woman gets, the incidence of aneuploidy 
increases (Figure 9).  For example, at the age of 28 the average incidence of aneuploidy 
at the blastocyst stage is approximately 25% whereas the incidence at the age of 44 is 
greater than 80% (Frasnasiak et al., 2014).  Interestingly, the incidence of aneuploidy stays 
relatively constant from 25 to 35 years old, but after 35, the incidence increases 
approximately 5% year over year (Frasnasiak et al., 2014).   
Figure 9: Analysis of 4,500 blastocysts screened for aneuploidy and the rate of individual 
chromosomal abnormalities stratified by maternal age (Data courtesy of Alison Coates 
from Oregon Reproductive Medicine). 
 
It should be noted that some chromosomes are more likely to malsegregate than others 
during preimplantation development.  For example, in a large dataset of 15,169 
















16, 18, 19, 21, and 22 were the most common chromosomal aneuploidy present at the 
blastocyst stage.  Interestingly, these are also the most common in product of 
conceptions, meaning that these abnormalities may not be selected against until after 
implantation (Sahoo et al., 2016).  Certain chromosomes are more prone to aneuploidy 
simply due to the location of the centromere along the chromosome.  Chromosomes with 
the centromere located near the end of the chromosome are more prone to aneuploidy, 
followed by chromosomes with the centromere in the middle, and then chromosomes 
with a centromere in-between the middle and the end are least susceptible to aneuploidy 
(Frasnasiak et al., 2014).  It is not just the incidence of aneuploidy during preimplantation 
development but also mosaicism that may influence embryological development. 
 
1.7 Chromosomal Mosaicism during Reproduction 
It is not just aneuploidy that can impact reproduction.  Another phenomena known as 
chromosomal mosaicism that is defined as the presence of two more chromosomally 
distinct lines can also influence embryological development.  At its core, chromosomal 
mosaicism is the failure of chromosomes to properly segregate during mitosis, leading to 
aneuploidy.  Chromosomal mosaicism has been implicated in genetic diseases, 
miscarriages, and preimplantation embryo wastage (Hassold and Hunt, 2001).  Moreover, 
mosaicism has been shown in cancer (Lengauer et al, 1998) and associated with ageing 
(Ly et al., 2000).  Although prevalent, the exact threshold at which mosaicism switches 
from clinically irrelevant to relevant is unknown and differs depending on the stage and 
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severity at onset.  Due to the prevalence and significance of mosaicism in the human 
species, it is important to understand the origins, mechanisms, and incidences of 
mosaicism throughout development.  
 
1.7.1 General Mosaicism  
General mosaicism is the presence of a two or more cell lines throughout the entire 
organism.  In order for the mosaic cell lineage to be present within the entire organism, 
the aneuploidy in question must derive from a mitotic event during the first days of 
embryonic development, prior to any cellular differentiation.  At this stage, mosaicism 
has been found to range between 65-70% (Mertzanidou et al., 2013; Wells and Delhanty, 
2000).  However, this incidence may be overstated due to technical limitations, sampling 
error, and cell phase of sample collection.  Simply because preimplantation embryos are 
mosaic does not mean that the abnormal cell line(s) will continue to propagate during 
development.  Research has shown that euploid cells proliferate at a higher rate than 
aneuploidy cells (Ruangvutilert et al., 2000).  Scott and colleagues (2012) describe live 
births from diagnosed aneuploid cleavage stage and blastocyst stage embryos, although 
at a significantly lower rate than from euploid embryos.  This indicates that aneuploidy 
and mosaicism may play a limited role in development, and its influence during 
development may be dependent on the degree of mosaicism and what chromosome is 
involved. 
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Chromosomal mosaicism is common during preimplantation development.  However, 
due to the low number of cells present during preimplantation development, any 
abnormality can have much more of an impact as development continues.  Furthermore, 
mosaicism can become isolated during embryonic development, leading to mosaicism 
confined to a particular area.  
 
1.7.2 Confined Mosaicism 
Confined mosaicism refers to chromosomal mosaicism that is only present in a particular 
area and has been reported in the brain (Yurov et al, 2007), placenta (Kalousek and Dill, 
1983), and gonads, amongst other places.  A major aspect of research about confined 
mosaicism deals with the relationship between the placenta and the developing fetus.   
Confined placental mosaicism (CPM) is defined as chromosomal differences between the 
fetus and placenta.  CPM was first reported in the human placenta by Warburton and 
colleagues (1978).  They discovered that roughly 10% of trisomic conceptions contained 
a mosaic cell line.  CPM has been linked to intrauterine growth retardation (Kalousek and 
Dill, 1990), spontaneous abortions, intrauterine death, still birth (Benn, 1998), and 
abnormal placental function (Koplan et al., 1991).  CPM is believed to occur in roughly 1-
2% of all placental tissue analyzed (Kalousek et al., 1991). 
There are two types of invasive procedures utilized in prenatal testing, chorionic villus 
sampling (CVS) and amniocentesis.  Both procedures determine the chromosomal 
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constitution of the fetus by sampling embryonic tissue rather than the fetus proper.  CVS 
involves the sampling of the chorionic villus from either the cytotrophoblast or 
extraembryonic mesoderm (EEM).  Alternatively, amniocentesis involves the removal of 
a sample of amniotic fluid, which is a product of extraembryonic ectoderm.  Both the 
extraembryonic ectoderm and EEM are derived from the ICM and epiblast of the 
developing embryo and are not part of the fetus proper, while the cytotrophoblast is 
derived from the trophoblast (Bianchi et al. 1993; Figure 8).  It should be noted that no 
test directly analyzes the chromosomes of the fetus proper during pregnancy.   
Regardless of whether mosaicism is present in the entire individual or is confined, the 
mechanisms that mosaicism occurs are the same.    
 
1.8 Mechanisms of Chromosome Malsegregation 
There are three main mechanisms of chromosomal aneuploidy and mosaicism that can 
occur, leading to a gain and/or loss of chromosomes: non-disjunction, anaphase lag, and 
chromosome gain referred to as endoreplication.  Anaphase lag accounts for the majority 
of chromosomal errors during embryonic development while non-disjunction and 




1.8.1 Non-disjunction  
Non-disjunction is the failure of sister chromatids to separate during mitosis.  Instead of 
separating, the entire chromosome (two chromatids) is pulled to one cell, creating a cell 
with a monosomy and another cell with a trisomy (Figure 10).  If non-disjunction occurs 
prior to cell differentiation, for example in a preimplantation embryo, a general mosaic is 
created.  Non-disjunction can also lead to a confined mosaicism.  For example, if the non-
disjunction event occurs in the trophoblast, after differentiation, then only the placenta 
will contain the mosaic cell lines, while the embryo proper could be euploid. 
The incidence of non-disjunction during preimplantation development is subject to 
debate, and depends greatly on the stage of development and chromosome involved.   
For example, non-disjunction has been shown to be the least prevalent mechanism 
associated with aneuploidy during meiosis I and II amongst the autosomes (Forman et al., 
2013a; Handyside et al., 2013a), but it is established as the main mechanism for sex 
chromosome malsegregation during the first cleavage stage divisions (Bean et al., 2001; 
Bean et al., 2002).  It is evident that chromosomes may be more or less susceptible to 







Figure 10: A non-disjunction event leading to a monosomy in one cell and a trisomy in 
another. 
 
1.8.2 Anaphase Lag 
Anaphase lag is the failure of a single chromatid to be incorporated into the daughter 
nucleus resulting in a monosomy of that chromosome in one cell and a disomy in the 
corresponding chromosome in the other cell (Figure 11).  Anaphase lag occurs when the 
chromatid fails to attach to the spindle or when the chromatid attaches to the spindle but 
then fails to be incorporated in the nucleus.  If this mechanism occurs prior to 
differentiation, then the organism will contain two distinct cell lines, thereby creating a 
general mosaic.  If this event occurs after differentiation in the trophoblast, then the 
placenta will contain a normal and monosomic cell line, an example of CPM.  
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In a study using discarded day 5 embryos, Ioannou et al. (2012) demonstrated that 
monosomy can occur at a 7x greater rate than trisomy.  This would implicate anaphase 
lag as the main source of mosaicism in human preimplantation development.  This 
observation is supported by Coonen and colleagues (2004) and Capalbo and colleagues 
(2013a) who found anaphase lag at rates of 5x and 3x that of non-disjunction, 
respectively.   
If a cell presents with a trisomy, then the process of anaphase lag ĐĂŶ  “ĐŽƌƌĞĐƚ ? ƚŚĞ
trisomy and revert the reciprocal chromosome back to disomy, a process referred to as 
trisomic rescue (Figure 12).  Although the frequency of this process is largely unknown, 
reports indicate that trisomy rescue of meiotic errors can occur during preimplantation 
development (Capalbo et al, 2013a; Barbash-Hazan et al., 2009). 
 
1.8.3 Endoreplication 
Endoreplication is the replication of a chromosome without division.  This results in a 
trisomic chromosome in one cell and a disomic chromosome in the other.  Chromosome 
gain is believed to derive from two mechanisms, a cell cycle malfunction when a 
chromosome is replicated without subsequent cytokinesis or when mitosis is initiated and 
shortly thereafter shutdown, resulting in a replicated chromosome.  Regardless of the 
mechanism, the result is the same: the gain of a single chromosome (Figure 13).  
Endoreplication can lead to polyploidy.  Polyploidy has been shown to exist in blood, gut, 
skin, and brain (for review see Fox and Duronio, 2013).  
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Figure 11: An anaphase lag event leading to a disomy in one cell and a monosomy in 
another. 
 
1.8.4 Uniparental Disomy 
Non-disjunction, anaphase lag, and endoreplication lead to aneuploidy.  However, there 
are mitotic events that lead to mosaicism, but still present a disomic cell line.  Instead of 
chromosomes presenting in a gain or loss fashion, a phenomenon known as uniparental 
disomy (UPD) can occur.  As UPD implies, there are two chromosomes present; however, 
instead of one maternal and paternal chromosome, there are two copies of either a 
maternal or paternal chromosomes.  This may be the result of a trisomic rescue event 
after an error during meiosis (Figure 14).   
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Figure 12: A trisomic rescue event whereby a trisomic chromosome undergoes an 
anaphase lag event that corrects the cell line back to disomy. 
 
The most frequent chromosome that UPD occurs in is chromosome 15, where two 
paternal copies is referred to as Angelman syndrome or two maternal copies is known as 
Prader-Willi syndrome.  Other chromosomes that can present with UPD are 






Figure 13: An endoreplication event resulting in a trisomy. 
 
UPD and endoreplication occur to a lesser extent while anaphase lag and non-disjunction 
seem responsible for the majority of whole chromosomal abnormalities within the human 
embryo (Daphnis et al., 2008).  These mechanisms promote improper chromosome 
segregation, leading to multiple cell lines presenting with either chromosome gain and/or 
loss.  Because of this, it is important to understand the origins of these mechanisms. 
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Figure 14: A uniparental disomy event resulting in a trisomy. 
 
1.9 Origins of Aneuploidy 
1.9.1 Paternal Origin 
The centrosome is inherited from the sperm and is responsible for the first mitotic 
divisions within the human embryo (Palermo, 1994).  The disruption of the sperm 
centrosome can produce mosaicism in the preimplantation embryo (Palermo et al, 1997).  
Furthermore, research has indicated that sperm aster formation could be delayed in 
infertile males when compared to fertile males (Yoshimoto-Kakoi et al, 2008; Terada et 
al., 2004).  A delay in sperm aster formation could cause a delay in syngamy and 
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subsequent cleavages and possibly induce aneuploidy.  Thus, studies have shown that 
chromosomal aneuploidies are more prevalent in patients with severe male factor 
infertility (Magli et al, 2009; Gianaroli et al., 2000; Silber et al., 2003).  If that is the case, 
then it is possible that mosaicism may also be more prevalent during preimplantation 
development in this group of patients.  
 
1.9.2 Maternal Origin 
The increase in aneuploidy with maternal age is well documented (Munne et al., 1995, 
2002a).  Although mosaicism is a mitotically derived phenomenon, the proper segregation 
of chromosomes can be hindered by maternal processes.  As previously stated, the 
centrosome is paternally inherited but the mitochondria and mRNA stores necessary for 
proper chromosome division originate from the oocyte.  Indeed, research has indicated 
that mitochondrial function is affected by maternal age, possibly influencing chromosome 
segregation (Wilding et al., 2001; Schon et al., 2000).  
The oocyte pool in a woman has been arrested at prophase since prenatal development.  
As the woman ages, so too does the length of exposure of the oocytes to reactive oxygen 
species and environmental factors that may have negative effects during embryological 
development.  Furthermore, an increase in reproductive age correlates with a decrease 
in the cohesion molecule that is responsible for binding the sister chromatids together 
(Duncan et al., 2012; Hodges et al., 2005).  If this cohesion is reduced in older women, 
this could cause an unequal separation of chromosomes leading to aneuploidy.  
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Depending on when and where in development the error occurs, this could lead to 
mosaicism.  Finally some of the genes necessary for mitosis have been shown to be down 
regulated in fibroblasts from older patients when compared to younger patients (Ly et al., 
2000), although unfortunately this study did not give an indication of the actual ages.  
Interestingly no correlation has been observed between the incidence of preimplantation 
chromosomal mosaicism and maternal age (Munne and Cohen, 1998; Munne et al., 
2002b). 
Abnormalities in spindles are also more prevalent in older women.  For example, meiotic 
spindles from older women can have an abnormal shape and produce more chromosome 
misalignment compared to spindles of younger women, which appear to have normal 
configurations (Battaglia et al., 1996).  Although the meiotic spindle does not directly 
influence mitotic chromosome segregation, it is possible that the presence of abnormal 
meiotic spindles could suggest that the process of chromosome segregation in older 
women is flawed from the onset, leading to mosaicism.  An increase in mitotic spindle 
abnormalities of arrested day 3 and day 4 embryos compared to blastocysts has been 
reported (Chatzimeletiou et al. 2005).  Furthermore, poor quality blastocysts have been 
shown to have more abnormal spindles when compared to good quality ones (Hashimoto 
et al., 2013).  If abnormal spindles are present within a human embryo, then one would 
expect a higher incidence of aneuploidies, which may indicate a direct relationship 
between maternal age, spindle abnormalities, and chromosomal mosaicism.  
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While there is a direct relationship between advanced maternal age and aneuploidy, no 
relationship between maternal age and mosaicism has been shown.  Aneuploidy has also 
been shown to be prominent in young, fertile, oocyte donors and women <35 years old 
(Munne et al., 2006; Baart et al., 2006; Fragouli et al. 2009; Ata et al., 2012).  It is possible 
that other cells within the embryos tested in these studies could present with different 
cell lines which would indicate the presence of mosaicism. 
 
1.9.3 External Influences 
External factors also contribute to mosaicism.  For example, the production of oocytes for 
IVF requires controlled ovarian hyperstimulation of ovaries by exogenous follicle 
stimulating hormone.  Hyperstimulation has been implicated in increased rates of 
cleavage stage aneuploidy.  Munne and colleagues (1997) have demonstrated different 
mosaicism rates between IVF centers, implicating differences in stimulation protocols as 
a potential reason.  However, other research has shown that even embryos derived from 
unstimulated ovaries produce similar rates of chromosomal aneuploidies (Verpoest et al., 
2008).   
Munne and colleagues (1997) have suggested that embryo culture conditions may also 
cause differences in mosaicism.  Improper culture conditions can compromise embryo 
quality.  Furthermore, 5% oxygen versus atmospheric oxygen levels has been found to 
improve embryo quality and decrease sex chromosome mosaicism when compared to 
culture in atmospheric oxygen levels (De Los Santos et al. 2013; Bean et al., 2002).  Proper 
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embryo culture is essential for embryo development and poorer quality embryos tend to 
have higher rates of chromosomal abnormalities (Munne et al., 2007).  Thus, it is plausible 
that embryo culture may increase aneuploidy and subsequent mosaicism in the human 
preimplantation embryo (Beyer et al., 2009).  However, in-vitro derived blastocysts have 
lower rates of aneuploidy when compared to cleavage stage embryos (Fragouli et al., 
2014).  The reason for the decrease in aneuploidies at the blastocyst stage is due to the 
selection against embryos carrying multiple aneuploidies, resulting in a large number of 
embryos becoming arrested at the cleavage or morula stage (Vega et al., 2014).  Embryos 
that develop to the blastocyst stage have progressed further than cleavage stage embryos 
and so the culture media may have less of an effect on chromosome segregation as 
development progresses.   
 
1.10 Incidence of Mosaicism 
1.10.1 Incidence in Cleavage Embryos 
Mosaicism occurs in approximately 15% to 90% of all cleavage stage human embryos 
(Rubio et al., 2007; Daphnis et al., 2005; Harper et al., 1995).  It is believed that if the 
majority of the cells are diploid, then these embryos could be deemed viable, even though 
they are general mosaics.  In a systematic review looking at all the cells from each embryo, 
van Echten-Arends and colleagues (2011) found that 73% of 815 cleavage embryos 
examined were mosaic and 59% of all embryos were diploid-aneuploid mosaic.  The 
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authors noted that not all embryos were examined with the same technology, indicating 
that the mosaic rate may be higher when more chromosomes are analyzed.  However, 
other research indicates similar rates of mosaicism at the cleavage stage (Mertzanidou et 
al, 2013; Vanneste et al., 2009; Wells and Delhanty, 2000).  A majority of research at the 
cleavage stage examining mosaicism was conducted utilizing FISH, a technique which has 
been shown to be inaccurate and difficult to perform due, possibly causing an 
overstatement in cleavage stage mosaicism (Northrop et al., 2010).  Nonetheless, it seems 
that mosaicism and aneuploidies are routine during the first cleavage divisions in human 
preimplantation development.   
 
1.10.2 Incidence in Blastocysts 
The blastocyst is composed of two distinct parts, the trophectoderm, which will become 
the placenta, and the ICM, which will become the fetus (Figure 8).  Thus, the blastocyst 
represents the first stage of cellular differentiation in human embryonic development 
whereby totipotent cells become pluripotent cells.  Compared to cleavage stage embryos, 
similar rates of mosaicism appear to exist in the human blastocyst.  Liu et al. (2012) 
reported that 69% of abnormal blastocysts from women of advanced age are mosaic for 
both the ICM and trophectoderm.  However research from younger women has 
demonstrated that 80% of blastocysts are euploid, with the majority of the abnormal 
blastocysts presenting with only one or two structural chromosome abnormalities.  This 
suggested a lower level mosaicism at the blastocyst stage (Johnson et al, 2010).  Fragouli 
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et al. (2011) demonstrated that roughly one-third of all blastocysts are mosaic, while 
Northrop and colleagues (2010) found that only 16% (8/50) were mosaic.  Currently, 
research has not demonstrated an association between maternal age and mosaicism 
(McCoy et al., 2015).  Similar to cleavage stage mosaicism detection, one of pitfalls of 
mosaicism detection at the blastocyst stage is technical errors.  Some researches argue 
that technical aspects of the test may be overcalling mosaicism and limiting our 
understanding of mosaicism (Capalbo et al. 2017a; 2017b).  Regardless of the variability 
in results, mosaicism may still be prevalent at the blastocyst stage.  
 
1.10.3 Incidence Post Implantation 
CPM is detected via CVS samples typically at 10-12 weeks and is typically conducted on 
patients who are at an increased risk of genetic abnormalities; therefore, the true 
incidence of CPM in a general population is unknown.  Research indicates that 1-2% of 
viable pregnancies present with a chromosomally abnormal placenta but a normal fetus 
(Ledbetter et al., 1992).  The diagnosis of CPM is determined from a limited number of 
cells from one particular biopsy site, and it is also possible that the cells sampled could 
accidently be from the mother (a euploid individual), an artifact known as maternal 
contamination.  When maternal contamination is controlled for, CPM exists in roughly 6% 
of all pregnancies (Griffin et al, 1997).  CVS sampling takes place at 10-12 weeks, when 
the placenta is not yet fully mature, therefore CPM quantified at CVS sampling has been 
shown to be different to that in term placenta (Schuring-Blom et al., 1993).  When term 
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placentas have been reanalyzed after a 10 week diagnosis of CPM, trisomic cells have 
been found within both the cytotrophoblast and the EEM (Figure 8; Schuring-Blom et al, 
1993; Artan et al, 1995).   
The majority CPM abnormalities are autosomal trisomies (Lestou and Kalousek, 1998).  
Unfortunately there is not always concordance between the EEM and cytotrophoblasts.  
For example, trisomies 2 and 17 are more prevalent in the EEM while trisomies 3, 6, 9, 12, 
13, 14, 16, 18, 20, 21, and 22 are more prevalent in the cytotrophoblasts.  The trisomies 
that present equally between the two tissues are chromosomes 4, 5, 7, 8, 11, and 15 
(Hahnemann and Vejerslev, 1997; Lebedev, 2011).  These errors could be attributed to 
either meiotic errors or mitotic errors during development.  If meiotic in origin, the errors 
would also be present throughout the embryo including the EEM unless trisomic rescue 
occurred prior to differentiation.  Likewise, it is possible that a non-disjunction event or 
endoreplication occurred at the onset of cellular divergence to either the EEM or 
cytotrophoblasts creating a mosaic within those lines compared to other embryonic and 
extraembryonic tissue.  Regardless of how the error occurred, it is evident that 
chromosomes are differently affected during development. 
 
1.11 Clinical Consequences 
The clinical consequences of mosaicism are dependent on a variety of factors including 
when during development the error occurs and if the error can continue to propagate.  
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Because the cleavage stage embryo only contains 4 to 8 cells, the consequences of 
chromosomal mosaicism are much more pronounced during this stage then if mosaicism 
occurs when more cells are present.  For example, it was previously mentioned that the 
rate of mosaicism at the cleavage stage varies greatly from 15-90%, however the rate of 
mosaicism seen in prenatal diagnosis ranges from 1-2% (Ledbetter et al., 1992).  This 
would indicate a selection mechanism against mosaicism in the later stages of 
development.  Therefore, mosaicism during the preimplantation stage has a greater 
consequence than post implantation mosaicism. 
It is believed that the actual fetus only derives from three cells of the ICM (Markert and 
Peters, 1978).  Any cells not destined to become the fetus may not be a true 
representation of the fetus itself but rather of extraembryonic tissue (i.e., EEM, 
cytotrophoblasts, placenta, chorion, etc.).  Studies have shown that abnormal cells can be 
forced away from the fetus lineage (James and West, 1994).  Stetten and colleagues 
(2004) have found that 76% of CVS samples which are identified as mosaics have a normal 
amniocentesis result; however, they note that it is unknown if the fetus presents with 
low, undetectable levels of mosaicism.  These tissues could be mosaic while the fetus 
itself is normal, at least phenotypically.  In line with this, Staals and colleagues (2003) 
reported a mosaic female for trisomy 12 with normal development.  Down syndrome 
patients with low levels of mosaicism tend to have less severe manifestations than typical 
Down syndrome patients, indicating that the clinical significance of mosaicism is directly 
associated with the ratio of abnormal to normal cells (Leon et al., 2010). 
60 
As previously mentioned, mosaic cell lines can arise from either mitotic or meiotic 
circumstances.  If a meiotic error has occurred and the error is corrected at the cleavage 
stage, mosaicism will result.  It is possible then that the abnormal cells are forced into the 
trophoblast while the normal (rescued) cells are destined to become the fetus (Figure 15).  
Conversely, it is also possible that the meiotic error is corrected at the cleavage stage, and 
the mosaic cell lines do not become isolated but rather persist throughout the 
trophectoderm and ICM (Figure 16).  In either case, the meiotic errors are typically more 
devastating due to the initial onset of the abnormality, which allows the mosaic cell line 
to dominate.  However mitotic errors may be as severe as meiotic errors depending on 
when they occur.  If a mitotic error occurs in the first one or two divisions, then the mosaic 
cell line could be present through all embryonic tissues (Figure 17).  However, if the 
mitotic error occurs further along in development, the mosaic cell line could be confined 
to that particular region (Figure 18; Figure 19).  
Figure 15: A meiotic error that is corrected at the cleavage stage resulting in a mosaic 
cleavage stage embryo.  When forming a blastocyst, the mosaic cell line is isolated to the 
trophectoderm while the euploid cell line is isolated to the ICM. 
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Figure 16: A meiotic error that is corrected at the cleavage stage resulting in a mosaic 
cleavage stage embryo.  When forming a blastocyst, the mosaic cell line does not become 
isolated and persist throughout the trophectoderm and ICM. 
 
 
Figure 17: A mitotic error at the cleavage stage that resulted in a mosaic cleavage stage 
embryo.  When forming a blastocyst, the mosaic cell line does not become isolated and 







Figure 18: A mitotic error that occurred in the trophectoderm of the blastocyst.  The 
blastocyst is a mosaic, however the error is isolated to the trophectoderm while the ICM 
remains euploid. 
 
Figure 19: A mitotic error that occurred in the ICM of the blastocyst.  The blastocyst is 
mosaic, however the error is isolated to the ICM while the trophectoderm remains 
euploid. 
 
The clinical consequences of confined mosaicism are dependent upon the location of the 
mosaicism.  For example, germ line mosaicism has been found to be associated with an 
increase in trisomic oocytes (Delhanty, 2011).  In one report, CPM of trisomy 16 was 
discovered to also have propagated in the oocytes of the corresponding fetus 
(Stavropoulous et al., 1998).  Likewise, confined mosaicism for trisomy 21 was detected 
in the ovaries of eight fetuses that were phenotypically normal (Hulten et al., 2008).  It is 
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evident that the effects of the mosaicism depend greatly on the location of the mosaic 
cell line along with what chromosome is involved.  
The clinical consequences of mosaicism are difficult to pinpoint and explain due to 
differences between individual chromosomes.  For example, mosaicism of a particular 
chromosome may affect muscular development while mosaicism of another chromosome 
may affect organ development.  It is not only the particular chromosome that matters but 
the prevalence or sheer numbers of the particular mosaic cell line.  If an individual has a 
few muscle cells that are mosaic and the remaining are normal, then the effects of those 
abnormal cells is masked by the number of normal cells.  The opposite also holds true, if 
all but a few muscle cells are mosaic, then the normal cells will be masked by the mosaic 
cells.    
As previously mentioned, certain trisomies are more prevalent in certain tissues.  This 
would suggest that there is a selection against some chromosomal abnormalities at 
certain stages of fetal development.  This could be due to different growth rates of 
abnormal and normal cells.  Likewise, each chromosome acts differently under different 
conditions and at different times during prenatal development.  For example, if trisomy 
13, 18, and sex chromosomes are detected in CVS, they typically will also present 
themselves within the fetal lineage (Hahnemann and Vejerslev, 1997), while CPM 
presenting with trisomy 2, 3, 7, and 8 are typically not associated with any adverse events 
and normally lead to a chromosomally normal fetus (Kalousek et al., 1996; Hahnemann 
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and Vejerslev, 1997; Sifakis et al, 2010; van Haelst et al, 2001).  Taken together, the clinical 
relevance and consequences of mosaicism depends on a variety of factors.  
 
1.12 Preimplantation Genetic Screening Biopsy Techniques 
As previously alluded to, aneuploidy and mosaicism can have serious and disastrous 
consequences during pre-and post-implantation development.  Thus, the screening of 
embryos and transferring of euploid embryos seems justified.  In order to test embryos 
for their chromosomes, a piece of the oocyte or embryo must be removed and processed.  
Currently, there are three different stages that a biopsy can occur: the polar body, 
cleavage stage, and blastocyst (Harper et al., 2012).  Each of these represent a different 
stage of development and each present with their own set of advantages and 
disadvantages. 
 
1.12.1 Polar Body Biopsy 
As previously discussed during the course of oocyte maturation, two polar bodies are 
produced; therefore, there are two biopsy possibilities.  First, the biopsy and analysis of 
the first polar body and second, the biopsy and analysis of the first and second polar body. 
There are a multitude of ways to perform polar body biopsy.  In general though, the 
mature oocyte must be placed in Hepes buffered media supplemented with 10% serum 
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ĂŶĚŽǀĞƌůĂǇĞĚǁŝƚŚŽŝů ?dŚĞŽŽĐǇƚĞ ?ǁŝƚŚƚŚĞƉŽůĂƌďŽĚǇĂƚ ? ?Ž ?ĐůŽĐŬŝs held in place by 
suction applied to a holding pipette.  The ZP is either breached with a sharp biopsy needle, 
mechanically stripped by acid, or ablated by a laser, allowing the biopsy needle to aspirate 
the polar body.  The first polar body is expelled before the completion of the first meiotic 
division; thus, further incubation may be required to allow completion of meiosis even 
though the polar body is visible (Wang et al. 2001; Verlinksy et al., 1990).  If one is just 
removing the first polar body, then this procedure is performed on every mature oocyte 
prior on the day of retrieval.  If this procedure is being performed on the first and second 
polar body, then the procedure is typically performed after fertilization when both polar 
bodies are present.  One potential problem with waiting until after fertilization is that it 
would be unknown which polar body is the first or second polar body as there are no 
predictable markers to determine this (Forman et al., 2013a; Salvaggio et al., 2014). 
 In general there are many advantages to polar body biopsy.  For example, polar bodies 
are considered extraembryonic tissue and are not involved in embryonic development; 
consequently, their removal should not impede embryological development.  Because 
they are not part of the embryo, they have no legal status and ethical limitations are 
minimal or non-existent (Corveleyn et al., 2008).  Also, polar bodies are produced at the 
beginning of the IVF process and this allows for five to six days for analysis thereby 
facilitating fresh transfer.  Biologically, the majority of aneuploidy is derived from the first 
meiotic division (the first polar body), so the biopsy of the first polar body could detect 
the majority of abnormalities present in the fetus.  The problem with this approach is that 
sometimes the second meiotic division can correct the error in the first meiotic division 
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thus having a first aneuploidy polar body and euploid fetus (Forman et al. 2013; Scott et 
al., 2012).  Further research has also demonstrated that polar body biopsy is less 
predictive of implantation than blastocyst biopsy, 40% and 51% respectively (Salvaggio et 
al., 2014). 
From a technical standpoint, polar body biopsy is much more time consuming than either 
cleavage stage or blastocyst biopsy.  With polar body biopsy it is possible that biopsied 
embryos may not have any reproductive potential.  Moreover, after biopsy, embryos 
must be kept separate during culture, increasing the amount of time needed for culture 
preparation and grading of embryos under the microscope when compared to group 
culture.  Lastly, the testing of two polar body can be an expensive add on to an already 
expensive IVF procedure and to pay hundreds of dollars for testing on embryos that may 
not develop is difficult to justify for the patient. 
Because of the inability to detect post zygotic errors and technical difficulties surrounding 
polar body biopsy, the IVF field focused on cleavage stage (or blastomere) biopsy. 
 
1.12.2 Cleavage Stage Biopsy 
The first PGD cycles were performed at the cleavage stage for X-linked diseases and the 
process involves breaching of the ZP and removing either one or two cells from the 
embryo on day 3 (Handyside et al., 1990; Griffin et al. 1994).  Previously, this was the most 
utilized procedure for PGS (Harper et al., 2012).  Over the years there have been additions 
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to the technique in hopes to optimize the procedure.  Regardless of technique or 
modifications the principle is the same: remove a single cell from a day 3 embryo, perform 
testing on this cell and relate the results back to the embryo.   
Cleavage biopsy is performed on good quality embryos presenting with six to eight 
blastomeres on day 3 of development (Figure 20A).  Embryos selected to undergo the 
procedure are isolated and put into individual drops of calcium and magnesium (Ca/Mg) 
free media (Cooper Sage, Trumbull, Connecticut, USA) supplemented with 10% serum.  
Ca/Mg free media breaks down the gap junctions of the cleavage stage embryo and allows 
for easier separation of the individual blastomeres.  With the aid of a biopsy pipette (Cook 
Medical, Bloomington, IL, USA) and either acid or laser (Zilos-tk, Hamilton Thorne, 
Beverly, Massachusetts, USA), a single cell is removed from the embryo (Figure 20B and 
20C).  The cell remains in the Ca/Mg free media while the embryo is washed in Hepes 
buffered media supplement with protein, before being placed back into culture media 
and the incubator.  The individual cells are then prepped for PGS testing.  After biopsy, 
embryos must be cultured individually to allow for identification post PGS results. 
ůĞĂǀĂŐĞƐƚĂŐĞďŝŽƉƐǇǁĂƐƵƚŝůŝǌĞĚĚƵƌŝŶŐƚŚĞĐŽƵƌƐĞŽĨ/s&ĨƌŽŵƚŚĞŵŝĚ ? ? ? ? ?ƐƚŽůĂƚĞ
 ? ? ? ? ?Ɛ ?  dŚŝƐ ŵĞƚŚŽĚ ŵĂǇ ƐĞĞŵ ĚĞƚƌŝŵĞŶƚal to embryo development but there are 
multiple reports that support the use of cleavage stage and PGS (Marquez et al. 2000; 
Munne et al. 2000; Hardy et al., 1990; Grifo et al. 1994).  Due to research that has shown 
there was no benefit to PGS at the cleavage stage, along with potential damage caused 
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by the biopsy procedure, many clinics have transitioned to blastocyst biopsy 
(Mastenbroek et al., 2007; Scott et al., 2013). 
Figure 20: A) An 8 cell day 3 embryo being held in place by a holding pipette.  The small 
red dot is where the laser will fire and the pipette on the right is the biopsy pipette.  B) 
An opening is made in the ZP by firing the laser.  The hole is just big enough for the biopsy 
pipette to grab the cell.  C) The biopsy pipette removing the cell from the embryo, care if 












1.12.3 Blastocyst Stage Biopsy 
Blastocyst biopsy refers to the removal of tissue from the trophectoderm layer of cells 
during preimplantation growth (Dokras et al., 1990).  Although initially a proof of principle 
ƐƚƵĚǇ ? ŝƚ ǁĂƐŶ ?ƚ ƵŶƚŝů ^ĐŚŽŽůĐƌĂĨƚ ĂŶĚ ĐŽůůĞĂŐƵĞƐ  ? ? ? ? ? ) ƉƵďůŝƐŚĞĚ ƚŚĞŝƌ ǁŽƌŬ
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demonstrating a pregnancy rate of 82.2% that blastocyst biopsy became more 
mainstream.  
To facilitate hatching of the blastocyst out of the ZP, day 3 cleavage stage embryos are 
removed from the incubator and assisted hatching (AH) is performed with the aid of a 
laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA).  Using a pulse of 610 µs, the ZP is 
breached with 2-3 shots of the laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA).  
After breaching the ZP with the laser, the embryos are placed back into the incubator until 
day 5. 
On the morning of day 5 (112-115 hours post insemination), day 6 (136-139 hours post 
insemination), or day 7 (160-163 hours post insemination) embryos are removed from 
the incubator and those blastocysts that have a good or fair trophectoderm protruding 
from the ZP, along with good or fair quality ICM are biopsied (Figure 21A).  If blastocysts 
are not suitable for biopsy on day 5, they are reevaluated on day 6.  If embryos do not 
meet the criteria for biopsy on day 6, they are discarded.   
Only blastocysts that present with a good or fair quality ICM and trophectoderm undergo 
the biopsy procedure.  Briefly, blastocysts are placed in a drop of modified human tubal 
fluid (Irvine scientific, Santa Ana, California, USA) + 10% serum substitute supplement 
(SSS; Irvine scientific, Santa Ana, California, USA) and suction is applied to the blastocysts 
via a holding pipette (Humagen, Charlottesville, Virginia, USA).  A biopsy pipette 
(Humagen, Charlottesville, Virginia, USA) gently aspirates the trophectoderm into the 
biopsy needle (Figure 21B).  A laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA), with 
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a pulse length of 610 µs ?ŝƐƵƐĞĚƚŽ “ĐƵƚ ?ƚŚĞƚƌŽƉŚĞĐƚŽĚĞƌŵĨƌŽŵƚŚĞďůĂƐƚŽĐǇƐƚ ?ƚĂŬŝŶŐ
care not to expose the trophectoderm to unnecessary laser pulses (Figure 22C).  The piece 
of trophectoderm is prepped according to the reference laboratories procedures for 
aCGH, next generation sequencing (NGS), single nucleotide polymorphism (SNP), or qPCR.   
Figure 21: A) A blastocyst presenting with a good quality ICM and trophectoderm.  The 
red circle is where the laser will fire and the biopsy pipette is shown at the 3 Ž ?ĐůŽĐŬ
position.  B) The trophectoderm being suctioned into the biopsy pipette.  The red circle is 
ǁŚĞƌĞ ƚŚĞ ůĂƐĞƌ ǁŝůů ĨŝƌĞ ĂŶĚ  “ĐƵƚ ? ƚŚĞ ƚƌŽƉŚĞĐƚŽĚĞƌŵ ƉŝĞĐĞ ?   ) dŚĞ ƉŝĞĐĞ ŽĨ ƚŚĞ








1.13 PGS Platforms 
As previously eluded to, PGS has been performed at multiple stages during the IVF 
process.  Not only is the stage of biopsy important but also the technique that the genetic 
analysis occurs also can influence results.  Previously, the most widely used method for 
analysis was fluorescence in-situ hybridization (FISH).  More recently however, PGS has 
transitioned to testing at the blastocyst stage and using techniques that can detect 
aneuploidies across all chromosomes, referred to as comprehensive chromosome 
screening (CCS; Treff et al., 2010a, 2012; Gutierrez-Mateo et al., 2011). 
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1.13.1 Fluorescence In-Situ Hybridization 
FISH allows for the detection of a limited number of chromosomes (Griffin et al., 1994).  
Aneuploidy, as demonstrated by FISH, is well documented in scientific literature (Baart et 
al., 2006; Li et al., 2005; Rubio et al., 2005; Munne et al., 1995).  FISH was widely utilized 
on individual blastomeres from cleavage stage biopsy.  Initially, FISH was limited to three 
to twelve chromosomes; however, more recently, FISH technology has evolved to include 
all 24 chromosomes (Ioannou et al., 2012).  Regardless of how many chromosomes are 
examined, the principle remains the same. 
As previously discussed, a cell is removed from the embryo on day 3.  This cell is then 
exposed to hypotonic solution, allowed to swell, and placed on a glass slide (Munne et al., 
1993).  Fixative is dropped onto the slide and breaks the cell open, dispersing the 
cytoplasm and fixing the nucleus to the slide. 
Probes containing different fluorochromes are added to the slide and hybridized, allowing 
for the probe to bind to the chromosomes.  These probes target certain loci within specific 
chromosomes and when attached emit a signal that is seen under a microscope.  Thus, if 
two signals are seen under the microscope then two chromosomes are present in the 
nucleus.  Similarly, if there are three signals or one signal present, then the nucleus is a 
trisomy or monosomy, respectively.  To maximize the number of chromosomes one can 
examine with FISH, probes with different color fluorochromes are added, each color 
representing a different chromosome.  This method was limited due to the number of 
colors available.  Moreover, for more chromosomes to be viewed, new probes had to be 
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added after the slide is washed clean.  It was very possible that washing and hybridization 
of probes degraded DNA causing inefficiencies in the technique.  FISH as a technique was 
extremely difficult to perfect; moreover, FISH technology was also limited in that it only 
viewed whole chromosomes and could not detect segmental aneuploidy.  Thus, limiting 
its clinical application as a screening tool for embryos during the course of IVF. 
dŚŝƐƚĞĐŚŶŝƋƵĞǁĂƐŚĞĂǀŝůǇƵƚŝůŝǌĞĚŝŶƚŚĞ ? ? ?ƐĂŶĚĞĂƌůǇƚƵƌŶŽĨƚŚĞĐĞŶƚƵƌǇǁŝƚŚƐƵĐĐĞƐƐ
being demonstrated in retrospective and prospective studies (Gianaroli et al., 1997; 
Gianaroli et al., 1999; Pehlivan et al., 2003; Rubio et al., 2013a).  However, multiple 
randomized control trails demonstrated a detrimental effect or no benefit on pregnancy 
rates leading to the reduction in the use of FISH in IVF (Mastenbroek et al., 2007; Twisk 
et al., 2008; Debrock et al., 2010). 
 
1.13.2 Whole Genome Amplification 
Whole Genome Amplification (WGA) allows for multiple copies of DNA to be produced in 
an effective and efficient manner.  One cell typically contains approximately 6pg of DNA; 
however, CCS using microarrays requires much more DNA, typically 0.2-1.0 µg, thĂƚ ?ƐĂ
1000 fold increase (Dolezel et al. 2003).  WGA is utilized to increase the amount of DNA 
that is needed for microarray analysis.  WGA is performed by lysing the cell and then 
subjecting it to polymerase chain reaction based methods or multiple displacement 
amplification (Handyside et al., 2004; Sher et al., 2007; Fiegler et al., 2007).  These two 
methods effectively increase the amount of DNA.   
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Increasing the DNA is not without its drawbacks.  Current WGA have two distinct 
drawbacks.  First, allele dropout is a phenomena when an allele fails to amplify; thus, the 
WGA product has an area of DNA that failed to amplify (although present in the original 
cell).  In the final WGA product this would manifest as that specific allele not being present 
but in actuality that allele is present within the original cell.  This can produce errors in 
the diagnosis.  ADO is less of a problem with array based PGS due to the multiple alleles 
that are examined along the entire chromosome (Ling et al., 2009).  ADO is more of a 
problem with single gene disorders.  For example, the array for CCS examines 50 alleles 
along a chromosome but determines that only 49 are present, it may call the loss of one 
allele an ADO event and thus all 50 alleles are present on the chromosome.  However, if 
the ADO event occurs in an allele that is specific for a single gene disorder, than the final 
diagnosis will be a cell that is negative for the single gene disorder but in actuality the 
single gene disorder is present, it just failed to amplify.  Another problem with WGA is 
that different protocols yield different results and depending upon what one needs to 
examine, should dictate the WGA product one uses (Treff et al., 2011).  It is entirely 
feasible that aneuploidy as determined by CCS platforms may be artifacts produced by 
the WGA procedure and not biological in nature (Capalbo et al., 2015).  Methods 





1.13.3 Array Comparative Genomic Hybridization 
aCGH has been adapted from comparative genomic hybridization (CGH) to be streamlined 
for the use of preimplantation embryos (Voullaire et al, 2000; Wells et al., 2002).  CGH 
will not be discussed in detail here; however, it should be noted that CGH was original 
developed for karyotyping tumor cells and is extremely labor and time consuming 
(Kallioniemi et al., 1992; Kallioniemi et al., 1993).  These aspects make it not ideal for the 
use on preimplantation embryos. 
Much like FISH, aCGH involves the hybridization of probes and fluorescence dyes to DNA.  
These probes and fluorescence dyes attach not to just a single reference point but to 
thousands of points of DNA across the entire genome.  Initially, WGA DNA from the 
embryo is labeled with Cy5 (red) and the DNA from a known reference material is labeled 
with Cy3 (green).  These two aliquots of DNA are mixed together in equal portions and 
placed on the microarray slide.  The slide contains thousands of cloned DNA strands from 
known locations within the human genome.  The slide with the DNA undergoes 
hybridization, which denatures the DNA and makes it single stranded.  The single stranded 
DNA from both the reference and embryo compete for the same sites of cloned DNA on 
the slide.  After hybridization the slide is visualized under a microscope using a computer 
program.  If there is more embryo DNA (green) than reference DNA (red) then the green 
fluorescence will be visible.  While if there is more reference DNA (red) than embryo DNA 
(green) then red fluorescence will be visible.  If there are equal parts embryo DNA (green) 
and reference DNA (red), then yellow is visible.  The computer program is able to 
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distinguish the different fluorescent probes and realign the colors with their 
corresponding cloned DNA location in the human genome and output chromosomal copy 
number changes of the embryo sample compared to the reference. 
Although robust and well utilized within the IVF community for PGS testing, aCGH does 
have limitations.  Namely that is not able to detect polyploidy within a sample and cannot 
deduce if the error is of mitotic or meiotic in nature.  Regardless, due to the screening of 
all chromosomes and to studies demonstrating superior pregnancy and implantation 
rates compared to FISH, aCGH quickly became the gold standard for CCS (reviewed in 
Rubio et al., 2013b). 
 
1.13.4 Single Nucleotide Polymorphism Array 
SNPs are biallelic genetic markers that are utilized by SNP arrays to detect chromosome 
ĐŽƉǇ ŶƵŵďĞƌ ?  ^EW ĂƌƌĂǇƐ ĂƌĞ ƵƐĞĚ ƚŽ ĚĞƚĞĐƚ ƐƉĞĐŝĨŝĐ E^W ?Ɛ ĂůŽŶŐ ƚŚĞ ůĞŶŐƚŚ ŽĨ ƚŚĞ
ĐŚƌŽŵŽƐŽŵĞ ?ĞĐĂƵƐĞƚŚĞƌĞĂƌĞŵŽƌĞƚŚĂŶ ? ? ? ? ? ? ?^EW ?ƐŝŶƚŚĞŚƵŵĂŶŐĞŶŽŵĞ ?^EW
arrays provide much more information and sensitivity than aCGH and qPZ ?^EW ?ƐĂƌĞ
able to detect uniparental disomy (UPD), parental origin of aneuploidy, polyploidy, and 
ƚŚĞĂďŝůŝƚǇƚŽ “ĐůĞĂŶ ?ĚĂƚĂ ?,ĂŶĚǇƐŝĚĞet al., 2010; Johnson et al., 2010; Treff et al., 2011). 
UPD refers to the presence of two chromosomes from the same parent and can result in 
the manifestation of recessive disorders or imprinting disorders such as Angelman or 
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Prader-Willi syndrome.  Although only present in <1% of blastocysts and newborns, it can 
only be detected with SNP array (Robinson et al., 1997; Gueye et al., 2013).   
Parental origin of aneuploidy is the ability to determine which parents caused the 
aneuploidy within the embryo.  Since all embryo chromosomes are a combination of 
maternal and paternal chromosomes, it is possible to compare the SNW ?ƐŽĨƚŚĞĞŵďƌǇŽ
ƚŽ ƚŚĞ ^EW ?Ɛ ŽĨ ƚŚĞ ƉĂƌĞŶƚƐ ƚŽ ĚĞƚĞƌŵŝŶĞ ƚŚĞ ^EW ŚĞƌŝƚĂŶĐĞ  ?:ŽŚŶƐŽŶet al., 2010; 
Handyside et al. ? ? ? ? ? ) ?hƐŝŶŐƚŚŝƐƐĂŵĞƉƌŝŶĐŝƉůĞ ?ŝƚŝƐƉŽƐƐŝďůĞƚŽ “ĐůĞĂŶ ?ƚŚĞ^EWƌĞƐƵůƚƐ
by removing errors.  For example, in the figure below, one of ƚŚĞ^EW ?ƐŝŶƚŚĞĞŵďƌǇŽŝƐ
ŶŽƚƉŽƐƐŝďůĞǁŝƚŚƚŚĞŵĂƚĞƌŶĂůĂŶĚƉĂƚĞƌŶĂů^EW ?Ɛ ?dŚƵƐ ?ƚŚŝƐ^EWǁŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚ
ĂŶĞƌƌŽƌŝŶƚŚĞt'ŽƌĂŶĂůǇƐŝƐĂŶĚĚŝƐĐĂƌĚĞĚ ?ĂƉƌŽĐĞƐƐƌĞĨĞƌƌĞĚƚŽĂƐ “ĐůĞĂŶŝŶŐ ? ? 
Figure 22: An overview of the SNP algorithm and an example of how the SNP protocol can 
ŐŝǀĞƉĂƌĞŶƚĂůŽƌŝŐŝŶŽĨĂŶĞƵƉůŽŝĚǇĂŶĚ “ĐůĞĂŶ ?ĚĂƚĂ ? 
Maternal SNP  Paternal SNP  Embryo SNP Inheritance 
AA + AA = AA Unknown 
BA + BB = BA Maternal 
AB + BA = AB Maternal 
AA + BB = BB Paternal 
BB + BB = AA Error 
 
^EW ?Ɛability to provide whole chromosomal aneuploidy calls, along with high resolution, 
ability to clean data and provide linkage based analysis for parental origin of aneuploidy, 
makes SNP a truly powerful tool. 
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1.13.5 Quantitative Polymerase Chain Reaction 
qPCR is one of the most extensively validated CCS platforms, being validated with positive 
and negative controls and against known cell lines (Scott et al., 2012; Treff and Scott, 
2013).  In regards to cell lines, not all chromosomes are tested against known cell lines 
because most whole aneuploid cell lines are not commercially available.  This prevents 
the complete validation of any platform, including qPCR, against all chromosomes.  It is 
entirely possible that some chromosomes tested by qPCR are more accurately detected 
than others.   
As previously mentioned aCGH and SNP look at thousands of loci along the chromosome, 
while qPCR only examines four loci on the chromosome.  The reasoning behind the 
minimal number of sites is two-fold.  First, WGA is known to have errors; thus, any 
platform that requires WGA will produce inaccurate results.  qPCR does not utilize WGA 
and therefore is not confounded by this variable.  Secondly, as previously discussed, the 
main reason for miscarriages and embryo wastage is whole chromosomal aneuploidy.  So, 
perhaps a platform such as aCGH looks at too many loci and some of these errors may 
not be clinically significant and are actually throwing away viable embryos.  Research by 
Capalbo and colleagues (2015) demonstrated that aCGH overcalls aneuploidy compared 
ƚŽ^EWĂŶĚƋWZ ?ůƚŚŽƵŐŚ^EWƵƐĞƐt' ?ŝƚƐĂďŝůŝƚǇ Ž “ĐůĞĂŶ ?ƚŚĞĚĂƚĂŵŝŶŝŵŝǌĞƐt'
errors and provides a more accurate result. 
Because of the limited amount of coverage, qPCR cannot detect segmental aneuploidy 
and large duplications/deletions; however, the clinical significance of these errors has yet 
78 
to be determined.  Research has demonstrated an incidence of segmental aneuploidy in 
preimplantation embryos approximately 15% while the incidence in products of 
conception is approximately 5% (Rabinowitz et al., 2012; Sahoo et al., 2016).  This 
suggests that some segmental aneuploidy may be clinically significant and is missed by 
qPCR.  Moreover, due to the lack of coverage along the chromosome, if an error occurs it 
could more easily influence results due to the limited number of sights observed.  This 
could cause an increase in false negatives (i.e., embryo deemed euploid but is actually 
aneuploid). 
Although extensively validated, qPCR has minimal clinical data associated with it.  One of 
the objectives of this thesis is to determine the clinical outcomes of blastocysts screened 
with qPCR or aCGH. 
 
1.13.6 Next Generation Sequencing 
NGS is another method that chromosomal aneuploidy is determined.  Instead of binding 
DNA to a microscope slide like aCGH, NGS simply sequences the DNA.  Similar to qPCR 
where one can adjust how many loci one views, one can adjust how much DNA one should 
sequence in order to determine aneuploidy.  Thus, one can sequence the entire genome 
and gain a massive amount of information or one can sequence just enough to obtain the 
desired information. 
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NGS can be targeted, much like qPCR where WGA is not performed, and only a limited 
number of loci are examined (Goodrich et al., 2016; Kinde et al., 2012).  Conversely, NGS 
utilize WGA and examine areas similar to other tests (Fiorentino et al., 2014).  Regardless, 
NGS involves sequencing. 
Sequencing refers to the process that the sample DNA is denatured and spliced into 
sections and labeled with adaptors.  The adaptors are complimentary to the DNA that is 
desired.  The adaptors allow the sample DNA to bind to specific clusters of desired DNA 
on the flow cell.  When the binding occurs, the sample DNA is then amplified multiple 
times.  Thus, we have hundreds of thousands of small, single strands of sample DNA that 
is bound to the flow cell.  Sequencing begins when unbound nucleotides are allowed to 
bind with the sample DNA attached to the flow cell.  Each unpaired nucleotide is attached 
to a different color fluorescence probe and when it binds to the sample DNA, the 
fluorescent probe is excited and the color produced is recorded by a computer.  The 
computer then analyzes the colors produced to determine the aneuploidy call.   
The most common NGS on the market, Veriseq by Illumina, simply sequences the same 
sites that aCGH examines.  Thus, the validation of Veriseq is based off of aCGH (Fiorentino 
et al., 2014).  As previously discussed, the validation of aCGH is based on FISH.  Research 
by Treff and colleagues (2010b) demonstrates that FISH is inaccurate compared to SNP.  
By validating Veriseq off of aCGH then it is possible that Veriseq is also inaccurate.  This 




The ultimate goal of IVF is a delivery of a single healthy baby.  I have previously discussed 
developmental biology, aneuploidy, mosaicism, biopsy techniques, and PGS platforms.  In 
order to provide patients with the highest chances of pregnancy, an understanding is 
needed between all five of these topics.  Unfortunately, the biological implications and 
understanding of PGS is not well understood by IVF technicians while the limitations and 
implications of the biopsy techniques are not understood by geneticists.  Thus, there is a 
gap between the two fields.  This gap may be hindering IVF labs from adopting PGS while 
also limiting geneticists in understanding the limitations of PGS testing.  One of the goals 
of the thesis to help bridge that gap between genetics and the IVF lab.  As a geneticist it 
is important to understand that biologically, aneuploidy may be a natural occurrence and 
as a field, we may be discarding viable embryos.  As an embryologist it is important to 








1.15 Aims of This Thesis  
As stated above, chromosome malsegregation is the most common cause of miscarriages, 
failed IVF, and embryo wastage.  However, the incidence of aneuploidy during 
preimplantation tells us that aneuploidy and mosaicism may be common during 
embryological development.  What is more important is trying to identify the clinical 
consequences of aneuploidy and mosaicism during preimplantation development.  In 
fact, some aneuploidies may be clinically insignificant while others may not.  The purpose 
of the work described in this thesis is to improve our understanding on the limitations of 
PGS for a biological and technical standpoint, identify patients that may or may not 
benefit from PGS, and to gain a greater understanding of preimplantation development 
through the use of PGS.  With these objectives in mind, the specific aims of this thesis 
were to ask the following technical and biological questions: 
1. Can we develop a technique that reconstructs a virtual image of a blastocyst after 
^ŝŶŽƌĚĞƌƚŽ “ŵĂƉ ?ĐŚƌŽŵŽƐŽŵĂůŵŽƐĂŝĐŝƐŵ ? 
2. What is the reproductive potential of poor quality blastocysts that would be 
discarded? 
3. Can PGS be successfully extended to previously frozen blastocysts by thawing, 
biopsing, refreezing and rethawing?  
4. Are there clinical differences between euploid blastocysts that develop on day 5 
as opposed to day 6? 
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5. Are there differences in PGS outcomes between fertile and infertile couples 
undergoing IVF? 
6. Are there differences in chemical and clinical pregnancy rates between blastocysts 
screened with qPCR or aCGH? 
7. What mechanisms can a diagnosed aneuploid cleavage stage embryo develop to 
euploid blastocyst?  
8. Are aneuploidy rates different between the polar, mid, and mural trophectoderm? 
9. Does a diagnosed aneuploid trophectoderm predict the chromosomal 
constitution of the entire blastocyst?  
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2.1 Specific aim 1.  Can we develop a technique that reconstructs a virtual 
ŝŵĂŐĞŽĨĂďůĂƐƚŽĐǇƐƚĂĨƚĞƌ^ŝŶŽƌĚĞƌƚŽ “ŵĂƉ ?ĐŚƌŽŵŽƐŽŵĂůmosaicism? 
For this specific aim, the following published works are presented: 
Taylor TH ?tŝŶŐZ ?'ƌŝĨĨŝŶ< ? ? ? ? ? ?ƚĞĐŚŶŝƋƵĞƚŽ “ŵĂƉ ?ŵŽƐĂŝĐŝƐ ĂƚƚŚĞďůĂƐƚŽĐǇƐƚ
stage using comprehensive chromosome screening. Fertil Steril. 104;3:e274. 
 
Taylor TH, Griffin DK, Katz SL, Crain JL, Johnson L, Gitlin SA. 2015. Technique to isolate 
individual cells of the human blastocyst and reconstruct a virtual image of their location. 
J Clin Embryo. 18;2:31-38. 
 
Taylor TH, Griffin DK, Katz SL, Crain JL, Johnson L, GitůŝŶ ^ ?  ? ? ? ? ? dĞĐŚŶŝƋƵĞ ƚŽ  ‘ŵĂƉ ?
chromosomal mosaicism at the blastocyst stage. Cytogenet Genome Res. 149;262-66. 
 
 
2.1.1 My Personal Contribution to the Work  
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
Dr. Nathan Treff helped with the idea of biopsing in sections; however, I developed the 
technique to isolate individual cells.  Moreover, I analyzed the data, and wrote the 
manuscript. 
 
2.1.2 Chapter Summary 
The purpose of this proof of concept study is to identify a technique that allows for CCS 
of individual cells within the human blastocysts along with the approximation of their 
location in the trophectoderm relative to the ICM.  Three blastocysts were held by a 
holding pipette and the ICM was removed.  While still being held, the blastocyst was 
further biopsied into quadrants.  To separate the individual cells from the biopsied 
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sections, the sections were placed in Ca2+/Mg2+ free medium with serum for 20 minutes.  
A holding pipette was used to aspirate the sections until individual cells were isolated.  
Individual cells from each section were placed into PCR tubes and prepped for either 
aCGH or NGS.  A total of three blastocysts underwent the segregation technique.  Of 
those, the first blastocyst was analyzed by aCGH and the second and third were analyzed 
by NGS.  From the first blastocyst, analyzed with aCGH, a total of 18 cells were sent for 
analysis, 15 (83.3%) amplified and provided a result and three (16.7%) did not.  Fifteen 
cells were isolated from the trophectoderm, 13 (86.7%) provided an aCGH result while 
two (13.3%) did not amplify.  Twelve cells were euploid (46, XX) while one was complex 
abnormal (44, XX) presenting with monosomy 7, 10, 11, 13, 19 and trisomy 14, 15, 21.  A 
total of three cells were isolated from the ICM, two were euploid (46, XX) and one did not 
amplify.  The second and third blastocysts underwent NGS.  Twenty-eight and 23 
individual cells were isolated from those blastocysts, respectively.  From the second 
blastocyst, two trophectoderm pieces and the ICM were mosaic.  Of the 22 cells isolated 
from the trophectoderm, 15 (68.2%) were euploid, three (13.6%) were aneuploid, and 
four (18.2%) returned no result.  Of the six cells isolated from the ICM, five (83.3%) were 
euploid and one (16.7%) was aneuploid.  From the third blastocyst, two trophectoderm 
pieces were mosaic, while the ICM was euploid.  A total of 20 cells were analyzed from 
the trophectoderm, nine (45.0%) were euploid, three (15.0%) were aneuploid, and 7 
(35.0%) returned no result.  Of the three cells analyzed from the ICM, two (66.7%) were 
euploid and one (33.3%) returned no result.  Since the blastocyst sections were biopsied 
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in regard to the position of the ICM, it was possible to reconstruct a virtual image of the 
ďůĂƐƚŽĐǇƐƚǁŚŝůĞƉƌĞƐĞŶƚŝŶŐǁŝƚŚĞĂĐŚĐĞůů ?ƐŝŶĚŝǀŝĚƵĂů^ƌĞƐƵůƚƐ ? 
 
2.1.3 Introduction 
The presence of two or more distinct cell lines, commonly referred to as chromosomal 
mosaicism, is one of the potential pitfalls when analyzing embryos by CCS.  The ability to 
detect mosaicism accurately is determined by the technology used, number of 
chromosomes examined and number of cells analyzed (Taylor et al., 2014a).  Even if 
mosaicism is present, the impact on subsequent development varies depending upon 
which chromosome is involved and at what stage the chromosomal abnormality occurs 
(Taylor et al., 2014a). 
CCS requires that the cells be pipetted into a PCR tube for analysis rather than fixed on a 
slide as previously performed with FISH studies (Magli et al., 2000).  To examine individual 
cells, each cell needs to be pipetted individually into a PCR tube, and each tube must 
undergo the CCS procedure.  This makes the process labor intensive and expensive 
compared to FISH.   
Although multiple studies have examined mosaicism at the blastocyst stage with CCS, 
these studies have all involved biopsied sections with multiple cells in each section, 
perhaps masking the true extent of mosaicism (Capalbo et al., 2013b; Liu et al., 2012; 
Fragouli and Wells, 2011).  The examination of individual cells at the blastocyst stage is 
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particularly important to gain insight into possible origins and mechanisms of mosaicism, 
such as non-disjunction, endoreplication, anaphase lag, uniparental disomy, and their 
prevalence during preimplantation development (Taylor et al., 2014a).  Indeed, 
mosaicism could be responsible both for false negative and false positive PGS diagnoses 
(Haddad et al., 2013; Werner et al., 2014).  
In this present study, I expand upon a novel technique, by which individual cells of a 
blastocyst could be isolated and a virtual image of the blastocyst with CCS results could 
be created (Taylor et al., 2016a).  Unfortunately, the previous study did not perform CCS.  
With this report, I have successfully isolated individual cells from the blastocyst, mapped 
their location in reference to the ICM, and successfully performed CCS on the individual 
cells.  This proof of concept study could allow insights into the mechanism through which 
mosaicism arose in the blastocyst.  
 
2.1.4 Methods 
This study was approved by an institutional review board (WIRB #1138244) and utilized 
blastocysts deemed not viable and destined for discard.  The University of Kent Research 
Ethics Advisory Group also approved this study. 
 One blastocyst from a 33 year old patient and two poor quality blastocysts from a 37 year 
old, donated to research, that did not initially have AH, underwent the following 
procedure.  The whole blastocyst was placed into a 20 µL drop of Ca2+/Mg2+ free medium 
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(Cooper/Sage, Trumbull, CT, USA) with 10% SSS (Irvine Scientific, Santa Ana, California, 
USA) and overlayed by oil (Irvine Scientific, Santa Ana, California, USA).  The blastocyst 
was held with a holding pipette (Origio, Denmark), positioning the ICM at tŚĞ ?Ž ?ĐůŽĐŬ
position (Figure 23A).  A laser was used to create a hole in the trophectoderm at the 3 
Ž ?ĐůŽĐŬ ƉŽƐŝƚŝŽŶ ?   ďŝŽƉƐǇ ƉŝƉĞƚƚĞ ǁĂƐ ŝŶƐĞƌƚĞĚ ŝŶƚŽ ƚŚĞ ďůĂƐƚŽĐǇƐƚ ĂŶĚ ƚŚĞ /D ǁĂƐ
removed with gentle suction and isolated (Figure 23B).  The ICM was removed from the 
drop and placed into another drop of Ca2+/Mg2+ free with 10% SSS.  Using a similar 
method, Capalbo and colleagues (2013b) demonstrated a 2% trophectoderm 
contamination rate when removing the ICM.   
The blastocysts underwent four further biopsies, thereby separating the blastocyst into 
quadrants (Figure 23C and Figure 23D).  After each biopsy, the biopsy needle was changed 
and the biopsied piece was pipetted out of the biopsy drop and into an individual drop of 
Ca2+/Mg2+ free medium + 10% SSS for 20 minutes (Figure 23E).  This process was repeated 
after each section so there was no cross contamination or mislabeling of sections during 
the procedure.  After 20 minutes, a holding pipette was used to gently aspirate the 
sections of the blastocysts (Figure 23F).  Doing so allowed the sections of the blastocyst 
to break apart into smaller pieces.  Therefore, multiple, individual cells were obtained 
from each quadrant (Figure 23G).  
The cells of the blastocyst were identified under a dissecting scope.  Cells were rinsed in 
wash solution and prepped for aCGH or NGS.   
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Figure 23: (A) The whole blastocyst with the quadrants and ICM marked prior to biopsy.  
(B) Blastocyst undergoing ICM removal, the quadrants are marked.  (C) The blastocyst 
ĚƵƌŝŶŐƚŚĞďŝŽƉƐǇŽĨƚŚĞ “ ?ƋƵĂĚƌĂŶƚ ?dŚĞ “ ?ƋƵĂĚƌĂŶƚŚĂƐĂůƌĞĂĚǇďĞĞŶďŝŽƉƐŝĞĚ ? ? )
dŚĞďůĂƐƚŽĐǇƐƚĂĨƚĞƌƚŚĞďŝŽƉƐǇŽĨ/D ?ƋƵĂĚƌĂŶƚ “ ? ?ĂŶĚƋƵĂĚƌĂŶƚ “ ? ? ? )YƵĂĚƌĂŶƚ
 “ ?ŽĨƚŚĞďůĂƐƚŽĐǇƐƚƉƌŝŽƌƚŽƐĞƉĂƌĂƚŝŽŶŝŶƚŽƐŝŶŐůĞĐĞůůƐ ? ?& )YƵĂĚƌĂŶƚ “ ?ďĞŝŶŐƉŝƉĞƚƚĞĚ
ƚŚƌŽƵŐŚƚŚĞŚŽůĚŝŶŐƉŝƉĞƚƚĞ ? ?' )/ŶĚŝǀŝĚƵĂůĐĞůůƐŽĨYƵĂĚƌĂŶƚ “ ?ƉƌŝŽƌƚŽƉůĂĐĞŵĞŶƚŝŶƚŽ


















From the first blastocysts, a total of 18 cells from one blastocyst were sent for aCGH.  Of 
the 15 cells isolated from the trophectoderm, 13 (86.7%) provided a result while two 
(13.3%) did not amplify.  Twelve were euploid (46, XX) and one was complex abnormal 
(44, XX) presenting with monosomy 7, 10, 11, 13, 19 and trisomy 14, 15, 21.  The complex 
ĂŶĞƵƉůŽŝĚĐĞůůǁĂƐůŽĐĂƚĞĚŝŶƌĞŐŝŽŶ “ ? ?ǁŚŝĐŚŝƐĨƌŽŵƚŚĞƉŽůĂƌƚƌŽƉŚĞĐƚŽĚĞƌŵĂĚũĂĐĞŶƚ
to the ICM (Figure 24).  A total of three cells were isolated from the ICM, 2 (66.7%) were 
euploid and one did not amplify (Figure 24; Table 1).  
Table 1: Chromosomal results of individual cells within the first blastocyst, tested by 
aCGH. 
Section Cell No. Result 
ICM 
1 46, XX 
2 46, XX 
3 None 
Troph A 
1 46, XX 
2 46, XX 
3 Complex 
Troph B 
1 46, XX 




1 46, XX 
2 46, XX 
3 46, XX 
4 46, XX 
5 46, XX 
Troph D 
1 46, XX 
2 46, XX 
3 46, XX 
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Figure 24:  Reconstructed trophectoderm and ICM of the first blastocyst analyzed with 
aCGH. 
 
A second and third blastocyst underwent the same procedure but testing was performed 
with NGS.  A total of 26 and 23 cells were analyzed from these blastocysts, respectively.  
Both blastocysts exhibited evidence of mosaicism.  In the second blastocyst, 24 of 28 
(92.3%) cells received a diagnosis resulting in four different cell lines.  In the third 
blastocyst, 13 of 23 (56.5%) cells received a diagnosis, resulting in three different cell lines.  
Any cell presenting with 3 or more aneuploidies was classified as complex aneuploid.   
From the second blastocyst (table 2) tested with NGS, 20/28 (71.3%) cells were euploid, 
four (14.3%) were aneuploid, and four (14.3%) returned no result.  Of the four 
trophectoderm sections, two were mosaic.  Moreover, the ICM was also mosaic (with a 
single cell displaying a complex pattern and the remainder euploid).  Of the 22 cells 
isolated from the trophectoderm, 15 (68.2%) were euploid, three (13.6%) were 
aneuploid, and four (18.2%) returned no result.  Of the six cells isolated from the ICM, five 
(83.3%) were euploid and one (16.7%) was aneuploid.  A reconstructed image of this 
blastocyst is shown in Figure 25. 
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Table 2: Chromosomal results of individual cells within the second blastocyst, tested by 
NGS. 
Section Cell No. Result 
ICM 
1 46, XX 
2 46, XX 
3 46, XX 
4 46, XX 
5 46, XX 
6 Complex 
Troph A 
1 46, XX 
2 46, XX 
3 46, XX 
4 46, XX 
5 46, XX 
Troph B 
1 46, XX 
2 47, XX, +6 
3 46, XX 
4 None 
5 45, XX, -22 




3 46, XX 
4 46, XX 
Troph D 
1 47, XX, +4 
2 None 
3 46, XX 
4 46, XX 
5 46, XX 






Figure 25: Reconstructed trophectoderm and ICM of the second blastocyst, as analyzed 
by NGS.  
 
From the third blastocyst (table 3), 12/23 (52.2%) of the cells were euploid, three (13.0%) 
cells contained a single aneuploidy, and 8 (34.8%) cells returned no result.  Of the four 
sections of the trophectoderm, two were mosaic.  The ICM was uniformly euploid.  A total 
of 20 cells were analyzed from the trophectoderm, 10 (50.0%) were euploid, three 
(15.0%) were aneuploid, and 7 (35.0%) returned no result.  Of the three cells sent from 
the ICM, two (66.7%) were euploid and one (33.3%) returned no result.  A reconstructed 






Table 3: Chromosomal results of individual cells within the third blastocyst as tested by 
NGS. 
Section Cell No. Result 
ICM 
1 46, XX 
2 None 














1 45, XX, -8 




1 46, XX 
2 46, XX 
3 46, XX 
4 47, XX, +6 
5 46, XX 
6 46, XX 
 
2.1.6 Discussion  
This project describes a novel approach that is believed to be the first to combine isolation 
of individual blastocyst cells with the utilization of CCS.  This powerful approach can be 
used to determine the extent of mosaicism in the human blastocyst.  Moreover, by 
examining the CCS results of individual cells within the blastocyst, the mechanisms of 
mosaicism can be determined (e.g.; non-disjunction, uniparental disomy, 
endoreplication, or anaphase lag; Taylor et al., 2014a).  I must caution however, that this 
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study utilized poor quality blastocysts and it is difficult to ascertain the true nature of 
aneuploidy utilizing poor quality embryos.  
Figure 26: Reconstructed trophectoderm and ICM of blastocyst number two tested with 
NGS. 
 
Multiple studies have attempted to determine mosaicism at the blastocyst stage with 
mosaicism rates ranging from 16-70% (Liu et al., 2012; Fragouli and Wells, 2011; Northrop 
et al., 2010).  All three of these studies examined mosaicism in two to three sections of 
the trophectoderm, each containing several cells.  Examining these large of sections 
would not allow the chromosome constitution of individual cells within the blastocyst to 
be determined and thus, the true rate of mosaicism may be masked by the presence of 
multiple cells.  In order to minimize the impact of multiple cells on the rate of mosaicism, 
the chromosome results for individual cells must be examined. 
As previously mentioned, the detection of mosaicism is dependent upon on how many 
cells are analyzed.  All of these aforementioned studies examined mosaicism in these 
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large sections that contained multiple cells.  In this study, the blastocyst was mosaic but 
this mosaicism would not have been detected had individual cells been analyzed.  Eight 
individual aneuploidies were detected in the trophectoderm.  In a background of 
otherwise euploid cells I would infer that each was an individual post-zygotic error.  In the 
absence of a reciprocal pattern for each (i.e. a corresponding trisomy and monosomy of 
the same chromosome) I would infer that the +14, +15, +21 aneuploidies arose via 
independent chromosome gain (perhaps some mechanism involving endoreplication) 
and the monosomies -7, -10, -11, -13, -19 by independent chromosome loss (anaphase 
lag).  Using FISH, Delhanty and colleagues (1997) and Ioannou and colleagues (2012) 
demonstrated a lack of mitotic non-disjunction (3+1 pattern), suggesting that mitotic non-
disjunction is rare as a mechanism for post-zygotic aneuploidy in human development.  
dŚŝƐƉƌŽũĞĐƚĚŝĚŶ ?ƚƚĞƐƚŝŶĚŝǀŝĚƵĂůĐĞůůƐĂŶĚŝƚ ?ƐƉŽƐƐŝďůĞƚŚĂƚƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐƌĞĐŝƉƌŽĐĂů
ĂŶĞƵƉůŽŝĚŝĞƐǁĞƌĞ  “ŵŝƐƐĞĚ ? ? &ƵƌƚŚĞƌƐƚƵĚŝĞƐĂƌĞĐĞƌƚĂŝŶůǇǁĂƌƌĂŶƚĞĚƚŽ ŝŵƉƌŽǀĞƵƉŽŶ
this technique.   
The way mosaicism presents itself during the blastocyst stage can influence PGS results.  
For example, if a population of aneuploid cells lines are clumped within the 
trophectoderm, it is likely that the biopsy portion will remove a section of the abnormal 
cell line, thereby giving a false positive aneuploid result as the majority of the blastocyst 
is truly euploid.  Of the twelve pieces of trophectoderm biopsied, five (41.7%) contained 
an aneuploid cell line.  Only one (20.0%) would have returned an aneuploidy result, while 
the other four (80.0%) would have returned a euploid result because the majority of the 
cells were euploid.  Thus, results of CCS following blastocyst biopsy may mask the true 
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nature of mosaicism in the embryo.  The opposite (false negative) scenario is also possible 
in that the blastocyst could be diagnosed euploid when the majority of the embryo 
(including the ICM) is in fact aneuploid.   
Mosaicism in the developing fetus is well documented and can lead to a normal live birth 
with limited to no clinical consequences (Staals et al., 2003; Leon et al., 2010).  Studies in 
the mouse have shown that the fetus does not develop from the entire ICM, rather only 
a certain number of cells are destined to become the fetus (Markert and Peters, 1978).  
Thus, the ICM is responsible for both the fetus and parts of the placenta and aneuploid 
cell lines in the ICM could give rise to CPM, as could an aneuploid trophoblast with a 
euploid ICM (Haddad et al., 2013; Bianchi et al., 1993).  With this in mind, as well as simply 
determining the presence of chromosome copy number, the need to determine the origin 
of the error as well is paramount.  Approaches that can achieve this have been described 
within the last five years using SNP chips and the approach could easily be adapted to 
analysis of NGS data (Handyside et al., 2010; Gabriel et al., 2011).  Aneuploidy arising at 
meiosis tends to affect 50%-100% of embryo cells depending on whether subsequent 
post-ǌǇŐŽƚŝĐĞǀĞŶƚƐ “ƌĞƐĐƵĞ ?ƚŚĞƚƌŝƐŽŵǇ ?tĞďďet al., 1995).  Even when trisomy rescue 
occurs, uniparental disomy can arise and the majority of mosaic trisomies with adverse 
obstetric outcomes are meiotic in origin.  Conversely, many mosaic trisomies (e.g. those 
with CPM) that have arisen via post-zygotic errors proceed uneventfully to term.  Indeed 
it is likely that the majority of these remain undetected for this reason (Webb et al., 1995).  
In this study, even by analysis of only three embryos, the presence of 7 out of 32 
aneuploid cells in the trophectoderm, representing seven independent post-zygotic 
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chromosome segregation errors, would support this notion.  Importantly, these findings 
stress the need to perform a much larger similar study on a greater number of embryos 
with the ultimate aim of both improving diagnosis for PGS families and better 
understanding the nature of our own early development.  
A meiotic error should be present in the entire, or at least the majority, of cells analyzed.  
In this proof of concept study, only one cell contained aneuploidies while the remaining 
cells were euploid.  This would suggest that the error arose during mitosis and not 
meiosis.  Previous research has demonstrated that approximately 25% of polar bodies are 
aneuploid while approximately 50% of blastocysts are aneuploid (Northrop et al., 2010; 
Salvaggio et al, 2014; Taylor et al., 2014b, Taylor et al., 2014c).  Interestingly, patients 
with advanced maternal age have demonstrated a polar body aneuploidy rate of 63% 
(Geraedts et al., 2011).  This would indicate that polar bodies from patients with advanced 
maternal age have a higher rate of meiotic aneuploidy than mitotic.  A higher incidence 
of aneuploidy at the blastocyst stage would suggest that the majority of aneuploidy may 
be mitotic in origin.  However, the incidence of meiotic and mitotic aneuploidies may be 
heavily influenced by maternal age.  Indeed, previous research has indicated that mitotic 
errors are not associated with maternal age but meiotic errors are.  Moreover, mitotic 
errors are the dominant mechanism for aneuploidy within the blastocyst (McCoy et al., 
2015).  My approach described in this study will allow us to test the hypothesis that post-
zygotic aneuploidy of individual cells is commonplace in the trophoblast during human 
development but less so in the ICM.  
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This research utilized aCGH and NGS, unfortunately, this particular protocol has not been 
verified against single cells.  However, it is unknown if the tubes contained single cells or 
multiple cells.  Moreover, the amplification failure seen in this proof of concept study was 
high.  This is likely due to the fact that individual cells are incredibly small and visualization 
of cells into the tubes is extremely difficult.  Thus, the failure of the amplification may be 
due to the lack of genetic material rather than the NGS procedure.   
It cannot be overlooked that an aneuploid diagnosis could be due to an error in the CCS 
test.  Capalbo and colleagues (2015) demonstrated that aCGH overcalls aneuploidy.  
However, Capalbo and colleagues (2015) also demonstrated that on a per chromosome 
basis the accuracy of aCGH is >98%.  Another sourcĞŽĨĞƌƌŽƌĐŽƵůĚďĞĚƵĞƚŽ  “ŶŽŝƐĞ ?
ǁŝƚŚŝŶ ƚŚĞƉůŽƚŽĨ ƚŚĞ^ ƌĞƐƵůƚ ?  ^ŽŵĞE'^ƉƌŽƚŽĐŽůƐ ŵŝŶŝŵŝǌĞ  “ŶŽŝƐĞ ? ĂŶĚƉƌŽĚƵĐĞ
cleaner CCS plots, reducing the chance of misdiagnosis.  The NGS used in this study had 
not been validated on single cells when this study occurred, whereas aCGH had 
(Gutierrez-Mateo et al., 2011).  Moreover, Fiorentino and colleagues (2014) reran 192 
aCGH samples with NGS and found 191 (99.5%) were concordant.  Nonetheless, future 
studies should utilize validated NGS platforms to reduce the chances of misdiagnosis.   
Ozawa and Hansen (2011) were able to desegregate individual bovine blastocysts by 
exposure to trypsin and pipetting the blastocysts through a small glass pulled pipette.  
Similarly, this project utilized a holding pipette designed for holding the oocyte or embryo 
during micromanipulation procedures.  This pipette had a very small bore size and 
assisted in the separation of cells from the trophectoderm.  This technique could also 
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prove valuable for human embryonic stem cells (hESC).  Often times these cells are in 
clumps and clusters and the isolation of single hESC may be desired for hESC culture.  
Prowse et al. (2009) performed a similar process, by which clumps of hESC were washed 
with Ca2+/Mg2+.  After the wash, they added trypsin to help in the dissociation of cells.  
Similarly, Hasegawa and colleagues (2006) also disassociated clumps of hESC into 
individual cells using trypsin.  Trypsin was not added to the blastocyst cells and it is 
unknown if this would have aided in separation.  In these studies, trypsin was used on 
hESC whereas this study dealt with trophectoderm cells and trypsin may not separate 
trophectoderm cells as easily as hESC cells.  Ca2+/Mg2+ free media was utilized because it 
was readily available and has been used in conjunction with CCS tests and embryo biopsy 
for years and its influence on CCS results would be minimal (Orris et al., 2010).  Another 
problem is the difficulty in the visualization of the cells after isolation.  One suggestion 
could be the addition of a hypotonic solution to the isolated cells, thereby allowing them 
to swell and become more easily distinguishable under a microscope (Drey et al., 2013).  
Another technique referred to as optical tweezing allows for the control of small particles 
and possibly could be used to isolate individual cells (Grier, 2003; Prada et al., 2016).  
However, this technique would require an expensive piece of equipment and training, 
neither that this technique requires.   
Given the success with this proof of concept study, larger studies are certainly warranted, 
despite the cost of CCS.  Even increasing the number of blastocysts to 10 would utilize 
approximately 200-250 CCS tests and patients may present with different rates of 
mosaicism thereby making a well-designed, high powered study difficult and costly.  
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These findings stress the need to perform a similar study on a greater number of embryos 
with the ultimate aim of both improving diagnosis for PGS families and better 
understanding the nature of our own early development. 
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2.2 Specific aim 2.  What is the reproductive potential of poor quality 
blastocysts that would be discarded? 
For this specific aim, the following published works are presented: 
Taylor TH, Patrick JL, Das D, Gitlin SA, Katz SL, Griffin DK. Clinical experience transferring 
embryos deemed unbiopsiable and unfreezeable on day 6 of a fresh in-vitro fertilization 
cycle.  Submitted 2017. 
 
2.2.1 Personal Contribution to the Work 
For this study I did the majority of the embryology including setup and transfers.  I 
developed the idea, analyzed the data, and wrote the manuscript. 
 
2.2.2 Chapter Summary 
During course of extended culture, embryos must be of sufficient quality to frozen, 
transferred, or biopsied.  The reproductive potential of these embryos that are of not 
sufficient quality to be frozen, transferred, or biopsied is not known.  The purpose of this 
study is to determine the reproductive potential of poor quality embryos transferred ET 
on day 6 of a fresh IVF cycle.  Patients undergoing routine IVF treatment with no 
preimplantation genetic screening, with a fresh day 6 ET where implantation and live birth 
was either 100% or 0%.  Of the 256 IVF cycles that had a day 6 ET, 100 cycles had good 
quality blastocysts (group 1), 88 cycles had fair quality blastocysts (group 2), and 79 cycles 
had poor quality embryos transferred (group 3).  The control group were all other cycles 
that had a day 6 ET during their fresh IVF cycle and the embryo that implanted could not 
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be determined (group 4).  A total of 159, 132, 130, and 147 embryos were transferred in 
groups 1, 2, 3, and 4 respectively.  Implantation rates were significant between group 1 
(74/159, 42.8%), group 2 (40/132, 30.3%), group 3 (5/130, 3.8%), and group 4 (65/147, 
44.2%; P<0.0001).  Live births were significantly higher between group 1 (61/159, 38.4%), 
group 2 (29/132, 22.0%), group 3 (2/130, 1.5%), and group 4 (49/147, 33.3%; P<0.0001).  
When poor quality embryos are subdivided based on morphology, only full blastocysts 
exhibited the ability to result in a live birth.  A total of 26 full blastocysts were transferred 
on day 6 of a fresh IVF cycle, and only 2 (7.7%) resulted in a live birth.  This data suggest 
that poor quality day 6 embryos have a minimal chance of resulting in a live born.  
Therefore, the utilization of only good and fair quality embryos during extended culture 
is warranted.  
 
2.2.3 Introduction 
Extended culture to the blastocyst stage has become a routine practice in the field of IVF 
and has been credited with an increase in pregnancy rates while decreasing multiples 
(Gardner and Lane, 1997; Gardner et al., 1998).  Furthermore, extended culture allows 
for the ability to more accurately select embryos capable of a live born and more optimal 
synchronization between embryo and endometrium compared to cleavage stage transfer 
(Jones and Trounson, 1999; Tsirigotis, 1998).   
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Although research indicates that extended culture can lead to higher implantation rates, 
the correct patient population that this technology has been shown to be beneficial has 
ďĞĞŶĐŽŶĨůŝĐƚŝŶŐ ?&ŽƌĞǆĂŵƉůĞ ?ƐƚƵĚŝĞƐƌĂŶĚŽŵŝǌŝŶŐ “ŐŽŽĚ ?ƉƌŽŐŶŽƐŝƐƉĂƚŝĞŶƚƐƚŽĞŝƚŚĞƌ
cleavage stage or blastocyst stage transfer have shown a beneficial effect when the latter 
ŝƐƵƚŝůŝǌĞĚ ?ǁŚŝůĞƐƚƵĚŝĞƐŝŶĂŐĞŶĞƌĂůŽƌ “ƉŽŽƌ ?ƉĂƚŝĞŶƚƉŽƉƵůĂƚŝŽŶŚĂǀĞǇŝĞůĚĞĚĐŽŶĨůŝĐƚŝŶŐ
results (Gardner et al., 1998; Coskun et al., 1000; Levitas et al., 2004; Glujovsky et al., 
2012).  One of the ƌŝƐŬƐŽĨĞǆƚĞŶĚĞĚĐƵůƚƵƌĞŝŶĂ “ƉŽŽƌ ?ƉĂƚŝĞŶƚƉŽƉƵůĂƚŝŽŶŝƐƚŚĞŝŶĂďŝůŝƚǇ
ƚŽŵĂŬĞďůĂƐƚŽĐǇƐƚƐ ŝŶǀŝƚƌŽ ?  /Ĩ ƚŚĞƐĞƉĂƚŝĞŶƚƐ ?ĞŵďƌǇŽƐĂƌĞĐƵůƚƵƌĞĚƚŽƚŚĞďůĂƐƚŽĐǇƐƚ
ƐƚĂŐĞ ƚŚĞǇ ŵĂǇ ŶŽƚ ƐƵƌǀŝǀĞ ĂŶĚ ƚŚĞƌĞĨŽƌĞ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ƚƌĂŶƐĨĞƌ ǁŝůů ďĞ ĐĂŶĐĞůĞĚ ?
Papanikolaou and colleges (Papanikolaou et al., 2008) demonstrated an increase in 
canceled transfers when a general patient population utilized extended culture rather 
ƚŚĂŶ “ŐŽŽĚ ?ƉƌŽŐŶŽƐŝƐƉĂƚŝĞŶƚƐ ? 
As previously mentioned, a benefit of extended culture is the ability to select those 
embryos that are most likely to result in a live birth (Gardner et al., 1998).  Studies have 
demonstrated that the transfer of a single blastocyst does not drastically lower live birth 
rate but does significantly reduce the risk of twins (Mullin et al., 2010).  Unfortunately, 
extended culture is also decreasing additional embryos available to the patient because 
only good or fair quality blastocysts are transferred or cryopreserved (Papanikolaou et al., 
2008; Papanikolaou et al., 2005; Papanikolaou et al., 2006). 
More recently, extended culture is being utilized for blastocyst biopsy and freeze all cycles 
(Schoolcraft et al., 2009; Shapiro et al., 2011).  During these processes is typical to only 
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utilize good or fair quality blastocysts whilst discarding the remaining poor quality 
embryos (Taylor et al., 2014b, Taylor et al., 2014c).  Therefore, the reproductive potential 
of those discarded, poor quality embryos is unknown.  It is the goal of this study to 
determine the reproductive potential of poor quality embryos that would have otherwise 
been discarded during extended culture.  I hypothesize that poor quality embryos have 
minimal reproductive potential and that utilization of only good and fair quality, 
blastocysts during extended culture is warranted.   
 
2.2.4 Methods 
This study is retrospective in nature and was deemed exempt from institutional review 
board (Sterling IRB, #4445).  Only cycles in which patients undergoing IVF at Reproductive 
Endocrinology Associates of Charlotte between 2008 and 2014 that had a fresh embryo 
transfer on day 6 were included in this study.  No patients undergoing PGS were included 
in this study.  Patients only had a transfer on day 6 during a fresh IVF cycle if the most 
advanced embryos on day 5 could not be selected.  Due to this, embryos were given one 
more day in culture to correctly identify the best embryo.  Only cycles in which embryo(s) 
transferred could be correctly identified as implanted (i.e., an implantation rate of 100% 
or 0%) were included in the data analysis.  All cycles that had a day 6 transfer were 
subdivided into three groups.  Group 1 were cycles in which only good quality blastocysts 
were implanted, group 2 were cycles in which only fair quality blastocysts were 
implanted, and group 3 were cycles in which only poor quality embryos were implanted.  
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The control group were those patients that had a day 6 ET during a fresh IVF cycle 
whereby the embryos that implanted could not be identified (Figure 27). 
 
2.2.4.1 Oocyte and Embryo Culture 
Oocytes were retrieved from follicular aspirations.  All oocytes were designated for ICS); 
therefore, all oocytes were trimmed of excess cumulus cells and pipetted into 10 µL drops 
of Cumulase (Origio, Mt. Laurel, New Jersey, USA) covered in oil (Irvine Scientific, Santa 
Ana, California, USA) at 37C.  While exposed to Cumulase, oocytes were stripped of 
cumulus cells with the use of increasing smaller diameter pipette tips until the oocytes 
were cleaned of all cumulus cells.  Oocytes were then rinsed in Hepes (Cooper Surgical, 
Trumbull, Connecticut, USA) buffered media with 10% SSS (Irvine Scientific, Santa Ana, 
California, USA).  Because this data analysis encompassed such a large time period; two 
different culture systems were implemented.  From January 2008 to March 2011, a 
sequential culture system with sage protein plus (Cooper Surgical, Trumbull, Connecticut, 
USA) overlayed with oil Irvine (Scientific, Santa Ana, California, USA) and from March 
2011-December 2014, CSC+10%SSS overlayed with oil was used.  Oocytes were 
segregated based on maturity and pipetted into culture drops overlayed with oil and 
placed into the incubator at 370C with 95% N2 and 5% CO2 for one and half hours prior 
to ICSI. 
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ICSI was performed as previously described by Nagy and colleagues (1995).  Briefly, a 
single sperm was injected into an oocyte while the polar body was located at the 12 
Ž ?ĐůŽĐŬƉŽƐŝƚŝŽŶ ?ĨƚĞƌ/^/ ?ŽŽĐǇƚĞƐǁĞƌĞƌĞƚƵƌŶĞĚƚŽƚŚĞŝŶĐƵďĂƚŽƌƵŶƚŝů ? ?-18 hours. 
Oocytes presenting with two pronuclei and two polar bodies were deemed successfully 
fertilized.  Those that were fertilized were placed back into the incubator until day 3.  
Embryos were not visualized on day 2.  On day 3, embryos were removed from the 
incubator and examined for cell number, fragmentation, and symmetry.  After 
observation, all embryos were placed back into the incubator.  On day 4, embryos were 
removed from the incubator and visualized, embryo quality recorded, and returned to 
the incubator.  On day 5, embryos were removed from the incubator and observed.  If the 
best embryos were a morula or less on day 5, no transfer was performed, and embryos 
were given to day 6 to demonstrate viability by continuing progression. 
On day 6, those embryos that progressed to at least the morula stage were transferred 
into the patient.  Pregnancy was detected with beta hCG levels at 10 days post ET.  Those 
patients that presented with a positive hCG level were continually monitored with blood 
and ultrasound.  After 6 weeks, those presenting with a fetal cardiac heartbeat were 
released from the IVF practice to be monitored by their physician.   
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Figure 27: Flow chart of inclusion criteria. 
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2.2.4.2 Blastocyst Grading 
Embryos were graded identically on day 5 and day 6.  Embryos were given a grade of 
 “ŐŽŽĚ ? ? “ĨĂŝƌ ? ?Žƌ “ƉŽŽƌ ? ?ŵďƌǇŽƐƚŚĂƚǁĞƌĞĂŶĞĂƌůǇďůĂƐƚŽĐǇƐƚ ?ŵŽƌƵůĂ ?ŽƌĞĂƌůǇŵŽƌƵůĂ
ǁĞƌĞĐŽŶƐŝĚĞƌĞĚ “ƉŽŽƌ ?ƋƵĂůŝƚǇ ?ƚŚĞƌĞĨŽƌĞ ?ŽŶůǇƉŽŽƌƋƵĂůŝƚǇĞŵďƌǇŽƐĂƌĞembryos that 
would not be biopsied during a PGS cycle.  Only expanded blastocysts, hatching 
ďůĂƐƚŽĐǇƐƚƐ ?ŽƌŚĂƚĐŚĞĚďůĂƐƚŽĐǇƐƚƐƌĞĐĞŝǀĞĚĂŐƌĂĚĞŽĨ “ŐŽŽĚ ?Žƌ “ĨĂŝƌ ? ?ůĂƐƚŽĐǇƐƚƐǁĞƌĞ
graded based on the number and symmetry of cells within the trophectoderm and ICM.  
Grades of the trophectoderm and ICM ǁĞƌĞŐŝǀĞŶĂŶ “ ?ĨŽƌŐŽŽĚ ? “ ?ĨŽƌĨĂŝƌ ?Žƌ “ ?ĨŽƌ
ƉŽŽƌƋƵĂůŝƚǇ ?ŶǇďůĂƐƚŽĐǇƐƚƐƚŚĂƚƌĞĐĞŝǀĞĚĂŐƌĂĚĞŽĨ “ ?ĨŽƌĞŝƚŚĞƌƚŚĞ/DĂŶĚ ?ŽƌƚŚĞ
ƚƌŽƉŚĞĐƚŽĚĞƌŵǁĂƐĐŽŶƐŝĚĞƌĞĚ “ŐŽŽĚ ?ƋƵĂůŝƚǇ ?ůĂƐƚŽĐǇƐƚƐǁŝƚŚŐƌĂĚĞƐŽĨ “ ?ĨŽƌďŽƚŚ
ƚŚĞ/DĂŶĚƚƌŽƉŚĞĐƚŽĚĞƌŵǁĞƌĞĐŽŶƐŝĚĞƌĞĚ “ĨĂŝƌ ?ƋƵĂůŝƚǇ ?ůĂƐƚŽĐǇƐƚƐƚŚĂƚƌĞĐĞŝǀĞĚĂ
ŐƌĂĚĞŽĨ “ ?ĨŽƌĞŝƚŚĞƌƚŚĞ/DĂŶĚ ?ŽƌƚƌŽƉŚĞĐƚŽĚĞƌŵǁĞƌĞĐŽŶƐŝĚĞƌĞĚ “ƉŽŽƌ ?ƋƵĂůŝƚǇ ? 
 
2.2.5 Results 
Only patients in which the good, fair, or poor quality embryos could be determined to 
implant and result in live birth were included in this study.  A total of 256 cycles had a day 
6 fresh ET.  Of those, 100 cycles had a day 6 transfer in which only good quality blastocysts 
(group 1) implanted, 88 cycles had a day 6 transfer which only fair quality blastocysts 
(group 2) implanted, and 79 cycles had only poor quality embryos (group 3) implanted.  
Out control group were those cycles which patients had a day 6 ET and it is unknown 
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which embryos implanted.  A total of 159, 132, 130, and 147 embryos were transferred 
in group 1, group 2, group 3, and the control group, respectively.  Maternal age at time of 
retrieval was significant between group 1 (32.6±3.9 years), group 2 (33.7±4.2 years), 
group 3 (35.0±4.6 years), and control (34.0±4.4; P=<0.001; Table 4). 
Table 4: Cycle characteristics of patients undergoing a fresh embryo transfer on day 6 of 
an IVF cycle. 
 














No. Cycles 100 88 79 62  
Avg. Maternal 
Age (± SD) 
32.6±3.9a 33.7±4.2 35.0±4.6a 34.0±4.4 <0.0011 
No. Embryos 
d ?Ě 




2.0±0.4b 2.2±0.6 2.2±0.7 2.4±0.7b <0.0011 
No. Implantation 
(%) 
74 (42.8%) 40 (30.3%) 5 (3.8%) 65 (44.2%) <0.0012 
No. Fetal Cardiac 
Activity (%) 





13 (17.6%) 11 (27.5%) 3 (60.0%) 16 (24.6%) 0.13422 
No. Live Birth 
(%) 
61 (38.4%) 29 (22.0%) 2 (1.5%) 49 (33.3%) <0.0012 
1 = Kruskal-Wallis Test 2 = Chi-square test       
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Average number of embryos transferred was significant between group 1 (2.0±0.4), group 
2 (2.2±0.6), group 3 (2.2±0.7), and control (2.4±0.7; P=0.0045; Table 4).  Implantation 
rates, as defined by the detection of a gestational sac, were significant between group 1 
(74/159, 42.8%), group 2 (40/132, 30.3%), group 3 (5/130, 3.8%), and control (65/147, 
44.2%; P<0.001; Table 4).  Likewise, fetal cardiac heartbeats were significant between 
group 1 (68/159, 42.8%), group 2 (35/132, 26.5%), group 3 (2/130, 1.5%) and control 
(56/147, 38.1%; P<0.001).  Live born rates was also significant between group 1 (61/159, 
38.4%), group 2 (29/132, 22.0%), group 3 (2/130, 1.5%), and control (49/147, 33.3% 
P<0.001; Table 4). 
When poor quality embryos are subdivided based on morphology, only full blastocysts 
exhibited the ability to result in a live birth.  No early morulas (n=3), morulas (n=9), early 
blastocysts (n=39), blastocysts (n=28), or expanded blastocysts with either a  “ ?ŐƌĂĚĞ
trophectoderm or ICM (n=25), resulted in a live birth (Table 5).  A total of 26 full 
blastocysts were transferred on day 6 of a fresh IVF cycle, and only 2 (7.7%) resulted in a 
live birth (Table 6).   
 
2.2.6 Conclusion 
This data supports the hypothesis that poor quality embryos have a very minimal chance 
of resulting in a live born.  Only two poor quality embryos resulted in live births (1.5%), 
both were graded full blastocysts.  The utilization of only expanded blastocysts and better 
during extended culture cycles is warranted.  
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Table 5: Description based on grade of the ICM or trophectoderm of the blastocyst. 
ICM Grade Description 
A ICM easily distinguishable with multiple 
cells that are tightly compacted 
B ICM distinguishable with fewer cells that 
are loosely joined together 
C ICM not distinguishable or very few cells 
that are not joined together or appear 
necrotic 
  
Trophectoderm Grade Description 
A Uniform layer of cells in a continuous 
layer around the blastocoel 
B Non-uniform layer of cells around the 
blastocoel, cells may be larger and not 
continuous 
C Very few, large cells formed around the 
blastocoel, non-uniform, possibly 
necrotic 
 














0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (7.7%) 0 (0%) 0.1495 
 
Multiple reports have demonstrated implantation and live birth rates of day 6 blastocysts, 
however these tend to be good quality blastocysts.  For example, Elgindy and Elsedeek 
(2012) demonstrated that blastocysts that were expanded by day 6 had a significantly 
lower implantation rate than those blastocysts that were expanded by day 5.  In this 
study, the majority of the embryos that were expanded were deemed to be fair quality 
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embryos and the implantation rate for fair quality blastocysts was 30.3%, higher than the 
19% reported by Elgindy and Elsedeek (2012).  Similarly, Elgindy and Elsedeek (2012) 
report that the later that blastocyst expands, the lower the implantation percentage.  In 
their study, 40% of those expanded by day 5 implanted while only 19% of those that were 
expanded on day 6, implanted.  Only poor quality blastocysts that resulted in a live birth 
were graded as a full blastocyst with a poor quality ICM and poor quality trophectoderm.  
This blastocyst was expanded at time of transfer, yet was ŐƌĂĚĞĚ “ƉŽŽƌ ?ďĞĐĂƵƐĞŽĨƚŚĞ
poor quality trophectoderm and ICM.   
These data demonstrated that poor quality, unbiopsiable embryos result in live birth 
roughly 1.5% of the time.  It could be potentially higher as only cycles with 100% or 0% 
implantation were included.  Maternal age was higher in the poor quality group, possibly 
influencing the observed decrease in implantation.  There were multiple other cycles that 
had a combination of good, fair, and poor quality embryos transferred where only one or 
two embryos implanted.  It is unknown if the resultant live born derived from the good, 
fair, or poor quality embryo.  Regardless, on those cycles that I could determine the live 
birth rate of poor quality embryos, the percentage remains significantly lower.  This study 
only examined the outcomes of poor quality, unbiopsiable and unfreeze embryos at 
transfer on day 6.  It is entirely possible that extended culture as a procedure may be 
causing some embryos that would be viable to perish.  This is evident in research that 
indicates blastocyst culture and embryo transfer increases implantation rates in good 
prognosis patients but has shown no increase in implantation rates in poor quality 
patients over cleavage stage transfer (Blake et al., 2007; Weissman et al., 2008).  The term 
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 “ƵŶďŝŽƉƐŝĞĚ ?ĞŵďƌǇŽƐŝƐƐƵďũĞĐƚŝǀĞ ?ZĞƐĞĂƌĐŚŚĂƐŶŽǁĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚĞǀĞŶŵŽƌƵůĂ
stage embryos can be biopsied (Kort et al., 2016).  However, this research biopsied 
morulas on day 5 and it is possible that if cultured to day 6 that these morulas would be 
of sufficient quality to biopsy or transfer.  In our study, morulas on day 5 were cultured 
to day 6 to allow for them to demonstrate development.  Lastly, biopsy occurs when the 
blastocyst is properly developed on day 5 or day 6.  There are no published cases of good 
quality embryos on day 5 that are cultured an extra day (day 6) in order to gain more cells.  
Research has suggested a direct relationship between the number of cells taken at biopsy 
and a higher incidence of miscarriage rates; thus, if a good quality blastocyst is given more 
time to develop then the biopsy should have less of an impact (Neal et al., 2017).  Further 
research is needed to determine if this particular IVF approach is warranted. 
Along with discarding embryos during blastocyst biopsy, IVF may also be discarding 
embryos during freeze all cycles.  Freeze all cycles, in which embryos are cryopreserved 
and used in a subsequent FET cycle, have become increasingly popular due to recent 
research suggesting that the transfer of a blastocysts during an unstimulated cycle yield 
a higher pregnancy rate than transfer during a fresh IVF cycle (Shapiro et al., 2011; Coates 
et al., 2017).  The selection criteria for blastocysts cryopreserved during a freeze all cycle 
is similar, if not identical, to the selection criteria for blastocysts utilized during a 
blastocyst biopsy cycle.  Thus, many centers only biopsy those embryos that have been 
deemed as good or fair quality (Taylor et al. 2014b; 2014c).  Regardless, it seems that the 
discarding of viable embryos during the course of freeze all or blastocyst biopsy cycles 
seems to be incredibly low, approximately 1.5%. 
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In regards to using blastocyst culture in conjunction with PGS, this data suggest that poor 
quality embryos, that are otherwise unbiopsiable, although rare, can result in a live born.  
/Ŷ ŽƌĚĞƌ ƚŽ ĨƵůůǇ ŵĂǆŝŵŝǌĞ Ă ƉĂƚŝĞŶƚ ?Ɛ ĐǇĐůĞ ? ŝƚ ŵĂǇ ďĞ ďĞƐƚ ƚŽ ŬĞĞƉ ƉĂƚŝĞŶƚƐ ŽŶ
progesterone during their IVF cycle; thereby allowing them to transfer embryos that are 
not biopsiable but could potentially result in a live birth.  Although good quality 
blastocysts are typically utilized in during a blastocyst biopsy cycle, they are not the only 
embryos that can result in a live birth, and patients should be made aware of this 
limitation concerning blastocyst biopsy. 
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2.3 Specific aim 3.  Can PGS be successfully extended to previously frozen 
blastocysts by thawing, biopsing, refreezing and rethawing? 
For this specific aim, the following published works are presented: 
Taylor TH, Das D, Whitesides D, Crain JL, Wilson M, Patrick JL. 2013. Pregnancy, 
implantation, and live birth rates of blastocysts that were thawed, warmed, biopsied, 
vitrified, and rewarmed for euploid blastocysts transfer. Fertil Steril. 100;3:S134. 
Taylor TH, Patrick JL, Gitlin SA, Wilson JM, Crain JL, Griffin DK. 2014. Outcomes of 
blastocyst biopsied and vitrified once versus those cryopreserved twice for euploid 
blastocyst transfer. Reprod Biomed Online. 29:59-64. 
 
2.3.1 Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.3.2 Chapter Summary 
Trophectoderm biopsy with CCS has been shown to increase implantation and pregnancy 
rates.  Some patients desire CCS for previously cryopreserved blastocysts, resulting in 
blastocysts that are thawed/warmed, biopsied, vitrified, and warmed again.  The effect 
of two cryopreservation procedures and two thawing/warming procedures on outcomes 
has ŶŽƚďĞĞŶĞĨĨĞĐƚŝǀĞůǇƐƚƵĚŝĞĚ ?WĂƚŝĞŶƚƐ ?ĐǇĐůĞƐǁĞƌĚŝǀŝĚĞĚŝŶƚŽƚǁŽŐƌŽƵƉƐ ?ŐƌŽƵƉ ?
underwent a cryopreserved embryo transfer with euploid blastocysts that were vitrified 
and warmed once.  Group 2 had a cryopreserved embryo transfer of a euploid blastocyst 
that was cryopreserved, thawed/warmed, biopsied, vitrified, and warmed.  A total of 85 
and 17 women aged 35.6±3.9 and 35.3±4.9 years (not significantly different) were 
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included in groups 1 and 2, respectively.  The survival rate between group 1 (114 of 116, 
98.3%) and the second warming in group 2 (21 of 24, 87.5%) was significantly different 
(P=0.0463).  There was no difference between biochemical (68.2% and 62.5%) and clinical 
pregnancies (57.6% and 50.0%), implantation (58.4% and 52.4%), and live birth/ongoing 
pregnancy rates (53.9% and 47.6%) between groups 1 and 2, respectively.  Although it is 
unconventional to thaw/warm, biopsy, revitrify, and rewarm blastocysts for 
cryopreserved embryo transfer, the results indicate that outcomes are not compromised.   
 
2.3.3 Introduction 
Typically, only good quality blastocysts derived from a fresh cycle of IVF are utilized in 
trophectoderm biopsy with CCS.  This approach has yielded pregnancy outcomes higher 
than standard morphological assessment alone (Scott et al., 2013a).  Clinical pregnancy 
rates using this technology range from 60-75% which is comparable to anonymous oocyte 
donation (Grifo et al, 2013).  However promising, the utilization of this technology is 
typically limited to blastocysts derived from fresh IVF cycles. 
In order to benefit from trophectoderm biopsy and CCS, a patient has to undergo a fresh 
IVF procedure or have zygote or cleavage stage embryos previously cryopreserved 
thawed and cultured to the blastocyst stage.  There are a large number of patients who 
have had IVF previously and have good quality, unbiopsied blastocysts cryopreserved 
(Zhu et al., 2013).  These patients could simply want to utilize the current technology or 
have previous outcomes that may warrant utilization of CCS with trophectoderm biopsy.  
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For example, if a patient suffered a miscarriage or had failed attempts with fresh embryos, 
they may choose to utilize trophectoderm biopsy and CCS on previously cryopreserved 
blastocysts to allow for the transfer of a euploid embryo.   
Blastocyst biopsy involves the removal of 3-10 cells from the trophectoderm of 
blastocysts at either day 5 or 6 of culture (Scott et. al, 2013b).  If a blastocyst is biopsied 
on day 5, it is possible to get results by day 6 for a fresh transfer.  Most clinics do not 
conduct onsite CCS, therefore the majority of the time, blastocysts are vitrified post 
biopsy.  Current research indicates that the transfer of an embryo into an unstimulated 
uterus may yield higher pregnancy outcomes than a transfer during a fresh cycle (Shaprio 
et. al, 2011).   
After biopsy, the sample is sent to the genetics laboratory while the blastocysts remain 
cryopreserved awaiting results.  Even in the hands of the most experienced embryologist 
and geneticists, readings are not possible 100% of the time (Harton et al., 2011).  
dŚĞƌĞĨŽƌĞ ?ŝƚŝƐƉŽƐƐŝďůĞƚŚĂƚƚŚĞ^ƌĞƉŽƌƚǁŽƵůĚƌĞǀĞĂůĂ “ŶŽƌĞƐƵůƚ ? ?/ŶƚŚŝƐƉĂƌƚŝĐƵůĂƌ
instance, the patients are left with a cryopreserved blastocyst that has no genetic result. 
Although biopsy, obtaining CCS results, and transfer without the need to vitrify can be 
achieved, particularly with methods such as four-hour quantitative real-time polymerase 
chain reaction, this approach cannot be utilized by every IVF clinic, due to logistics (Treff 
and Scott, 201 ? ) ?ĞĐĂƵƐĞŽĨƚŚŝƐ ?ďůĂƐƚŽĐǇƐƚƐǁŝƚŚĂ  “ŶŽƌĞƐƵůƚ ? ?ĂƐǁĞůůĂƐ blastocysts 
that have been previously cryopreserved without undergoing trophectoderm biopsy 
during the fresh cycle would need to be thawed/warmed for biopsy or rebiopsy and 
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subsequently cryopreserved again while awaiting CCS results.  Furthermore, if euploid, 
these blastocysts would undergo an additional warming procedure before being 
transferred into the uterus.  Few studies have focused on patients that have previously 
cryopreserved blastocysts that undergo thawing/warming, biopsy, vitrifying, and a 
second warming prior to a cryopreserved embryo transfer.  The purpose of this study was 
to test the hypothesis that blastocysts, which were previously cryopreserved can be 
successfully utilized for subsequent trophectoderm biopsy and CCS, and to determine the 




This retrospective chart review was deemed exempt by Sterling Institutional Review 
Board.  Patients attending Reproductive Endocrinology Associates of Charlotte from 
January 1, 2009 to April 31, 2013 were included in this study.  Cycles were subdivided into 
two groups.  Group 1 (n=85 cycles, 113 blastocysts) consisted of patients who underwent 
the traditional method of trophectoderm biopsy and CCS, by having their oocytes 
retrieved via IVF, embryos cultured to the blastocyst stage, and having all viable 
blastocysts biopsied and vitrified according to laboratory protocol.  Group 2 consisted of 
cycles that had cryopreserved blastocysts and subsequently desired to have their 
blastocysts biopsied (n=19 cycles, 70 blastocysts) or those who desired a rebiopsy due to 
Ă  “ŶŽ ƌĞƐƵůƚ ?  ?ŶA? ?cycles, 3 blastocysts; Figure 27; Table 7).  Outcomes consisted of 
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biochemical pregnancy (positive beta-hCG test), clinical pregnancy (visualization of 
gestational sac on ultrasound), fetal cardiac activity (FCA), and ongoing/live birth rates. 
Figure 28: Flow chart of study design. 
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Table 7: Cycle characteristics between patients undergoing a euploid blastocyst transfer with a single vitrified and warm blastocyst 
(group 1) compared to patients that underwent euploid blastocysts transfer with twice cryopreserved and rewarmed blastocysts 
(group 2).  Group 2 is subdivided into the possible interventions. Bx=biopsy, vit=vitrification, FET=frozen embryo transfer, slow=slow 
cryopreservation, rebx=rebiopsy 











No. patients (thaws) 85 9 6 2 17  
Age at retrieval (years) 35.6±3.9 35.3±4.8 34.1±5.5 39.0±2.8 35.3±4.9 0.5314a 
No. transfers 85 9 5 2 16  
No. blastocysts 
cryopreserved 




114 (98.3%) 12 (100.0%) 7 (77.8%) 2 (66.7%) 21 (87.5%) <0.0001b 
Avg. No. transferred 
during FET 
1.3±0.6 1.3±0.5 1.2±0.8 1.0±0.0 1.2±0.6 0.7801a 
No. embryos 
transferred during FET 
113 12 7 2 21  
+hCG (%) per FET 58 (68.2%) 6 (66.7%) 4 (80.0%) 0 (0%) 10 (62.5%) 0.2105b 
+sac (%) per FET 52 (61.2%) 5 (55.6%) 4 (80.0%) 0 (0%) 9 (56.3%) 0.2655b 
+fca (%) per FET 49 (57.6%) 5 (55.6%) 3 (60.0%) 0 (0%) 8 (50.0%) 0.4453b 
Implantation (%) 66 (58.4%) 6 (46.2%) 5 (71.4%) 0 (0%) 11 (52.4%) 0.3112b 
No. clinical 
miscarriages (%) 
3 (5.8%) 0 (0.0%) 1 (25.0%) 0 (0.0%) 1 (11.1%) 0.4455b 
Live birth/ongoing (%) 61 (53.9%) 6 (46.2%) 4 (57.1%) 0 (0%) 10 (47.6%) 0.4954b 
a = one-way ANOVA         b = chi-square test for independence
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2.3.4.1 In-Vitro Fertilization and Embryo Culture 
Oocytes were retrieved under ultrasound guidance and placed in Hepes buffered solution 
(Cooper Surgical, Trumbull, Connecticut, USA) +10% serum protein substitute (SPS; 
Cooper Surgical, Trumbull, Connecticut, USA) overlayed with oil (Irvine Scientific, Santa 
Ana, California, USA).  All oocytes were designated for intracytoplasmic sperm injection 
(ICSI) and trimmed and stripped of excess cumulus cells as described by Taylor and 
colleagues (2006).  Oocytes were separated based on maturity and placed back into the 
incubator.  After 2 hours, all mature oocytes underwent ICSI (Nagy et al., 1995). 
Because this study occurred over a long period of time, two different culture systems 
were utilized.  From January 2009 to August 2012 sequential media (Cooper Surgical, 
Trumbull, Connecticut, USA) + 10% SPS overlayed with oil was used.  From September 
2012 to present, a continuous single culture media (CSC; Irvine Scientific, Santa Ana, 
California, USA) + 10% SSS (Irvine Scientific, Santa Ana, California, USA) overlayed with oil 
was utilized.  Regardless of what culture system was utilized, all oocytes and embryos 
were cultured in 95% N2, 5% C02, and 98% humidity. 
 
2.3.4.2 Trophectoderm Biopsy and aCGH 
With the aid of a laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA), all embryos from 
group 1 underwent AH on day 3.  Group 2 included blastocysts previously cryopreserved, 
these were thawed or warmed and AH was performed during the thawing/warming 
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procedure while the blastocyst was compacted.  Only blastocysts that presented with a 
good quality ICM and trophectoderm were biopsied.  Blastocysts were placed in a drop of 
modified human tubal fluid (Irvine Scientific, Santa Ana, California, USA) + 10% SSS.  
Gentle suction was applied to the blastocyst via a holding pipette (Cook Medical, 
ůŽŽŵŝŶŐƚŽŶ ? /ůůŝŶŽŝƐ ? h^ ) ? dŚĞ ŚĂƚĐŚŝŶŐ ƚƌŽƉŚĞĐƚŽĚĞƌŵ ǁĂƐ ůŽĐĂƚĞĚĂƚ ƚŚĞ  ?Ž ?ĐůŽĐŬ
position.  A biopsy pipette (Cook Medical, Bloomington, Illinois, USA) was used to gently 
ĂƐƉŝƌĂƚĞƚŚĞƚƌŽƉŚĞĐƚŽĚĞƌŵŝŶƚŽƚŚĞďŽƌĞŽĨƚŚĞŶĞĞĚůĞ ?>ĂƐĞƌƉƵůƐĞƐǁĞƌĞƵƐĞĚƚŽ “ĐƵƚ ?
the trophectoderm away from the blastocyst.  Care was taken to minimize the number of 
laser pulses needed to remove a piece of the trophectoderm.  The piece of trophectoderm 
was prepared for aCGH (Genesis Genetics, Detroit, MI, USA).  
Briefly, the tube with the sample of the trophectoderm was amplified according to 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ  ?^ƵƌĞƉůĞǆ ? ZƵďŝĐŽŶ 'ĞŶŽŵŝĐƐ ?ůƵĞŐŶŽŵĞ ?W ? ? ĂƉŝƚĂů
Park).  Those samples that produced an amplification result were labeled with Cy3 dye for 
sample DNA and Cy5 dye for reference male DNA (Bluegnome) according to 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ?  ^ĞƉĂƌĂƚĞůǇ ? ƚŚĞ ƐĂŵƉůĞ E ĂŶĚ ƌĞĨĞƌĞŶĐĞ E ǁĞƌĞ
denatured at 74oC.  After hybridization, the sample and test DNA were mixed together 
and added to the microarray (Bluegnome).  The microarrays were hybridized overnight at 
470C.  After hybridization, microarrays were washed at room temperature for 10 minutes 
in a 2x SSC with 0.05% Tween-20, 10 minutes in 1 x SSC, 5 minutes in 0.1x SSC at 600C, 
and finally 2 minutes in 0.1x SSC.  Microarray slides were scanned and analyzed by 
Bluefuse (Bluegnome; Harton et al., 2013). 
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2.3.4.3 Vitrification 
Blastocysts were individually vitrified immediately following trophectoderm biopsy.  
Blastocysts were placed in equilibration solution (Irvine Scientific, Santa Ana, California, 
USA) for 15 min and then rinsed in vitrification solution (Irvine Scientific, Santa Ana, 
California, USA) for <1 min and placed on a Cryolock® (Biodiseno, Atlanta, Georgia, USA) 
and plunged into liquid nitrogen.  
 
2.3.4.4 Warming 
The cryolock was uncapped under liquid nitrogen and plunged into 370C warming solution 
 ?/ƌǀŝŶĞ ^ĐŝĞŶƚŝĨŝĐ ? ^ĂŶƚĂ ŶĂ ? ĂůŝĨŽƌŶŝĂ ? h^ ) ?  dŚĞ ďůĂƐƚŽĐǇƐƚ ǁĂƐ  “ŬŶŽĐŬĞĚ ? ŽĨĨ ƚŚĞ
cryolock and left in the warming solution for one minute.  The blastocyst was transferred 
to dilute solution (Irvine Scientific, Santa Ana, California, USA) for three minutes, and 
finally washing solution (Irvine Scientific, Santa Ana, California, USA) for 10 minutes.  For 
group 2, where the blastocyst had not been subjected to AH in the fresh cycle, AH was 
performed in the washing solution.  After warming, blastocysts were placed into CSC+20% 
SSS overlaid with oil.  Culture media was changed in October of 2013, therefore prior to 
that date, blastocysts were placed in sequential blastocyst media (Cooper Surgical, 
Trumbull, CT, USA) + 20% SPS (Cooper Surgical, Trumbull, CT, USA).   
Twenty blastocysts were initially cryopreserved using a slow freeze protocol (Cooper 
Surgical, Trumbull, CT, USA) prior to the introduction of vitrification.  Therefore, those 
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ďůĂƐƚŽĐǇƐƚƐ ǁĞƌĞ ƚŚĂǁĞĚ ĂĐĐŽƌĚŝŶŐ ƚŽ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ  ?ŽŽƉĞƌ ^ƵƌŐŝĐĂů ?
Trumbull, CT, USA).   
Regardless of how the embryos were initially cryopreserved, vitrification was used for the 
second cryopreservation of all blastocysts after trophectoderm biopsy. 
One-way ANOVA tests were utilized for the continuous variables and chi-squared test for 
independence was utilized for categorical variables.  When comparing two categorical 
ǀĂƌŝĂďůĞƐǁŝƚŚŶA? ? ?Ă&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚ-test was used.  Logistical regression was conducted 
to adjust for female age and asses the relationship between twice cryopreserved 
blastocysts and implantation.  Regardless of test, significance was set at P<0.05. 
 
2.3.5 Results 
Only patients who underwent a cryopreserved embryo transfer with euploid blastocysts 
were included in this study.  Group 1 included 85 cycles, in women aged 35.6±3.9 years, 
who underwent a cryopreserved embryo transfer with euploid blastocysts derived from 
a fresh cycle (once vitrified).  Group 2 included 17 cycles, in women aged 35.3±4.9 years, 
who underwent a cryopreserved embryo transfer with euploid blastocysts derived from 
previously cryopreserved, thawed/warmed, biopsied (or rebiopsied), vitrified, and 
rewarmed blastocysts (twice cryopreserved).  There are multiple scenarios that may 
require this treatment approach: 1) vitrification, warming, biopsy, revitrification, 
rewarming, and cryopreserved embryo transfer, 2) slow freezing, thawing, biopsy, 
vitrification, warming, and cryopreserved embryo transfer, 3) biopsy, vitrification, 
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warming, rebiopsy, revitrification, rewarm, and cryopreserved embryo transfer.  
Therefore, group 2 was further subdivided into these three scenarios (Table 7). 
Of the 73 total blastocysts from group 2 that were thawed/warmed for trophectoderm 
biopsy and revitrified, 20 of the blastocysts were initially frozen using a slow freeze 
protocol.  Of those 20 blastocysts, 18 (90.0%) survived the initial thaw, were biopsied, and 
vitrified.  From those, only 9 blastocysts have been warmed for a cryopreserved embryo 
transfer (Table 7).  A total of 53 vitrified blastocysts were warmed from group 2 and all 53 
survived (100%).  Blastocyst survival rate following warming of blastocysts from group 1 
(114 of 116, 98.3%) compared with initial thawing/warming from group 2 (71 of 73, 
97.3%) was not significantly different.  However, the survival rate for blastocysts 
undergoing second warming in group 2 was significantly lower (21 of 24, 87.5%) 
compared with the survival rate for blastocysts warmed in group 1 (114 of 116 
blastocysts, 98.3%; P=0.0463; Table 7).  From group 2, those blastocysts that underwent 
two vitrification and warming events showed the highest rate of survival post second 
warming (12 of 12 blastocysts, 100%), compared to those that were initially slow frozen 
(7 of 9 blastocysts, 77.8%), and those that underwent two biopsies (2 of 3, 66.7%), 
however the differences failed to reach statistical significance (Table 7). 
From group 1, a total 113 euploid blastocysts were transferred in 85 cycles, with an 
average of 1.3±0.6 blastocysts per transfer (Table 7).  From group 2 a total of 21 euploid 
blastocysts were transferred in 16 cryopreserved embryo transfer cycles with an average 
of 1.2±0.6 blastocysts per transfer (Table 7).  For the cycle in which no blastocysts survived 
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on the second warming, the two blastocysts were initially slow frozen.  The blastocysts 
survived the initial thaw and were biopsied; however they did not survive the second 
warming.   
Biochemical (58 of 85, 68.2% versus 10 of 16, 62.5%) and clinical pregnancy (49 of 85, 
57.6% versus 8 of 16, 50.0%), implantation rates (66 of 113, 58.4% versus 11 of 21, 52.4%) 
were not significantly different between group 1 and group 2 respectively (Table 7). 
Logistical regression analysis adjusted for maternal age  revealed that when blastocysts 
are exposed to two cryopreservation/thawing or warming events and biopsy, 
implantation rate was not impacted (P=0.5391; OR 0.7013, 95% CI 0.2444-2.0123). 
 
2.3.6 Discussion   
These data demonstrate that previously cryopreserved blastocysts can be successfully 
thawed/warmed, biopsied, revitrified, rewarmed and utilized for CCS.  Trophectoderm 
biopsy with CCS has been implicated in higher pregnancy rates and lower spontaneous 
abortions (Forman et. al., 2012).  However, research has focused on the biopsy, 
vitrification, and subsequent cryopreserved embryo transfer of euploid blastocysts.  A 
previous case report by Peng and colleagues (2011) demonstrated that a twice vitrified 
and warmed blastocyst in conjunction with trophectoderm biopsy can achieve live birth.  
However, to my knowledge this is the first published cohort study that demonstrates the 
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effectiveness of using previously cryopreserved blastocysts for use with trophectoderm 
biopsy and CCS.  
In this study, the thawing/warming, biopsy, and revitrification, were all performed on the 
same day, which may have caused the significantly lower warming survival rates in group 
2.  Therefore, an extra day may allow the blastocysts to recover from the warming and 
biopsy procedure.  This treatment approach may prove advantageous with day 5 
blastocysts as it has been shown that there is no difference in pregnancy rates if a 
blastocyst is transferred on day 5 or day 6 (Elgindy and Elsedeek, 2012).  However, in the 
case of day 6 blastocysts, an extra day would make that embryo a day 7 blastocyst; and 
day 7 blastocysts have been shown to result in lower pregnancy rates compared to day 
5/6 blastocysts (Kovalevsky et al., 2013).  Interestingly, some reports indicate similar 
pregnancy and implantation rates between vitrified day 5, 6, and 7 blastocysts (Hiraoka 
et al, 2009a; Hiraoka et al, 2008).   
In the two cryopresĞƌǀĞĚĞŵďƌǇŽƚƌĂŶƐĨĞƌĐǇĐůĞƐŽĨƚǁŝĐĞďŝŽƉƐŝĞĚ ?ĚƵĞƚŽĂ “ŶŽƌĞƐƵůƚ ? )
and twice cryopreserved blastocysts, neither resulted in a pregnancy (Table 7).  Of the 
three blastocysts that were twice biopsied and twice cryopreserved, two (66.7%) survived 
the second warming (Table 7).  The lower survival rate could be attributed to the low 
numbers or possible removal of too many cells from the trophectoderm.  However, 
research has shown that the trophectoderm biopsy procedure is not detrimental to 
implantation and live birth rates (Scott et al., 2013b).  Conversely, any additional 
intervention has the potential to damage an embryo; therefore, it is plausible that twice 
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biopsied blastocysts are severely impacted by the biopsy procedure due to the removal 
of too many trophoblast cells.  Furthermore, blastocysts that have been biopsied once 
prior to vitrification already have a hole in the ZP.  This hole allows for the direct exposure 
of cells to the cryoprotectants, which may affect warming survival rates.  The artificial 
collapse of blastocysts with the laser results in a similar size hole in the ZP and improves 
vitrification outcomes (Iwayama et al., 2011; Mukaida et al., 2006).  Likewise, the 
vitrification of blastocysts that are hatching or hatched from the ZP is a common practice 
with IVF.  Thus, the poor results in the twice biopsy group seem to be due to the biopsy 
procedure itself rather than direct exposure of the cells to the cryoprotectant. 
There are multiple reports showing that cryopreservation of embryos twice or 
cryopreservation of oocytes followed by cryopreservation of the resultant embryos does 
not affect outcomes.  However, these reports focus on vitrification at two different stages 
of development.  Cobo and colleagues (2013) showed no differences in live births 
between fresh embryos and vitrified oocytes that were later vitrified at either the 
cleavage or blastocyst stage.  Likewise, pregnancies have been achieved from vitrified 
cleaving embryos that were warmed and revitrified at the blastocyst stage (Hiraoka et. al, 
2009b).  Montag and colleagues (2006) demonstrated that previously frozen oocytes that 
were thawed and cryopreserved again at the pronuclear stage, can result in a live birth.   
Interestingly, there is little literature describing the outcomes of embryos twice 
cryopreserved on the same day using a slow freeze protocol.  This may be due to the lack 
of sufficient data concerning the subject or the inability of the slow freeze protocols to 
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offer this type of procedure successfully.  In this study, 20 blastocysts were initially 
cryopreserved using slow freeze protocols.  Of those, 18 survived the initial thaw (90.0%), 
while all of the previously vitrified blastocysts survived the initial warming.  Furthermore, 
of the 24 twice warmed blastocysts, three (12.5%) did not survive the second warming.  
Of those three, two were previously cryopreserved with a slow protocol.  This may 
indicate that blastocysts cryopreserved with slow freeze protocols are not as able to 
survive two cryopreservation procedures compared with vitrified blastocysts, larger 
studies are needed to confirm to support this conclusion.   
Lastly, the majority of patients desiring CCS on previously frozen blastocyst utilize this 
treatment approach for family balancing or because a miscarriage occurred during their 
initial fresh transfer.  Patients that utilize CCS initially are typically those that present with 
advanced maternal age or diminished ovarian reserve; therefore, controlling for these 
two patient populations is difficult.  Further studies, using larger subsets of patients are 
needed to confirm these findings.  
Although cryopreserved embryo transfer cycles using euploid blastocysts that have been 
subjected to two cryopreservation and two thawing/warming events are slightly 
compromised, the overall viability of this procedure is encouraging.  Even though survival 
appears to be lower, the overall data suggests similar outcomes.  Current blastocyst 
vitrification protocols support the ability to vitrify, warm, biopsy, revitrify, and rewarm 
blastocysts for subsequent cryopreserved embryo transfer.   
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2.4 Specific aim 4.  To determine the clinical differences between euploid 
blastocysts that develop on day 5 as opposed to day 6? 
For this specific aim, the following published works are presented: 
Taylor TH, Welch L, Katz S, Crain JL, Wilson M, Patrick JL. 2013. Comparison of aneuploidy, 
pregnancy, and implantation rates between day 5 and day 6 blastocysts, a sibling oocyte 
study. Fertil Steril 100;3:S84. 
Taylor TH, Patrick JL, Gitlin SA, Wilson JM, Crain JL, Griffin DK. 2014. Comparison of 
aneuploidy, pregnancy and live birth rates between day 5 and day 6 blastocysts. Reprod 
Biomed Online. 29;3:305-10. 
 
2.4.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.4.2 Chapter Summary 
CCS is typically utilized for aneuploidy analysis of blastocysts.  It is believed that either day 
of blastocyst development is acceptable.  This projected examined euploidy rates and 
outcomes between day 5 and day 6 blastocysts in two studies.  First, euploidy rates were 
examined between day 5 and day 6 blastocysts on a per embryo and per patient basis.  
Second, IVF outcomes were examined when only euploid day 5 or day 6 blastocysts were 
transferred in a cryopreserved embryo transfer cycles.  With cycles that had blastocysts 
biopsied on both day 5 and day 6, day 5 blastocysts had a higher chance of being euploid 
than day 6 blastocysts, 54.6% (125/229) and 42.8% (77/180), respectively (P=0.0231).  
When euploid rates are calculated on a per patient basis, 235/421 (55.8%) day 5 and 
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184/413 (44.6%) day 6 blastocysts were euploid (P=0.0014).  In the second study, 50 
patients (36.1±4.3 years) and 39 patients (35.1±3.8 years) had only euploid day 5 or 
euploid day 6 blastocysts transferred during a cryopreserved embryo transfer.  Although 
underpowered, these data suggests that euploid day 6 blastocysts are as capable of 
positive outcomes as their euploid day 5 counterparts. 
 
2.4.3 Introduction 
The relationship between chromosomal abnormalities and embryo development has 
been previously described (Kroener et al., 2012).  Often those embryos that are slower to 
progress present with chromosomal abnormalities compared with embryos that progress 
normally (Kroener et al., 2012; Rubio et al., 2007).  However, those data were from 
chromosome analysis of cleavage stage embryos.  With the advent of trophectoderm 
biopsy, the relationship between chromosomal abnormalities and those embryos that 
develop to blastocysts can be more completely examined.  
Trophectoderm biopsy is performed when the embryo has become a blastocyst, either 
on day 5 or 6 of development.  IVF clinics typically utilize day 5 blastocysts similarly to day 
6 blastocysts, allowing them to be transferred, cryopreserved, or biopsied for 
preimplantation genetic screening.  The transfer of cryopreserved day 6 blastocysts tends 
to result in slightly lower pregnancy rates when compared with the transfer of 
cryopreserved day 5 blastocysts (Muthukumar et al., 2013).  Likewise, those embryos that 
blastulate on day 6 have been shown to give a lower pregnancy rate than those that 
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blastulate on day 5 during a fresh cycle embryo transfer (Barrenetxea et al., 2005).  Using 
a time-lapse culture system, Campbell and colleagues (2013a; 2013b) demonstrated that 
aneuploid blastocysts were slower to blastulate compared with euploid blastocysts.  The 
lower pregnancy and implantation rates associated with day 6 blastocysts could be 
attributed to spindle abnormalities, mitochondrial deficiencies, or gene expression 
(Shapiro et al., 2013; Hashimoto et al., 2013; Hsieh et al., 2004; Wood et al., 2007).  These 
deficiencies could impact the blastocysts ability to implant and develop in-utero.   
Since research has shown that embryos with poor progression tend to be chromosomally 
abnormal, then it would stand to reason that late developed blastocysts (i.e., those that 
develop on day 6 as opposed to day 5) should have higher rates of chromosomal 
abnormalities.  The purpose of this study is to test the hypothesis that blastocysts derived 
on day 6 have higher rates of chromosomal abnormalities than those derived on day 5.  
Regardless of chromosomal ploidy, a day 6 blastocyst is still one day behind in 
development, possibly indicating that an abnormality other than chromosomes is 
influencing growth.  In order to control for endometrial and embryonic synchrony, only 
cryopreserved embryo transfers into an unstimulated uterus should be considered when 
examining outcomes.  Therefore, this study compared pregnancy and implantation rates 






This study was deemed exempt from Institutional Review Board approval by Sterling IRB 
on 26th August 2013.  This project examined the differences in aneuploidy rates and 
outcomes between day 5 and day 6 blastocysts in two studies.  Only patients undergoing 
IVF, trophectoderm biopsy, and aCGH between January 2011 and April 2013 at 
Reproductive Endocrinology Associates of Charlotte (Charlotte, North Carolina, USA) 
were included in this study.  Aneuploidy rates between day 5 and day 6 blastocysts were 
compared by two different means.  First, aneuploidy rates were compared between 
patients that had trophectoderm biopsy on both day 5 and day 6 blastocysts in the same 
cycle (n=70).  If patients had trophectoderm biopsy on day 5 and not day 6, and vice-
versa, they were not included in the first calculation.  Second, the overall aneuploidy rates 
of day 5 and day 6 blastocysts were compared from all patients whom had a biopsy at the 
blastocyst stage (n=193).  The second study compared pregnancy, implantation, and live 
birth rates when only euploid day 5 (group 1, n=50) or only euploid day 6 (group 2, n=39) 
blastocysts were transferred in a subsequent cryopreserved embryo transfer.  All patients 
that had a euploid blastocyst transferred were included in this analysis. 
Because these data is not normally distributed, non-parametric tests were used.  For 
continuous variables, Wilcoxon matched pairs test and Mann-Whitney tests were utilized, 




2.4.4.1 Embryo Culture 
All oocytes were designated for ICSI.  Oocytes were retrieved, trimmed of blood, and 
stripped of cumulus cells as described by Taylor and colleagues (2006).  Oocytes were 
graded for maturity, separated, placed into a 60 mm dish (Thermo scientific, Rochester, 
New York, USA) containing 250 µL drops of CSC (Irvine Scientific, Santa Ana, California, 
USA) supplemented with 10% SSS (Irvine Scientific, Santa Ana, California, USA) and 
ŽǀĞƌůĂǇĞĚ ǁŝƚŚ  ? ŵ> ?Ɛ ŽĨ Žŝů  ?/ƌǀŝŶĞ ^ĐŝĞŶƚŝĨŝĐ ? ^ĂŶƚĂ ŶĂ ? ĂůŝĨŽƌŶŝĂ ? h^ ) ?  dŚĞ ĚŝƐŚ
containing the oocytes was placed into an incubator at 37oC, 6% CO2 and 5% O2 for 2-3 
hours.  After 2 hours, all oocytes presenting with a polar body underwent ICSI as described 
by Nagy and colleagues (1995), placed back into the same dish, and put back into the 
incubator. 
The next morning, 16-18 hours post ICSI, oocytes were evaluated for fertilization by the 
presence of two pronuclei.  Embryos that exhibited two pronuclei were group cultured in 
a fresh dish of CSC+10%SSS overlayed with oil and placed back into the incubator.  
Embryos were not viewed on day 2.   
On day 3, the embryos were removed from the incubator, graded, and AH was performed 
on all cleaving embryos with the aid of a laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, 
USA).  AH facilitated the protrusion of the trophectoderm from the ZP.  Using a pulse of 
610 µs, the ZP was breached with 2-3 shots of the laser (Zilos-tk, Hamilton Thorne, 
Beverly, Maine, USA) and was breached where there were no blastomeres that could be 
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directly affected by the laser pulse.  After breaching the ZP with the laser, the embryos 
were left in the same drop and placed back into the incubator. 
On the morning of day 5 (112-115 hours post insemination) and day 6 (136-139 hours 
post insemination), embryos were removed from the incubator, blastocysts were graded 
based on Schoolcraft and colleagues (1999), and those blastocysts that had a good or fair 
trophectoderm, which was protruding from the ZP, along with good or fair quality ICM 
were biopsied.  Blastocysts were only viewed once in the morning and at no other times.  
If the blastocysts were not suitable for biopsy in the morning of day 5, they were 
reevaluated on the morning of day 6.  Blastocysts were biopsied on day 5 or day 6, which 
ever day they met the biopsy criteria.  If embryos did not meet the criteria for biopsy on 
day 6, they were discarded.  There was no difference between blastocysts that were 
biopsied on day 5 or day 6 other than the embryos needed an extra day to reach the 
appropriate stage for biopsy. 
 
2.4.4.2 Trophectoderm Biopsy 
Blastocysts that presented with a good or fair quality ICM and trophectoderm were placed 
in a drop of modified human tubal fluid (Irvine scientific, Santa Ana, California, USA) + 
10% SSS (Irvine scientific, Santa Ana, California, USA).  Suction was applied to the 
blastocysts via a holding pipette (Humagen, Charlottesville, Virginia, USA).  A biopsy 
pipette (Humagen, Charlottesville, Virginia, USA) gently aspirated the trophectoderm into 
the biopsy needle.  A laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA), with a pulse 
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length of 610µs ?ǁĂƐƵƐĞĚƚŽ “ĐƵƚ ?ƚŚĞƚƌŽƉŚĞĐƚŽĚĞƌŵĨƌŽŵƚŚĞďůĂƐƚŽĐǇƐƚ ?ƚĂŬŝŶŐĐĂƌĞ
not to expose the trophectoderm to unnecessary laser pulses.  The piece of 
trophectoderm was prepped according to the reference laboratories procedures for 
aCGH (Genesis Genetics, Detroit, Michigan, USA).  aCGH slides were supplied by 
Bluegnome (Cambridge, United Kingdom) and were validated through FISH reanalysis of 
embryos (Fragouli et al, 2011; Capalbo et al., 2013b).  
 
2.4.4.3 Vitrification 
Blastocysts were individually vitrified immediately following biopsy.  Blastocysts were 
placed in equilibration solution (Irvine Scientific, Santa Ana, California, USA) for 15 min 
and then rinsed in vitrification solution (Irvine Scientific, Santa Ana, California, USA) for 
<1 min and placed on a Cryolock® (Biodiseno, Atlanta, Georgia, USA), plunged into liquid 
nitrogen, and capped. 
 
2.4.4.4 Warming and Cryopreserved Embryo Transfer 
The Cryolock was uncapped under liquid nitrogen and plunged into 370C warming solution 
(Irvine Scientific, Santa Ana, California, USA).  The blastocyst was visualized while in the 
ƚŚĂǁŝŶŐƐŽůƵƚŝŽŶ ? “ŬŶŽĐŬĞĚ ?ŽĨĨƚŚĞƌǇŽůŽĐŬ ?ĂŶĚƌĞŵĂŝŶĞĚŝŶƚŚĞǁĂƌŵŝŶŐƐŽůƵƚŝŽŶĨŽƌ
one minute.  The blastocyst was transferred to dilute solution (Irvine Scientific, Santa Ana, 
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California, USA) for three minutes, and a washing solution (Irvine Scientific, Santa Ana, 
California, USA) for 10 minutes before being placed into CSC+20% SSS overlaid with oil.   
After warming, blastocysts were transferred to the uterus with a Wallace catheter (Smiths 
Medical, Dublin, Ohio, USA) under ultrasound guidance.  Regardless of if the blastocysts 
were day 5 or day 6, all cryopreserved embryo transfers occurred on the sixth day of 




In the first study I calculated differences in aneuploidy rates between day 5 and day 6 
blastocysts by two different means.  First, in order to minimize patient differences, only 
patients (n=70; 35.9±3.7 years) who had blastocysts to biopsy on both day 5 and day 6 
during the same IVF cycle were included in this study.  The mean number of blastocysts 
biopsied on day 5 was 3.3±2.2 while on day 6, a mean of 2.6±1.5 blastocysts were biopsied 
(P=0.0472; Table 8).  Blastocysts biopsied on day 5 had a significantly higher chance of 
being euploid than those biopsied on day 6, 54.6% (125/229) and 42.8% (77/180), 
respectively (Table 8; P=0.0231).  When this set of data are examined on a per patient 
basis, day 5 blastocysts had a significantly higher euploid rate compared to day 6 
blastocysts, 56.0 ± 35.7% and 43.9 ± 37.2%, respectively (Table 8; P=0.0351).  With an 
alpha of 0.05 and type II error of 0.20, a power analysis reveals that 824 embryos are 
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required per group to detect a 10% difference in aneuploidy rates between day 5 and day 
6 blastocysts.  Regardless, statistical significance is achieved. 
Table 8: Differences between day 5 and day 6 blastocysts euploid rates from the same IVF 
cycle, diagnosed by aCGH (n=70; maternal age, 35.9±3.7 years). 
 Day 5 Blastocyst Day 6 Blastocyst P value 
Average No. 
Biopsied (±SD) 
3.3 ± 2.2 2.6 ± 1.5 0.0472a 
Total Biopsied 229 180  
No. Euploid (%) 125 (54.6%) 77 (42.8%) 0.0231b 
% Euploid 
mean ± SD 
56.0% ± 35.7% 43.9% ± 37.2% 0.0351a 
a = Wilcoxon matched pairs test         b = chi-square test 
The overall aneuploidy rates were also calculated on a per embryo and patient basis.  A 
total of 193 patients (35.7 ± 4.2 years) had blastocysts biopsied on day 5 and/or day 6.  Of 
the 421 and 413 blastocysts biopsied on day 5 and day 6, 235 (55.8%) and 184 (44.6%) 
were euploid, respectively (Table 9; P=0.0014).  The average percent euploid per patient 
for day 5 and day 6 blastocysts was 55.0 ± 37.5% and 45.4 ± 36.6%, respectively (Table 9; 
P=0.0286).  A power analysis with an alpha of 0.05 and type II error of 0.20, reveals that 
822 embryos are required to detect a 10% difference in aneuploidy rates. 
Table 9: Aneuploidy rates of day 5 and day 6 blastocysts.  (n=193 patients; 35.7 ± 4.2 
years) 
 
 Day 5 Day 6 P value 
Total No. Biopsied 421 413 0.0014a 
Total No. Euploid (%) 235 (55.8%) 184 (44.6%) 
% Euploid (mean ± SD) 55.0% ± 37.5% 45.4% ± 36.6% 0.0286b 
a = chi-squared test                          b = mann-whitney test 
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In the second study I examined the difference in implantation and pregnancy rates in 
patients who had only euploid day 5 versus euploid day 6 blastocysts transferred in an 
FET cycle.  Fifty patients (36.1±4.3 years) had only euploid day 5 blastocysts transferred 
during a cryopreserved embryo transfer, while 39 patients (35.1±3.8 years) had only 
euploid day 6 blastocysts transferred during a cryopreserved embryo transfer (Table 10).  
An average of 1.3±0.5 and 1.2±0.6 blastocysts were transferred from day 5 and day 6 
cryopreserved embryo transfer groups, respectively (Table 10).  Biochemical pregnancy 
rates were not significantly different when only euploid day 5 or day 6 blastocysts were 
transferred, 34/50 (68.0%) and 25/39 (64.1%), respectively (Table 10).  Clinical pregnancy 
rates were not significant when only euploid day 5 or day 6 blastocysts were transferred, 
30/50 (60.0%) and 24/39 (61.5%), respectively (Table 10).  There was no significant 
difference in implantation rates when only day 5 euploid blastocysts were transferred 
(38/65, 58.5%) compared with day 6 euploid blastocysts (26/48, 54.2%; Table 10).   
There were no statistically significant differences between the two groups according to 
Mann-Whitney Test or chi-squared test. 
With an alpha of 0.05 and in order to detect a 10% difference in implantation rates 





Table 10: Outcomes of cryopreserved embryo transfer cycles with euploid day 5 or day 6 
blastocysts, diagnosed by aCGH. 
 Day 5 blastocysts Day 6 blastocysts P Value 
No. Patients 50 39  
Maternal Age at 
Retrieval (mean±SD) 
36.1±4.3 35.1±3.8 NSa 
No. transferred 
(mean ± SD) 
1.3±0.5 1.2±0.6 NSa 
Total no. transferred 65 48  
Positive HCG test 
(%) 
34 (68.0%) 25 (64.1%) NSb 
Gestational sac (%) 30 (60.0%) 24 (61.5%) NSb 
Fetal cardiac activity 
(%) 
27 (54.0%) 23 (59.0%) NSb 
Implantation (%) 38 (58.5%) 26 (54.2%) NSb 
No. clinical 
miscarriages (%) 
4 (13.3%) 1 (4.2%) NSc 
Live birth/ongoing 
(%) 
26 (52.0%) 23 (59.0%) NSb 
a = Mann-Whitney test b = Chi-square test c A?&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ 
 
2.4.6 Discussion 
The hypothesis that day 6 blastocysts present with higher rates of chromosomal 
aneuploidy when compared with day 5 blastocysts has been validated with these data.  
This is the first study that compares blastocyst aneuploidy rates between day 5 and day 6 
blastocysts using a sibling embryo model.  This model effectively minimizes any patient 
differences that could cause bias.  Kroener and colleagues (2012) demonstrated no 
difference in aneuploidy rates between day 5 and day 6 blastocysts.  However this 
research did not utilize sibling embryos and different patient populations have widely 
varying aneuploidy rates (Thum et al., 2008; Voullaire et al., 2007).  This research utilized 
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day 3 biopsy and aneuploidy screening; the high incidence of chromosomal mosaicism in 
cleavage embryos suggests that even those that are diagnosed as aneuploid may be 
euploid (Wells et al., 2000; Northrop et al., 2010).  Mosaicism is not just an artifact of 
cleavage stage embryos but also persists at the blastocyst stage.  For example, Northrop 
and colleagues (2010) biopsied multiple pieces of trophectoderm from the same 
blastocysts and found a mosaic rate of 24%, while Fragouli and colleagues (2011) 
demonstrated a mosaic rate of 32%.  Regardless of stage, mosaicism is present during 
preimplantation development.   
This study found that the risk of aneuploidy was 10% higher in the embryos that did not 
blastulate until day 6.  This would suggest that not all blastocysts are created equal and 
that delayed development to the blastocyst stage may be caused by chromosomal errors.  
Alfarawati and colleagues (2011) found a correlation between aneuploidy and blastocyst 
morphology whereby the most advanced blastocysts had lower rates of aneuploidy 
compared with those blastocysts of slower progression.  Similarly, studies have suggested 
that euploid embryos tend to blastulate before those that are aneuploid (Campbell 
2013a; Campbell 2013b).  These data parallels these reports; however, these data also 
suggest that even those embryos that are diagnosed as euploid can develop to the 
blastocyst stage at varying rates, suggesting that other factors aside from chromosomes 
influence growth.  For example, mitochondrial, spindle abnormalities, and specific gene 
expression have all been shown to influence embryo development (Hashimoto et al., 
2013; Hsieh et al., 2004; Wood et al., 2007). 
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The use of AH may confound these data, causing embryos to artificially blastulate 
prematurely.  However, AH on day 3 and the biopsy of protruding trophectoderm at the 
blastocyst stage is a common technique and has been shown not to affect implantation 
rates (Scott et al., 2013a).  This study utilized daily observations of embryos, a technique 
that may be proven obsolete with the development of time-lapse equipment (Kirkegaard 
et al., 2013; Montag et al., 2013; Sundvall et al., 2013).  However, daily observations are 
routine procedures for the majority of IVF clinics as many clinics cannot afford the cost of 
time-lapse equipment. 
Research on blastocyst morphology typically fails to include the day of blastulation as a 
parameter even though research has indicated that day 6 blastocysts have lower 
implantation rates than day 5 blastocysts (Shapiro et al., 2001).  Conversely, current 
research that transferred patients on day 5 and on day 6, regardless of day of blastulation 
found no difference in pregnancy and implantation rates (Elgindy et al., 2012). 
Because slower progression may affect implantation, outcomes of those patients that had 
a cryopreserved embryo transfer of only euploid day 5 or day 6 blastocysts were 
examined.  The numbers are small and it is difficult to draw conclusive results; however, 
these data suggest that there is no difference in pregnancy, implantation, or ongoing/live 
birth rates between day 5 and day 6 euploid blastocysts when they are utilized in FET 
cycles.  Larger studies are needed to support or rebut these findings, however even with 
larger studies there are numerous factors that need to be examined.  For example, the 
laboratory protocol is to transfer day 5 blastocysts first; thus, it is expected that a higher 
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implantation rate with day 5 cryopreserved embryo transfers is observed.  On the other 
hand, day 6 euploid blastocysts selected for transfer are typically patients that have 
utilized all their euploid day 5 embryos or only had day 6 blastocysts available for biopsy 
during their fresh cycle, possibly indicating slower developing embryos.  Secondly, it is 
possible that day 6 blastocysts were only slightly behind biopsy on day 5, therefore they 
had more cells and could be less damaged by the biopsy procedure.  This is unlikely as the 
transfer of day 6 euploid blastocysts yielded similar pregnancy rates as euploid day 5 
blastocysts.  Furthermore, blastocyst biopsy does not significantly impact implantation 
(Scott et al., 2013a).  Lastly, culture conditions, stimulation protocols, and other specific 
patient parameters could affect day of blastulation, while warming protocols and 
progesterone supplementation protocols during cryopreserved embryo transfer cycles, 
could influence implantation rates. 
Aneuploidy is directly linked to slow developing cleavage stage embryos (Kroener et al., 
2012).  Using a sibling embryo model, this study determined that embryos that did not 
blastulate until day 6 had a 10% increase in aneuploidy than those that blastulated on day 
5.  Although the data set is small, it demonstrated that day 6 euploid blastocysts, although 
a day behind, are just as capable of positive outcomes as their day 5 counterparts.  
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2.5 Specific aim 5.  To determine if there are differences in PGS outcomes 
between fertile and infertile couples undergoing IVF? 
For this specific aim, the following published works are presented: 
Taylor TH, Welch L, Wing R, Crain JL, Wilson M, Patrick JL. 2013. Pregnancy, implantation, 
and live birth rates of fertile and infertile patients following transfer of euploid 
blastocysts. Fertil Steril. 100;3:S195. 
 
Taylor TH, Patrick JL, Gitlin SA, Crain JL, Wilson JM, Griffin DK. 2014. Blastocyst euploidy 
ĂŶĚŝŵƉůĂŶƚĂƚŝŽŶƌĂƚĞƐŝŶĂǇŽƵŶŐ ?AM ? ?ǇĞĂƌƐ )ĂŶĚŽůĚ ?A? ? ǇĞĂƌƐ )ƉƌĞƐƵŵĞĚĨĞƌƚŝůĞĂŶĚ
infertile patient population. Fertil Steril. 102;1318-23. 
 
 
2.5.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.5.2 Chapter Summary 
The purpose of this study is to test the hypothesis that infertile patients exhibit a higher 
rate of aneuploidy and lower implantation potential of euploid blastocysts compared to 
a presumed fertile population.  This study compares blastocyst euploid rates in presumed 
ĨĞƌƚŝůĞĂŶĚŝŶĨĞƌƚŝůĞƉĂƚŝĞŶƚƐ ?ďŽƚŚĨƌŽŵĂǇŽƵŶŐ ?AM ? ?ǇĞĂƌƐ )ĂŶĚŽůĚ ?A? ? ?ǇĞĂƌƐ )ĨĞŵĂůĞ
patient population.  Furthermore, this study will compare pregnancy and implantation 
rates of the same presumed fertile and infertile patients in a corresponding FET cycle.  
Patients were divided into two categories, presumed fertile and infertile.  Presumed 
fertile patients were those undergoing IVF either with anonymous oocyte donor, social 
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sex selection, or single gene defect (excluding fragile X syndrome).  Infertile patients 
included all other diagnosis.  In order to gain further insight into the effect of age on 
ĂŶĞƵƉůŽŝĚǇ ?ƉĂƚŝĞŶƚƐǁĞƌĞƐƵďĚŝǀŝĚĞĚďĂƐĞĚŽŶŵĂƚĞƌŶĂůĂŐĞ ?AM ? ?ĂŶĚA? ? ?ǇĞĂƌƐŽůĚ ?ůů
patients underwent blastocyst biopsy with CCS and a transfer in a corresponding FET.  
There was no significant difference in number of euploid blastocysts between presumed 
fertile (68/118, 57.6%) and infertile (75/132, 56.8%) patients <35 years old.  Likewise, 
there was no significant difference in number of euploid blastocysts between presumed 
ĨĞƌƚŝůĞ ? ? ? ? ? ? ? ? ? ? ?A? )ĂŶĚŝŶĨĞƌƚŝůĞ ? ? ? ? ? ? ? ? ? ? ? ?A? )ƉĂƚŝĞŶƚƐA? ? ?ǇĞĂƌƐŽůĚ ?tŚĞŶƚŚŽƐĞ
same patients underwent a corresponding frozen embryo transfer (FET) cycle, presumed 
fertile patients demonstrated a significantly higher chemical pregnancy rate when 
compared to infertile patients, 28/33 (84.8%) and 50/81 (61.7%), respectively.  Moreover, 
presumed fertile patients exhibited significantly higher implantation rates compared to 
infertile patients, 36/42 (85.7%) and 54/109 (66.7%), respectively.  When subdivided by 
maternal age, no significant difference was seen in blastocyst euploidy rates between 
presumed fertile and infertile patients; however, chemical pregnancy and implantation 
rates were significantly higher in a presumed fertile patient population even when 
transferring only euploid blastocysts.  This would indicate infertility, as a disease, may 
encompass other aspects such as uterine or other unknown embryological factors that 
can influence outcomes. 




One of the factors contributing to the lack of success in IVF is the high incidence of whole 
chromosomal abnormalities, or aneuploidies in the developing embryo (Ledbetter, 2009).  
PGS was adopted to test for aneuploidies in preimplantation embryos in order to 
decrease miscarriages and increase live birth rates.  This concept was first applied to 
specific patient groups believed to be more prone to aneuploidies, such as patients 
diagnosed with recurrent pregnancy loss, multiple IVF failures, previous aneuploid 
conceptions, male factor, or patients of advanced maternal age (Platteau et al., 2005; 
Wilton et al., 2003; Munne et al., 2004; Silber et al., 2003; Staessen et al., 2004; Gianaroli 
et al., 1997).  Studies have indicated that the majority of embryos, regardless of patient 
diagnosis, contain aneuploidies (Van Echten-Arends et al., 2011; Wells and Delhanty, 
2000; Mertzanidou et al., 2013; Vanneste et al., 2009).  Because of the high incidence of 
aneuploidies during human preimplantation development, screening the embryos prior 
to transfer makes sense, as the majority of miscarriages and embryo wastage is derived 
from chromosomal aneuploidies (Hassold and Hunt, 2001).   
Since the majority of embryos analyzed during the course of IVF are derived from infertile 
couples or from discarded embryos, the true nature of preimplantation aneuploidy may 
be overrepresented (Baart et al., 2006).  The only embryos that may reflect the true 
incidence of preimplantation aneuploidy would be those derived from fertile, not 
infertile, patients.  Unfortunately, IVF is not heavily utilized by fertile patients; however, 
there are specific patient groups that are presumed to be fertile.  For example,  
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anonymous oocyte donors offer insights into aneuploidy rates in young and presumed 
ĨĞƌƚŝůĞƉĂƚŝĞŶƚƐďƵƚĨĂŝů ƚŽǇŝĞůĚĂŶĞƵƉůŽŝĚǇƌĂƚĞƐ ŝŶĂŶŽůĚĞƌ  ?A? ? ?ǇĞĂƌƐ ) ?ĨĞƌƚŝůĞƉĂƚŝĞŶƚ
ƉŽƉƵůĂƚŝŽŶ ? dŚĞƌĞĨŽƌĞ ?ƉĂƚŝĞŶƚƐƚŚĂƚĂƌĞA? ? ?ǇĞĂƌƐŽůĚ ?ƵŶĚĞƌŐŽŝŶŐ /s&ĨŽƌƐŝŶŐůĞŐĞŶĞ
disorder in combination with aneuploidy screening or social sex selection, offer a glimpse 
into the preimplantation aneuploidy in an older, presumed fertile population.  Given that 
the incidence of aneuploidy is patient dependent, it is possible that fertile patients may 
not exhibit the same rate of aneuploidy seen in infertile women of the same age (Thum 
et al., 2008; Voullaire et al., 2007).  
The purpose of this study is to test the hypothesis that infertile patients exhibit a higher 
rate of aneuploidy and lower implantation potential of euploid blastocysts compared to 
a presumed fertile population.  This study compares blastocyst euploid rates in presumed 
ĨĞƌƚŝůĞĂŶĚŝŶĨĞƌƚŝůĞƉĂƚŝĞŶƚƐ ?ďŽƚŚĨƌŽŵĂǇŽƵŶŐ ?AM ? ?ǇĞĂƌƐ )ĂŶĚŽůĚ ?A? ? ?ǇĞĂƌƐ )ĨĞŵĂůĞ
patient population.  Furthermore, this study will compare pregnancy and implantation 
rates of the same presumed fertile and infertile patients in a corresponding FET cycle. 
 
2.5.4 Methods 
This study was deemed exempt by Sterling Institutional Review Board (Atlanta, Georgia, 
USA).  Only patients attending Reproductive Endocrinology Associates of Charlotte for IVF 
and CCS at the blastocyst stage, using aCGH, SNP microarray, or qPCR between January 
2010 and January 2014 were included in this study.  Patients were divided into two 
categories, presumed fertile and infertile.  Presumed fertile patients were those 
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undergoing IVF either with anonymous oocyte donor, social sex selection, or single gene 
defect (excluding fragile X syndrome).  Infertile patients included all other diagnosis.  In 
order to gain further insight into the effect of age on aneuploidy, patients were 
ƐƵďĚŝǀŝĚĞĚďĂƐĞĚŽŶŵĂƚĞƌŶĂůĂŐĞ ?AM ? ?ĂŶĚA? ? ?ǇĞĂƌƐŽůĚ ? 
Kruskal-Wallis, Mann-Whitney U test, chi-ƐƋƵĂƌĞ ?ĂŶĚ&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚǁĞƌĞƵƚŝůŝǌĞĚĂŶĚ
significance was set at P<0.05.  
 
2.5.4.1 Embryo Culture 
Oocytes were retrieved, stripped of cumulus cells, separated by maturity, and placed into 
individual 250 µL drops of (Irvine Scientific, Santa Ana, CA, USA) media supplemented with 
10% SSS (Irvine Scientific, Santa Ana, CA, USA) overlayed with oil (Irvine Scientific, Santa 
Ana, USA).  The dish with the oocytes was placed into an incubator at 370C with 5% CO2, 
95% N2, and 95% humidity for two to three hours until ICSI.  
ICSI was performed on all mature oocytes as described by Nagy and colleagues (1995).  
Those with two pronuclei at 16-18 hours after ICSI were separated into a separate dish of 
CSC+10%SSS, overlayed with oil, and placed back into the incubator.  On day 3, all 
embryos underwent AH using a laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA).  
Two to three laser shots at a pulse of 610 µs were utilized to breach the ZP.  Embryos 
were placed back into the incubator and allowed to culture until day 5 or day 6. 
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Those blastocysts that were observed to have a good or fair quality ICM and 
trophectoderm that was protruding from the ZP were biopsied and vitrified the same day.  
When desired by the patients, those embryos with a poor quality ICM or trophectoderm 
were biopsied and vitrified.  Embryos were given until day 6 to reach the blastocyst stage; 
those that did not blastulate by day 6 were discarded. 
 
2.5.4.2 Trophectoderm biopsy 
Blastocysts were placed in a drop of modified human tubal fluid (Irvine scientific, Santa 
Ana, California, USA) + 10% SSS.  The protruding trophectoderm was aspirated into the 
biopsy pipette (Humagen, Charlottesville, Virginia, USA).  Laser pulses of 610 µs were used 
ƚŽ “ĐƵƚ ?ƚŚĞƚƌŽƉŚĞĐƚŽĚĞƌŵ ?ƚĂŬŝŶŐĐĂƌĞƚŽŵŝŶŝŵŝǌĞƚŚĞŶƵŵďĞƌŽĨůĂƐĞƌƐŚŽƚƐŶĞĐĞƐƐĂƌǇ ?
Reference labs were used for all CCS procedures; therefore the piece of trophectoderm 
was prepared according to their protocols.  
 
2.5.4.3 Vitrification 
Immediately following biopsy, blastocysts were individually vitrified.  Blastocysts were 
placed in equilibration solution (Irvine Scientific, Santa Ana, California, USA) for 15 min 
and then transferred to vitrification solution (Irvine Scientific, Santa Ana, California, USA) 
for <1 min.  Blastocysts were pipetted onto a Cryolock® (Biodiseno, Atlanta, Georgia, 
USA), plunged into liquid nitrogen, and capped. 
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2.5.4.4 Warming and transfer 
Only blastocysts with euploid results were warmed in a subsequent FET cycle.  The 
Cryolock® containing the blastocyst was uncapped under liquid nitrogen and plunged into 
370C thawing solution (Irvine Scientific, Santa Ana, California, USA) for one minute.  The 
blastocyst was transferred to dilute solution (Irvine Scientific, Santa Ana, California, USA) 
for three minutes, and finally washing solution (Irvine Scientific, Santa Ana, California, 
USA) for 10 minutes before being placed into CSC+20% SSS overlaid with oil.   
For FET cycles, the endometrial lining was prepped with estrogen patches for 
approximately 12 days.  Progesterone in oil was administered (Day 0) when the 
ĞŶĚŽŵĞƚƌŝĂů ůŝŶŝŶŐ ǁĂƐ A? ? ŵŵ ?  dŚĞ ďůĂƐƚŽĐǇƐƚƐ ǁĞƌĞ ǁĂƌŵĞĚ ŽŶ ƚŚĞ  ?th day of 
progesterone administration.  After warming, blastocysts were transferred to the uterus 
with a Wallace catheter (Smiths Medical, Dublin, Ohio, USA) under ultrasound guidance.  









2.5.5.1 Aneuploidy in Presumed Fertile and Infertile Patients, <35 Years Old 
A total of 48 CCS cycles from 42 patients were performed on women <35 years old.  
Eighteen (31.5±2.2 years; range, 21-34 years) presumed fertile patients underwent 21 IVF 
cycles and 24 infertile (32.1±2.1 years; range, 25-34 years) patients underwent 29 IVF 
cycles.  Twenty-one presumed fertile patients underwent CCS for the following reasons: 
single gene (n=6), gender selection (n=8), and anonymous oocyte donor (n=7).  Of those 
embryos derived from patients with single gene disorders, embryos may be diagnosed 
euploid but may be affected with the single gene in question; therefore, those embryos 
ǁĞƌĞŶŽƚĂǀĂŝůĂďůĞĨŽƌƚƌĂŶƐĨĞƌ ?dŚĞƉƌŝŵĂƌǇĚŝĂŐŶŽƐĞƐ ?ĨŽƌƚŚĞ ? ?ŝŶĨĞƌƚŝůĞĐǇĐůĞƐǁĞƌĞĂƐ
follows: polycystic ovarian syndrome (PCOS; n=4), severe male factor (n=6), recurrent 
pregnancy loss (RPL; n=9), diminished ovarian reserve (n=1), unexplained (n=5), 
secondary infertility (n=2), primary infertility (n=1), and endometriosis (n=1).  There was 
ŶŽ ƐŝŐŶŝĨŝĐĂŶƚ ĚŝĨĨĞƌĞŶĐĞ ďĞƚǁĞĞŶ ĞƐƚƌĂĚŝŽů ůĞǀĞů Ăƚ Ś' ? ĚĂǇ ŽĨ Ś' ? Žƌ ƚŽƚĂů /h ?Ɛ ŽĨ
gonadotropins used between presumed fertile and infertile patients <35 years old (Table 
11).  There was no significant difference between maternal age, average number of 
oocytes, average number of embryos, and number of euploid blastocysts between 
presumed fertile and infertile patients <35 years old (Table 11).  However, a significantly 
higher percentage of blastocysts were biopsied from the presumed fertile group 






Table 11: Cycle characteristics between presumed fertile and infertile patients <35 years 
old. 
 
 Presumed Fertile Infertile P value 
No. patients 18 24  
No. cycles 21 29  
Maternal age at retrieval ± 
SD 31.5±2.2 32.1±2.1 0.3470a 
E2 at hCG ± SD 3865.5±1413.6 4526.8±1708.6 0.2306a 
Total IU Gonadotropins ± SD 2787.3±1188.4 2782.2±1261.3 0.8983a 
Day of hCG ± SD 9.6±1.2 9.8±1.1 0.4818a 
Avg. No. eggs 17.2±6.8 18.1±7.3 0.7377a 
Avg. No. embryos 11.6±5.6 11.7±5.4 0.9057a 
No. eggs 361 525 -- 
No. embryos 244 340 -- 
No. blasts bx (%) 118 (48.4%) 132 (38.8%) <0.0001b 
Total euploid (%) 68 (59.3%) 75 (56.8%) 0.9992b 
Avg. No. Euploid (%) 3.2±2.0 2.4±1.9 0.1702a 
a = Mann-Whitney U test            b = Chi-square test for independence 
 
2.5.5.2 Aneuploidy in a Presumed Fertile and /ŶĨĞƌƚŝůĞWĂƚŝĞŶƚƐ ?ш ? ?zĞĂƌƐ
Old 
 ƚŽƚĂůŽĨ  ? ?^ ĐǇĐůĞƐǁĞƌĞƉĞƌĨŽƌŵĞĚŽŶĞŵďƌǇŽƐĚĞƌŝǀĞĚ ĨƌŽŵǁŽŵĞŶA? ? ?ǇĞĂƌƐ ?
Seventeen cycles from 13 presumed fertile (37.6±1.9 years; range, 35-42) patients and 49 
cycles from 38 infertile (38.3±2.2 years; range, 35-44) patients underwent IVF with 
blastocyst biopsy.  Seventeen presumed fertile cycles underwent CCS for the following 
ƌĞĂƐŽŶƐ PŐĞŶĚĞƌƐĞůĞĐƚŝŽŶ ?ŶA? ? ? )ĂŶĚƐŝŶŐůĞŐĞŶĞ ?ŶA? ? ) ?dŚĞƉƌŝŵĂƌǇĚŝĂŐŶŽƐĞƐ ?ĨŽƌ ? ?
infertile cycles were; unexplained (n=13), diminished ovarian reserve (n=8), 
endometriosis (n=2), severe male factor (n=4), PCOS (n=4), RPL (n=8), secondary infertility 
(n=2), uterine factor (n=2), and advanced maternal age (n=6).  Estradiol levels at day of 
hCG were not significantly higher in the presumed fertile group when compared to the 
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infertile group (Table 12).  Total gonadotropins used during the stimulation cycle were 
significantly lower in the presumed fertile group when compared to the infertile group, 
 ? ? ? ? ? ?A? ? ? ? ? ? ? /h ?Ɛ ĂŶĚ  ? ? ? ? ? ?A? ? ? ? ? ? ? /h ?Ɛ ? respectively (P=0.0061).  There was no 
difference in number of stimulation days, number of oocytes produced, and number of 
embryos generated, and number of blastocysts biopsied between presumed fertile and 
infertile patients (Table 11).  There was no difference in number of euploid blastocysts 
between presumed fertile patients (42/86, 48.8%) and infertile patients (97/206, 47.1%; 
P=0.8852; Table 12).  The average number of euploid blastocysts was also not significantly 
different between the presumed fertile group and the infertile group (Table 12). 
dĂďůĞ ? ? PŚĂƌĂĐƚĞƌŝƐƚŝĐƐďĞƚǁĞĞŶƉƌĞƐƵŵĞĚĨĞƌƚŝůĞĂŶĚŝŶĨĞƌƚŝůĞƉĂƚŝĞŶƚƐ ?A? ? ?ǇĞĂƌƐŽůĚ ? 
 Presumed Fertile Infertile P value 
No. patients 13 38  
No. cycles 17 49  
Maternal age at 
retrieval ± SD 37.6±1.9 38.3±2.2 0.4643a 
E2 at hCG ± SD 4455.1±2252.9 3852.0±2081.5 0.2979a 
Total IU 
Gonadotropins ± SD 2660.4±1039.8 3749.3±1362.6 0.0061a 
Day of hCG ± SD 9.7±1.4 10.5±1.3 0.0620a 
Avg. No. eggs 17.3±7.3 16.7±6.9 0.8086a 
Avg. No. embryos 11.5±4.7 9.8±4.7 0.3140a 
No. eggs 294 819 -- 
No. embryos 195 482 -- 
No. blasts bx (%) 86 (44.1%) 206 (42.7%) 0.8112b 
Total euploid (%) 42 (48.8%) 97 (47.1%) 0.8852b 
Avg. No. Euploid (%) 2.5±1.4 2.0±1.4 0.3478a 





Presumed fertile and infertile patients were grouped together when comparing 
ƉƌĞŐŶĂŶĐǇĂŶĚŝŵƉůĂŶƚĂƚŝŽŶƌĂƚĞƐŝŶĂĐŽƌƌĞƐƉŽŶĚŝŶŐ&dĐǇĐůĞ ?ƚŽƚĂůŽĨ ? ? ?&d ?ƐŽĨ
euploid blastocysts were analyzed.  Thirty-one presumed fertile patients underwent 33 
&d ?Ɛ ?ǁŚŝůĞ  ? ? ŝŶĨĞƌƚŝůĞƉĂƚŝĞŶƚƐƵŶĚĞƌǁĞŶƚ ? ?&d ?Ɛ ? dŚĞƉƌŝŵĂƌǇĚŝĂŐŶŽƐĞƐŽĨĂůůƚŚĞ
cycles undergoing an FET are presented in table 13.  Maternal age at time of retrieval was 
not statistically significant between presumed fertile and infertile patients, 34.2±3.8 years 
and 35.5±3.6 years, respectively (P=0.1168; Table 14).  All patients were urged to only 
transfer 1 euploid blastocyst; however, some patients decided to transfer two euploid 
blastocysts based on their medical history.  Regardless, the average number of euploid 
blastocysts transferred in an FET cycle was not significantly different between presumed 
fertile (1.3±0.5 blastocysts) and infertile (1.4±0.5 blastocysts) patients (Table 14; 
P=0.5695).  There was also no significant difference in embryo quality transferred 
between the two groups.  Chemical pregnancy rates, as defined by a positive beta hCG 
level, were significantly higher in the presumed fertile patients when compared to 
infertile patients, 28/33 (84.8%) and 50/81 (61.7%), respectively (Table 14; P=0.0251).  
Clinical pregnancies, as defined by the presence of a gestational sac, were significantly 
higher in the presumed fertile (28/33, 84.8%) patients compared to infertile patients 
(44/81, 54.3%; Table 14; P=0.0025).  Presumed fertile patients exhibited a significantly 
higher implantation rate of euploid blastocysts in a corresponding FET cycle when 
compared to infertile patients, 36/42 (85.7%) and 54/109 (66.7%), respectively (Table 14; 
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P=0.0001).  There was no difference between number of multiples or spontaneous 
abortions between presumed fertile and infertile patients (Table 14). 
 
2.5.6 Discussion 
These data do not support the hypothesis that infertile patients exhibit a higher rate of 
aneuploidy than age matched presumed fertile patients (Table 11; Table 12).  However, 
these data do support the hypothesis that euploid blastocysts derived from infertile 
couples have significantly lower implantation potential when compared to euploid 
blastocysts from presumed fertile couples (Table 14). 
Table 13: Primary diagnosis of patients undergoing an FET cycle in presumed fertile and 
infertile patients. 
 
 Presumed Fertile Infertile 
No. patients 31 62 
No. frozen embryo transfer cycles 33 81 
No. recurrent pregnancy loss (%) - 17 (21.0%) 
No. primary infertility (%) - 1 (12.4%) 
No. secondary infertility (%) - 2 (2.5%) 
No. polycystic ovarian syndrome (%) - 9 (11.1%) 
No. diminished ovarian reserve (%) - 8 (9.9%) 
No. uterine (%) - 2 (2.5%) 
No. severe male factor (%) - 13 (16.1%) 
No. unexplained (%) - 14 (17.3%) 
No. advanced maternal age (%) - 7 (8.6%) 
No. endometriosis (%) - 5 (6.2%) 
No. single gene (%) 10 (30.3%) - 
No. sex selection (%) 8 (24.2%) - 






Table 14: Outcomes in frozen embryo transfer cycles of euploid blastocysts in presumed 
fertile and infertile patients. 
 
 Presumed Fertile Infertile P value 
No. patients 31 62  
No. frozen embryo transfer cycles 33 81  
Maternal age at retrieval ± SD 34.2±3.8 35.5±3.6 0.1168a 
No. blastocyst thawed 43 109  
No. blastocyst survived (%) 42 (97.8%) 109 (100%) 0.2829b 
Avg. No. transferred ± SD 1.3±0.5 1.4±0.5 0.5695a 
No. transferred 42 109  
Good quality blastocysts (%) 12 (28.6%) 20 (18.4%) 
0.3790c Fair quality blastocysts (%) 28 (66.7%) 82 (75.2%) 
Poor quality blastocysts (%) 2 (4.8%) 7 (6.4%) 
+hCG (%) per transfer 28 (84.8%) 50 (61.7%) 0.0251b 
+sac (%) per transfer 28 (84.8%) 44 (54.3%) 0.0025b 
No. of sacs (% implantation) 36 (85.7%) 54 (66.7%) 0.0001c 
No. of multiples per pregnancy (%) 8 (24.2%) 10 (20.0%) 0.5607c 
No. clinical miscarriages (%) 3 (8.3%) 2 (4.0%) 0.3436b 
Avg. No. Euploid available 3.4±1.7 2.6±1.6 0.0154a 
a = Mann-Whitney U test    b A?&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚc = Chi-square for independence test 
In both age groups, no statistical difference in aneuploidy rates was seen between 
presumed fertile and infertile patients.  The literature is limited concerning the rate of 
ĂŶĞƵƉůŽŝĚǇŝŶĨĞƌƚŝůĞǁŽŵĞŶA? ? ?ǇĞĂƌƐĂƐƚŚŝƐƉĂƚŝĞŶƚŐƌŽƵƉƚǇƉŝĐĂůůǇĚŽĞƐŶŽƚƌĞƐort to 
IVF to achieve pregnancy.  Ata and colleagues (2012) described a direct relationship 
between aneuploidy and maternal age, indicating that approximately 30% of blastocysts 
from oocyte donors are aneuploid while approximately 80% of blastocysts from women 
A? ? ?ǇĞĂƌƐŽůĚĂƌĞĂŶĞƵƉůŽŝĚ ?dŚŝƐƐƚƵĚǇĨŽƵŶĚĂƉƉƌŽǆŝŵĂƚĞůǇ ? ?A?ŽĨďůĂƐƚŽĐǇƐƚƐƉƌŽĚƵĐĞĚ
by presumed fertile patients (which included oocyte donors) <35 years old, were 
aneuploid, which is similar to their rate of aneuploidy described in donor oocyte cycles.   
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Fragouli and colleagues (2009) utilized comparative genomic hybridization and examined 
the polar bodies from young donors.  They found a low aneuploidy rate of 3%.  In contrast, 
some reports indicate aneuploidy rates in polar bodies derived from donors as high as 
65% (Sher et al., 2007).  It is important to examine aneuploidy rates in an older, presumed 
ĨĞƌƚŝůĞ ƉĂƚŝĞŶƚ ƉŽƉƵůĂƚŝŽŶďĞĐĂƵƐĞ ŝŶĚŝǀŝĚƵĂůƐ ĂĐŚŝĞǀĞ ƉƌĞŐŶĂŶĐǇ ŝŶ ƚŚĞŝƌ ůĂƚĞ  ? ? ?Ɛ ĂŶĚ
ĞĂƌůǇ ? ? ?ƐǁŝƚŚŽƵƚƚŚĞĂŝĚŽĨ/s& ?tŚĞŶƐƵďĚŝǀŝĚĞĚďǇĂŐĞ, these data demonstrated that 
regardless if a patient is fertile or infertile, the incidence of preimplantation aneuploidy is 
similar.   
Fragouli and colleagues (2009) also hypothesize that during a natural cycle in a normal, 
proper functioning ovary, aneuploid oocytes may be selected against.  However, 
controlled ovarian hyperstimulation or aging may circumvent this mechanism.  
Presumably, fertile patients have proper functioning ovaries that are exposed to 
hyperstimulation drugs.  Therefore, regardless if a patient is fertile or not, the 
hyperstimulation of ovaries produces similar aneuploidy rates.  In this study, presumed 
fertile patients <35 years old had significantly higher blastocysts euploid rates (59.3%; 
Table 11) when compared to presumed fertile ǁŽŵĞŶA? ? ?ǇĞĂƌƐŽůĚ ? ? ? ? ?A? ?dĂďůĞ ? ? ) ?
The same trend was seen when blastocysts euploid rates were compared between 
ŝŶĨĞƌƚŝůĞƉĂƚŝĞŶƚƐAM ? ?ǇĞĂƌƐŽůĚ  ? ? ? ? ?A? ?dĂďůĞ  ? ? )ĂŶĚA ?ǇĞĂƌƐŽůĚ  ? ? ? ? ?A? ?dĂďůĞ  ? ? ) ?
Therefore, these data suggest that age and not hyperstimulation undermines this 
mechanism.  Further evidence of this is the fact aneuploidy is present in embryos derived 
from non-stimulated ovaries (Verpoest et al., 2008). 
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Other studies have reported similar pregnancy rates between fertile and infertile women 
when only euploid blastocysts were transferred during FET cycles (Harton et al., 2013).  
Pregnancy rates from euploid blastocysts have been reported to range 65-70% (Grifo et 
al., 2013).  Overall pregnancy rates are similar to this report (68.4%); however, this study 
also experienced a significantly higher pregnancy and implantation rate in the presumed 
fertile patients compared to infertile patients.  This would indicate that a factor other 
than chromosomes is hindering pregnancy in infertile patients such as an increase amount 
of mitochondrial activity, altered gene expression, or possible uterine factors (Hsieh et 
al., 2004; Wood et al., 2007).  One possible explanation for the increase in implantation 
rates seen with presumed fertile patients is the fact that they had more blastocysts to 
biopsy when compared to infertile patients (Table 11).  With more blastocyst to biopsy 
and vitrify, then these patients would have more euploid blastocysts to choose from in 
the corresponding FET cycle.  This assumption is correct, however, when embryo quality 
prior to warming is examined, there is no difference between presumed fertile and 
infertile patients (Table 14).  Lastly, the majority of presumed fertile patients underwent 
PGS for either sex selection or single gene disorders.  Therefore, the sex of the embryo or 
the single gene diagnosis, not embryo quality, was used as the first line of selection in this 
group of patients. 
Lastly, these data are retrospective and requires an understanding of presumed fertile 
and infertile.  There are many diagnoses that may include or exclude patients from these 
categories and possibly influence the results.  Presumed fertile patients were only those 
that desired IVF for either gender selection or single gene disorder.  All these patients, 
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theoretically, do not require IVF to get pregnant and therefore they were presumed 
fertile.  Infertile patients encompass a much larger spectrum of diagnosis; however, all 
these patients underwent IVF to achieve pregnancy.  First, only patients with severe male 
factor (<1 million per mL) were included in the infertile group.  Second, secondary 
infertility are patients that have exhibited previous fertility but have not been successful 
after a full year of unprotected intercourse.  Possibly reasons for secondary infertility 
included increased maternal age and weight gain.  In this study, all of the secondary 
infertility patients had a secondary diagnosis as well (advanced maternal age, ovulation 
disorder, or unexplained infertility).  Lastly, maternal age is the largest single factor 
affecting chromosomal aneuploidy and IVF success rates (Franasiak et al., 2014).  Patients 
with AMA were included in this study.  By definition, those patients that were presumed 
ĨĞƌƚŝůĞĂŶĚA? ? ?ǇĞĂƌƐŽůĚĐŽƵůĚďĞĚŝĂŐŶŽƐĞĚǁŝƚŚD ?ŚŽǁĞǀĞƌƚŚĞǇĚŝĚŶŽƚŶĞĞĚ/s&ƚŽ
achieve pregnancy.  Infertile patients diagnosed with AMA were undergoing IVF 
specifically because they could not conceive naturally.  The presumed fertile group was 
not undergoing IVF to conceive, but rather to select a child with certain characteristics.  
The infertile group was undergoing IVF specifically because they could not achieve a 
successful pregnancy. 
In conclusion, these data suggest that blastocyst euploidy rates are similar, regardless if a 
patient is presumed fertile or infertile.  Although the numbers are small, presumed fertile 
patients show a significantly higher pregnancy and implantation rate compared to 
infertile patients when a euploid blastocyst is transferred during an FET cycle.  This would 
indicate infertility as a disease may encompass other aspects such as uterine or other 
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unknown embryological factors that can influence outcomes.  Further studies are needed 
to determine these factors.  
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2.6 Specific aim 6.  To determine if blastocyst screened by qPCR have similar 
aneuploidy rates and implantation rates compared to blastocysts screened 
with aCGH? 
For this specific aim, the following published works are presented: 
Taylor TH, Griffin DK, Wilson JM, Wing RL, Johnson L, Katz SL. A comparison of aneuploidy 
rates and ongoing pregnancy rates between blastocysts screened using quantitative 
polymerase chain reaction or array comparative genomic hybridization, results from a 
single center.  Submitted. 
 
2.6.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.6.2 Chapter summary  
The use of CCS has become widespread in IVF.  Data comparing pregnancy and 
implantation rates utilizing different CCS platforms is lacking.  The goal of this study is to 
examine clinical outcomes of blastocysts tested with qPCR or aCGH. Our control group 
consisted of all patients undergoing an IVF cycle at the same time as the study patients 
where untested blastocysts were frozen and utilized in a FET.  Chemical clinical pregnancy 
rates did not differ between qPCR, aCGH, or untested blastocysts.  Loss of implantation, 
as defined as a positive beta pregnancy that was lost pre or post heartbeat was 
significantly different between euploid diagnosed aCGH blastocysts (9/68, 13.2%) and 
untested blastocysts (21/71, 29.6%; Table 2; P=0.0328).  The loss rate between qPCR 
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diagnosed euploid blastocysts (8/25, 32.0%) was similar to the loss rate of untested 
blastocysts (21/71, 29.6%; Table 2; P=0.8205).  Our study demonstrated that patients that 
have a euploid qPCR blastocysts transfer have a 32% chance of a miscarriage once a 
positive beta is achieved.  This rate more closely approaches patients that had untested 
blastocysts transferred (29%) than the aCGH euploid blastocysts (13.2%: P=0.0374).    
 
2.6.3 Introduction 
The use of technologies such as CCS, which allows for the simultaneous testing of all 24 
chromosomes, has allowed the field of in-vitro fertilization (IVF) to make radical advances 
towards the goal of a single healthy baby.  The four most common technologies utilized 
during CCS are aCGH, SNP array, NGS, and qPCR.   
A validation process has been described that all CCS platforms should undergo.  The 
validation process provides the patient and clinician the rate at which a positive diagnosis 
(euploid blastocyst) leads to a positive result (euploid live birth) and the rate at which a 
negative diagnosis (aneuploid blastocyst) leads to a positive result (euploid live birth; 
Scott et al., 2012). Moreover, the comparison of CCS tests to known cell lines should be 
undertaken.  Only qPCR and some NGS have been validated in this manner (Scott et al., 
2012; Treff et al., 2013; Werner et al., 2015).  aCGH was validated against fluorescence 
in-situ hybridization (FISH) which has been demonstrated to have higher rates of 
aneuploidy compared to SNP and have a detrimental effect on live birth rates, indicating 
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that aCGH and some NGS could be as problematic as FISH (Mastenbroek et al., 2007; Treff 
et al., 2010; Gutierrez-Mateo et al., 2011; Fiorentino et al., 2014). 
Pregnancy and implantation rates also need to be examined to determine the clinical 
efficiency of each platform.  Data comparing pregnancy rates utilizing different platforms 
is lacking.  The goal of this study is to examine the pregnancy rates of blastocysts tested 
with qPCR or aCGH.  Given the current research, we believe that qPCR will increase the 
likelihood of a euploid embryo, while maintaining high pregnancy and implantation rates 
associated with CCS testing. 
 
2.6.4 Methods 
This study was determined to be exempt from Institutional Review Board by Sterling IRB.  
Only patients attending Reproductive Endocrinology Associates of Charlotte and 
undergoing a fresh cycle from June 2013 to December 2014 were included in this 
retrospective study.  Starting in June 2013, doctors were given the option to send their 
patients desiring PGS to either The Foundation for Embryonic Competence (FEC; 
Morristown, New Jersey, USA) for qPCR or Genesis Genetics (Detroit, Michigan, USA) for 
aCGH (Figure 29).  Thus, some doctors decided to send their patients to FEC while others 
continued to send to Genesis.  This study was not randomized.  From the patients desiring 
PGS, two groups were created: those that had their blastocysts screened with qPCR at 
FEC and those patients that had their blastocysts screened with aCGH at Genesis Genetics.   
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To examine clinical outcomes between platforms a control group was determined.  Our 
control group consisted of all patients undergoing an IVF cycle at the same time as the 
study patients where untested blastocysts were frozen and later utilized in a FET.  Patients 
ǁŚŽŵŚĂĚĂĨƌĞƐŚďůĂƐƚŽĐǇƐƚƚƌĂŶƐĨĞƌĂŶĚƚŚĞŶƐƵďƐĞƋƵĞŶƚ&d ?ƐǁĞƌĞŶŽƚŝŶĐůƵĚĞĚŝŶƚŚĞ
control group.  The control group were not aged matched and did not have PGS 
performed during their fresh cycle (Figure 29). 
All patients, regardless of where they were sent for PGS or if they were in the control arm, 
underwent a retrieval and FET between June 2013 and January 2015.    
All patients underwent IVF with intracytoplasmic sperm injection, embryo culture, 
assisted hatching, and blastocyst biopsy, vitrification, and FET protocols as reviewed by 
Taylor and colleagues (2014b; 2014c).  Briefly, oocytes were retrieved, stripped of 
cumulus cells, separated by maturity, and placed into individual 250 µL drops of CSC 
(Irvine Scientific, Santa Ana, CA, USA) media supplemented with 10% SSS (Irvine Scientific, 
Santa Ana, CA, USA) overlayed with oil (Irvine Scientific, Santa Ana, USA).  The dish with 
the oocytes was placed into an incubator at 370C with 5% CO2, 95% N2, and 95% humidity 
for two to three hours until ICSI.  
ICSI was performed on all mature oocytes.  Those that properly fertilized were separated 
into a separate dish of CSC+10% SSS, overlayed with oil, and placed back into the 
incubator.  On day 3, all embryos underwent assisted hatching utilizing a laser (Zilos-tk, 
Hamilton Thorne, Beverly, Maine, USA).  Two to three laser shots at a pulse of 610 µs 
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were utilized to breach the zona pellucida.  Embryos were placed back into the incubator 
and allowed to culture until day 5 or day 6. 
Those blastocysts that were observed to have a good or fair quality inner cell mass and 
trophectoderm which was protruding from the zona pellucida were biopsied and vitrified 
on the same day.  Embryos were given until day 6 to reach the blastocyst stage; those 
that did not blastulate by day 6 were discarded. 





The primary diagnoses of all the cycles undergoing an FET are presented in table 15. To 
determine if there were differences in aneuploidy rates between qPCR and aCGH 
screened blastocysts, we examined all cycles undergoing PGS by either technique.  
Between June 2013 and January 2014, a total of 198 cycles underwent PGS, 38 for qPCR 
and 160 for aCGH (Table 16).  The maternal age at time of retrieval was not significant 
between qPCR (35.5 ± 6.6 years) and aCGH (36.2 ± 4.4 years; P=NS).  The number of 
blastocysts biopsied, number of euploid blastocysts, number of cycles with euploid 
ďůĂƐƚŽĐǇƐƚƐ ?ĂŶĚŶƵŵďĞƌŽĨďůĂƐƚŽĐǇƐƚƐƚŚĂƚŚĂĚĂ “ŶŽƌĞĂĚ ?ƐŝŐŶĂůǁĞƌĞŶŽƚƐŝŐŶŝĨŝĐant 
between qPCR and aCGH (Table 16).    
 We attempted to determine the reproductive outcome when transferring blastocysts 
diagnosed as euploid by qPCR (n=34 cycles) or aCGH (n=60 cycles) in a subsequent FET.  
Our control group consisted of patients who had an untested blastocyst transferred 
during a subsequent FET (n=102).   
For the corresponding FET cycles, maternal age at time of retrieval, biochemical 
pregnancy rates, and clinical pregnancy rates was not significant between groups (Table 
17).  More blastocysts were transferred in the untested group (1.7±0.5) as compared to 
the qPCR (1.2±0.4) and aCGH (1.2±0.4) groups (Table 17; <0.0001).  The total number of 
fetal heartbeats was significantly higher with aCGH euploid blastocysts (68/129, 52.7%) 
compared to untested blastocysts (64/168, 38.1%; Table 17; P=0.0166), however there 
was no significant difference between the number of heartbeats of qPCR euploid 
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blastocysts (20/41, 48.8%) compared to untested blastocysts (64/168, 38.1%; Table 17).  
Loss of implantation, as defined as a positive beta pregnancy that was lost pre or post 
heartbeat, was significantly different between euploid diagnosed aCGH blastocysts (9/68, 
13.2%) and untested blastocysts (21/71, 29.6%; Table 17; P=0.0328) and similar between 
qPCR diagnosed euploid blastocysts (8/25, 32.0%) and untested blastocysts (21/71, 
29.6%; Table 17; P=0.8205). 
Table 15: Cycle characteristics of the patient populations undergoing frozen embryo 
transfers. 
 qPCR aCGH Untested 
Total No. of patients 32 96 96 
No. frozen embryo transfers 34 104 102 
No. recurrent pregnancy loss (%) 5 (14.7%) 12 (11.5%) 2 (2.0%) 
No. secondary infertility (%) 1 (2.9%) 3 (2.8%) 4 (3.9%) 
No. polycystic ovarian syndrome (%) 2 (5.9%) 5 (4.8%) 5 (4.9%) 
No. tubal (%) 0 2 (1.9%) 9 (8.8%) 
No. diminished ovarian reserve (%) 0 2 (1.9%) 9 (8.8%) 
No. uterine (%) 0 1 (1.7%) 1 (1.0%) 
No. male factor (%) 5 (14.7%) 14 (13.5%) 15 (14.7%) 
No. unexplained (%) 1 (2.9%) 12 (11.5%) 21 (20.6%) 
No. advanced maternal age (%) 5 (14.7%) 6 (5.8%) 0 
No. endometriosis (%) 0 12 (11.5%) 21 (20.6%) 
No. sex selection (%) 6 (17.6%) 6 (5.8%) 0 
No. anonymous egg donor (%) 4 (11.8%) 6 (5.8%) 1 (1.0%) 
No. ovulation (%) 2 (5.9%) 8 (7.7%) 8 (7.8%) 
No. previous failed IVF (%) 2 (5.9%) 3 (2.9%) 2 (2.0%) 
No. other (%) 1 (2.9%) 5 (4.8%) 4 (3.9%) 










Table 16: IVF cycle characteristics and aneuploidy rates between qPCR and aCGH tested 
blastocysts. 
 
  qPCR aCGH P Value 
No. Cycles 38 160   
Avg. Age 35.5 ± 6.6 36.2±4.4 0.88081 
Avg. No. Eggs 15.5 ±  6.7 16.5 ± 7.1 0.60661 
Avg. No. Embryos 7.9 ±  3.9 9.8 ± 5.0 0.05071 
Avg. No. Biopsied 3.7 ± 2.4 4.0 ± 2.6 0.61501 
Total Biopsied 141 634 
0.11102 
Total Euploid (%) 76 (53.9%) 292 (46.1%) 
No. Cycles with no Euploid 
Blastocysts (%) 7 (18.4%) 38 (23.8%) 
0.36512 
No. Blastocysts with no read (%) 4 (2.8%) 37 (5.8%) 0.21013 
1 Mann-Whitney                            2 Chi-Square test 3 &ŝƐŚĞƌ ?ƐĞǆĂĐƚ 
Table 17: Pregnancy and implantation rates per cycle when euploid blastocysts 
diagnosed by qPCR, aCGH, and untested embryos are transferred during a frozen 
embryo cycle. 
 
   qPCR aCGH Untested P value  
Per FET 
No. Cycles 34 104 102   
Avg. Age 36.2 ± 5.1 36.2 ± 5.1 34.2 ± 4.5 0.14251 
Avg. No. ET'd 1.2 ± 0.4a 1.2 ± 0.4b 1.7 ± 0.5a,b <0.00011 
No. cycles w/+hCG (%) 25 (73.5%) 68 (65.4%) 71 (69.6%) 0.63172 
No. cycles w/+sac (%) 20 (58.8%) 63 (60.6%) 58 (56.9%) 0.86362 
No. cycles w/+FCA (%) 17 (50.0%) 59 (56.7%) 50 (49.0%) 0.51502 
No. cycles w/a loss (%) 
after +hCG 8 (32.0%) 9 (13.2%)c 21 (29.6%)c 0.03872 
No. clinical 
miscarriages (%) 3 (15.0) 4 (6.3%) 8 (13.8%) 0.3285 
Per 
Embryo 
Total No. ET'd 41 129 168  
Total No. +sac (%) 24 (58.5%) 73 (56.6%) 77 (45.8%) 0.11592 
Total No. FCA (%) 20 (48.8%) 68 (52.7%)d 64 (38.1%)d 0.03742 
1 Man-Whitney  2 Chi-square test 
a,b,c,d = indicates statistical significance between the two groups 





Our data demonstrates similar aneuploidy rates between blastocysts tested with qPCR 
and aCGH.  qPCR diagnosed euploid blastocysts had a higher rate of miscarriage 
compared to aCGH diagnosed euploid blastocysts.  The rate of loss described with qPCR 
tested blastocysts was similar to the loss observed in untested blastocysts, suggesting 
that qPCR diagnosed euploid blastocysts are not the same as euploid diagnosed 
ďůĂƐƚŽĐǇƐƚƐďǇĂ', ?tĞďĞůŝĞǀĞƚŚŝƐĚŝƐĐƌĞƉĂŶĐǇĐĂŶďĞĞǆƉůĂŝŶĞĚďǇƋWZ ?ƐŝŶĂďŝůŝƚǇƚŽ
detect segmental aneuploidy and deletions/duplications (Treff et al., 2013; Treff et al. 
2012). 
Research has indicated that the main cause of miscarriages and IVF failure are whole 
chromosomal abnormalities (Hassold and Hunt, 2001).  To test for whole chromosomal 
ĂďŶŽƌŵĂůŝƚŝĞƐ ?ƚŚĞƋƵĞƐƚŝŽŶďĞĐŽŵĞƐ “ŚŽǁŵĂŶǇůŽĐŝƐŚŽƵůĚďĞĂŶĂůǇǌĞĚƚŽĚĞƚĞƌŵŝŶĞ
ǁŚŽůĞĐŚƌŽŵŽƐŽŵĂůĞƌƌŽƌƐ ? ?ƋWZŽŶůǇĞǆĂŵŝŶĞƐĨŽƵƌůŽĐŝ ?dƌĞĨĨet al., 2013; Treff et al. 
2012).  The exact location of these loci is unknown however there are two on the p and q 
arm.  If those loci are present in the PCR reaction, then that dictates the diagnosis given.  
With only four loci examined, compared to the thousands loci examined with aCGH, the 
confidence in the copy number calls is greatly reduced.  For example, if one of the PCR 
reactions fails due to technical error then an embryo can be misdiagnosed as aneuploidy.  
Alternatively, if a technical error occurs with aCGH, multiple other loci are present to 
 “ĚŝƐƋƵĂůŝĨǇ ?ƚŚĞĞƌƌŽƌĂŶĚƚŚƵƐŝŶĐƌĞĂƐĞĐŽŶĨŝĚĞŶĐĞŝŶƚŚĞ diagnosis.  Moreover, the lack 
of loci examined prevents qPCR from detecting segmental aneuploidies or 
duplications/deletions which can cause miscarriages. 
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In terms of segmental aneuploidy, Rabonowitz et al. (2012) demonstrated the presence 
of segmental aneuploidy in approximately 15% of preimplantation embryos.  In 
spontaneous aborted tissue, the incidence decreases to approximately 5%, suggesting a 
selection against segmental aneuploidy slightly before or after implantation (Sahoo et al., 
2016).  Large deletions/duplications may cause a miscarriage as well.  Shen and colleagues 
(2016) demonstrated 5.3% of all spontaneous miscarriages contain a large duplication or 
deletion.  The incidence of large deletions/duplications within the blastocyst is currently 
unknown however preimplantation embryos are of particularly high risk for chromosome 
instability, resulting in chromosome breakage and fusion (Voet et al., 2011; Vanneste et 
al., 2012).  If these errors were present in the blastocyst, their diagnosis would be missed 
if qPCR were utilized.   
Utilizing the same technology, Forman and colleagues (2013) conducted a single embryo 
transfer of 140 euploid blastocysts and had 19/140 (13.6%) loss of implantation rate, 
which more closely resembles those of aCGH in our study.  In our dataset with qPCR, our 
clinical pregnancy rate was 58.8% and ongoing pregnancy rate was 50.0%.  The 
differences in loss of implantation could be attributed to different definitions for chemical 
pregnancy, different cutoffs for biochemical pregnancy, different patient populations, or 
different treatment protocols.   
Ours is not the first report to demonstrate a high miscarriage rate with qPCR.  Anderson 
and colleagues (2015) reported a similar pregnancy, implantation, and miscarriage rate 
between qPCR blastocysts and untested blastocysts.  However, these results could be 
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attributed to damage caused by the blastocyst biopsy procedure as they did not compare 
their pregnancy rates with another CCS platform.  In our study, patients underwent IVF 
for both qPCR and aCGH at the same time with the same embryologists, eliminating the 
effect of the blastocyst biopsy procedure.  Moreover, research has indicated that the 
blastocyst biopsy procedure does not affect implantation and that the blastocyst biopsy 
procedure seems consistent across multiple IVF centers and embryologists (Scott et al., 
2013; Capalbo et al., 2016).    
We believe that culture conditions, laboratory techniques, and FET protocols did not play 
a role in our high miscarriage rate with qPCR.  During this study, no media was changed, 
embryo biopsy was performed by the same personnel for both groups, and only proven 
vitrification and transfer methods were utilized (Taylor et al., 2014b; Taylor et al., 2014c).  
In terms of FET protocols, progesterone was administered on the same day for all 3 
groups.  Larger studies are needed to confirm our findings. 
Overall, those embryos diagnosed as euploid by qPCR may have up to a 20% chance of 
having either a segmental aneuploidy (15%) or large duplications/deletions (5%) that may 
cause a miscarriage.  These undiagnosed errors could have attributed to our high 
miscarriage rate.  Our data demonstrate that both technologies provide excellent 




2.7 Specific aim 7.  To determine the mechanisms by which diagnosed 
aneuploid cleavage stage embryos can produce euploid blastocysts? 
For this specific aim, the following published works are presented: 
Taylor TH, Patrick JP, Das D, Crain JL, Wilson JM, Griffin DK. Euploid live births from 
aneuploid cleavage stage embryos. Submitted 2017. 
Taylor TH, Patrick JP, Das D, Crain JL, Wilson JM, Griffin DK. Euploid live births from 
aneuploidy cleavage stage embryos. PGDIS 2014. 
 
2.7.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.7.2 Chapter summary  
From a single cell, normal human development requires one chromosome from each 
parent to replicate and evenly segregate into two daughter cells with identical diploid 
number.  When a malsegregation event occur, aneuploidy results.  Thus, the assumption 
is that an aneuploid cleavage stage embryo will give rise to an aneuploid pregnancy.  This 
research challenges the dogma for human development.  A total of 34 human embryos 
from 10 patients were biopsied at the cleavage and blastocyst stage.  Each blastomere 
was assessed for aneuploidy by single nucleotide polymorphism microarray.  Only 
cleavage stage embryos (Day 3) that were diagnosed as aneuploid were rebiopsied at the 
blastocyst stage (day 5 or 6.  Of the 34 cleavage stage embryos that were diagnosed as 
aneuploid, 16 (47.1%) were diagnosed as euploid.  On the basis of a euploid diagnosis at 
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blastocyst stage, three patients underwent four embryo transfers.  Two have resulted in 
chromosomally and phenotypically normal live births while two others have resulted in 
biochemical pregnancies.  The results suggest that the human embryo is prone to 
chromosomal abnormalities at the cleavage stage but the dogma of a uniformly euploid 
or aneuploid embryo should be reconsidered.  Chromosomal diagnosis at the cleavage 
stage may be an unreliable indicator of chromosome copy number in the child for 
biological or technical reasons. 
 
2.7.3 Introduction 
In human development (akin to virtually all diploid eukaryotic organisms), normal mitosis 
usually ensures faithful segregation of chromosomes so that one cell divides into two 
identical daughter cells in all subsequent divisions.  The received wisdom therefore is that 
euploid preimplantation embryo usually remains euploid in all later divisions and leads to 
a euploid individual.  Alternatively, an aneuploid embryo remains uniformly aneuploid, 
leading to implantation failure, miscarriages, and birth defects.   
In reality, it has been widely demonstrated that the human embryo is in fact commonly 
mosaic, containing two or more distinct cell lines (Delhanty et al., 1993; Fragouli et al., 
2011; Wells and Delhanty, 2000; Daphnis et al., 2008; Taylor et al., 2014a).  Proposed 
mechanisms of post-zygotic chromosome segregation error, which typically leads to 
chromosome mosaicism include: mitotic non-disjunction (where one daughter cell 
inherits three copies of a chromosomes pair and the other daughter cell inherits the 
remaining one copy); chromosome gain (presumably by some mechanism of 
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endoreplication) and chromosome loss (e.g. by anaphase lag) (Taylor et al., 2014a).  A 
variant of the latter is so-ĐĂůůĞĚ “ƚƌŝƐŽŵǇƌĞƐĐƵĞ ? ?ǁŚĞƌĞĂĐĞůůǁŝƚŚƚŚƌĞĞĐŚƌŽŵŽƐŽŵĞƐ
purportedly expels one of the chromosomes present.  These phenomena can lead to UPD 
and thence such disorders as Prader-Willi or Angelman syndromes.  
The clinical consequences of aneuploidy are well reported and were one of the reasons 
why PGS was developed (i.e. to selectively transfer embryos diagnosed as euploid).  
Ultimately this stemmed from the desire to improve IVF success rates, particularly in high-
risk groups (e.g. advanced maternal age, repeated implantation failure).  Previously, PGS 
required the removal of a piece of the embryo at the cleavage stage, followed by multi-
color fluorescence in-situ hybridization; FISH.  However, this was largely discredited 
following the results of randomized clinical trials (Staessen et al., 2004; Mastenbroek et 
al., 2007).  The practice of PGS with FISH at the cleavage stage largely under-estimated 
the phenomenon of chromosome mosaicism in the cleavage stage embryo, or at least 
thought it of sufficiently low incidence not to be clinically significant (reviewed in Taylor 
et al., 2014a).   
Recently, FISH technology has been superseded by aCGH or other CCS techniques for the 
diagnosis of preimplantation aneuploidy; however the contemporary CCS technology has 
a logistical drawback, namely its expense.  For this reason, current research points to a 
greater incidence of aneuploidy at the cleavage stage compared to the blastocyst stage 
(Adler et al., 2014).  This then raises the question of whether an embryo biopsied and 
diagnosed as aneuploid at day 3 could develop as a chromosomally normal fetus.  Of 
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course it would be unethical to knowingly transfer an embryo diagnosed as aneuploid in 
the absence of independent evidence that it was indeed chromosomally normal.  
However, the aforementioned evidence certainly lends credence to this hypothesis. 
 Several mechanisms have been described that might account for different patterns of 
ploidy in day 3 vs day 5 human embryos.  These mechanisms include preferential 
proliferation of euploid cell lines (Ruangvutilert et al., 2000) and preferential allocation of 
the aneuploid cells to the trophectoderm (James and West, 1994).  These proposed 
mechanisms, in addition to evidence that the cleavage stage mammalian embryo is 
particularly prone to chromosome segregation errors (Bean et al., 2001; Bean et al., 2002; 
Wells and Delhanty, 2000), suggest that the blastocyst stage is the most appropriate stage 
to perform embryo biopsy for PGS.  Moreover, recent randomized trial data provide 
indirect evidence to support this, by demonstrating the efficacy of trophectoderm biopsy 
followed by CCS (Scott et al., 2012 and 2013b).  To the best of my knowledge however, 
direct evidence showing that an embryo diagnosed as aneuploid at the cleavage stage can 
subsequently develop as a chromosomally normal fetus has yet to be established.  In this 
study I was fortunate enough to be able to analyze data from cycles that both cleavage 
stage and blastocyst biopsy was performed.  Retrospective data mining allowed us to test 
the hypothesis that chromosomal aneuploidy during the cleavage stage may not be 
clinically relevant to future development and can result in chromosomally normal live 
born offspring.  
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2.7.4 Materials and Methods 
Patients included in the study underwent IVF at Reproductive Associates of Charlotte 
between 2010 and 2012 and additionally received PGS using single nucleotide 
polymorphism (SNP) with cleavage stage biopsy due to either advanced maternal age 
(n=5), recurrent pregnancy loss (n=1), or previous IVF failures (n=4).  During this time, 
there was some evidence to suggest that blastocyst stage is a more ideal stage to perform 
PGS testing (Schoolcraft et al., 2010).  Therefore, if cleavage stage embryos diagnosed as 
aneuploid developed to a morphologically normal blastocyst, then these embryos were 
subject to a second biopsy to either confirm or refute the cleavage stage findings.  
Moreover, the re-biopsy at the blastocyst stage would confirm to the patient and to the 
clinicians that potentially viable embryos would not be discarded.  To this end, consent 
was sought from patients in order to allow us to rebiopsy and vitrify diagnosed aneuploid 
cleavage embryos if they developed to morphologically normal blastocysts.  This study 
was approved by Independent Review Consult (protocol #10040-01A) and by the 
University of Kent local research and ethics committee. 
All IVF procedures were conducted as routine standard of care.  Procedures for IVF, sperm 
preparation and intracytoplasmic sperm injection are extensively referenced elsewhere 
(Nagy et al, 1995; Taylor et al., 2014b; Taylor et al., 2014c).  A total of 34 human embryos 




2.7.4.1 Cleavage Stage Biopsy 
Embryos were group cultured using cleavage media (Cooper Sage, Trumbull, Connecticut, 
USA) + 10% SPS (Cooper Sage, Trumbull, Connecticut, USA) and overlayed with oil (Irvine 
Scientific, Santa Ana, California, USA) until day 3.  On day 3, embryos with greater than 
four blastomeres were placed in individual drops of Ca2+/Mg2+ free media (Cooper Sage, 
Trumbull, Connecticut, USA) supplemented with 10% SPS.  With the aid of a biopsy pipette 
(Cook Medical, Bloomington, IL, USA) and laser (Zilos-tk, Hamilton Thorne, Beverly, 
Massachusetts, USA) , a single cell was removed from a cleavage embryo and prepared 
for SNP microarray according to a reference lab protocol (Natera, San Carlos, California, 
USA).  After biopsy, embryos were cultured individually in blastocyst media (Cooper Sage, 
Trumbull, Connecticut, USA) supplemented with 10% SPS.  Those embryos that were 
diagnosed as aneuploid on day 3 and that developed to a morphologically normal 
blastocyst by day 6 were re-biopsied and vitrified. 
 
2.7.4.2 Blastocyst Biopsy 
Only blastocysts that presented with good quality ICM and trophectoderm were re-
biopsied.  Each individual blastocyst was placed in 20 µL of HEPES (Cooper Sage, Trumbull, 
Connecticut, USA) supplemented with 10% SPS overlayed with oil.  The blastocyst was 
held in place by a holding pipette (Cook Medical, Bloomington, Illinois, USA).  A biopsy 
pipette was then used to aspirate a piece of the trophectoderm into the bore of the 
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pipette.  Using a pulse of 610 µs and minimizing the number of pulses, a piece of the 
ƚƌŽƉŚĞĐƚŽĚĞƌŵ ǁĂƐ  “ĐƵƚ ? ĨƌŽŵƚŚĞďůĂƐƚŽĐǇƐƚ ? dŚŝƐƉŝĞĐĞŽĨ ƚƌŽƉŚĞĐƚŽĚĞƌŵ ǁĂƐ ƚŚĞŶ
prepared for SNP microarray according to reference lab protocol (Natera, San Carlos, 
California, USA).   
 
2.7.4.3 Blastocyst Vitrification 
After biopsy, blastocysts were individually vitrified.  Blastocysts were pipetted into 
equilibration solution (Irvine Scientific, Santa Ana, California, USA) for 15 minutes and 
then pipetted into vitrification (Irvine Scientific, Santa Ana, California, USA) solution for 
<1 minute.  From the vitrification solution, blastocysts were transferred to a Cryolock® 
(Biodiseno, Atlanta, Georgia, USA).  Care was taken to remove as much vitrification media 
as possible from the cryolock before plunging into liquid nitrogen.   
 
2.7.4.4 Frozen Embryo Transfer Cycles 
If a patient had no euploid embryos at the cleavage stage or failed to achieve pregnancy 
after the transfer of euploid diagnosed cleavage stage embryos, the patient was consulted 
on the prospect of using those blastocysts that were diagnosed as aneuploid at the 
cleavage stage yet euploid at the blastocyst stage.  Patients could utilize their euploid 
diagnosed blastocysts in a subsequent FET cycle.  Prior to their decision, all patients were 
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extensively counseled on the prospect of chromosomal mosaicism and possible clinical 
consequences, including live birth defects and miscarriages. 
 
2.7.5 Results 
SNP microarray results for the cleavage and blastocyst stage biopsy are represented in 
Table 18.  Only embryos that were biopsied at the cleavage stage and diagnosed as 
aneuploid were included in this study.  A total of 34 embryos from 10 patients were 
biopsied.  Embryo were only included if results were received from both a single cell from 
the cleavage stage and the trophectoderm at the blastocyst stage (Table 18).   
Of the 34 embryos diagnosed as aneuploid by SNP microarray at the cleavage stage, 16 
(47.1%) were found to be euploid when re-biopsied at the blastocyst stage. 
A total of 95 individual errors occurred at the cleavage stage and of those, 71/95 (74.7%) 
were not present in the blastocyst biopsy.  Both trisomic and monosomic errors at the 
cleavage stage were present at the same rate in the blastocyst biopsy, 34/95 (35.8%) and 
34/95 (35.8%), respectively (P=1.0000; chi-square test).  Overall, the autosomes 
presented with three nullisomies (3/95, 3.2%) at the cleavage stage, all that are not 
present in the blastocyst biopsy.  Seven non-disjunction events were observed with errors 
occurring at the cleavage stage, and the reciprocal error being detected at the blastocyst 
stage.  A total of 16/95 (16.8%) individual errors occurred at the cleavage stage that were 
also present in the blastocyst. 
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Data from the sex chromosomes were analyzed independently of the autosomes.  A total 
of 9 embryos presented with sex chromosome aneuploidies at the cleavage stage, six had 
an additional X, while 3 presented with XO.  Of the 6 embryos that presented with an 
additional X, all 6 (100%) were XX at the blastocyst stage.  All embryos that presented 
with XO on day 3 were XO at the blastocyst stage. 
Three patients underwent four transfers of seven abnormally diagnosed cleavage stage 
embryos that were identified as euploid at the blastocyst stage.  Of those four transfers, 
two have resulted in a live birth (patient #2, embryo #4 and patient #5, embryo #14; table 
18) and the other two resulted in a biochemical pregnancies (patient #10, embryos #29 
and 32; patient #10, embryos #31 and 34; table 18). 
 
2.7.6 Discussion 
Multiple studies have re-biopsied cleavage stage embryos diagnosed as aneuploid at the 
blastocyst stage (Li et al., 2005; Magli et al., 2000; Daphnis et al., 2008, Barbash-Hazan et 
al., 2009, Northrop et al., 2010; Capalbo et al., 2013a),  however, only one study by 
Capalbo and colleagues (2013a) has utilized CCS at all stages.  Northrop and colleagues 
(2010) re-biopsied aneuploid cleavage stage embryos diagnosed by FISH and 
subsequently performed CCS at the blastocyst stage.  Unfortunately, FISH has been shown 
to be insufficient in detecting chromosomal abnormalities; therefore, it is unknown if 
those diagnosed as aneuploid at the cleavage stage were truly aneuploid or if the 
abnormalities were a product of the FISH procedure (Treff et al., 2010).  Consequently, 
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ours is the second study to utilize CCS at both the cleavage and blastocyst stage and the 
first to report on live births from previously diagnosed aneuploid cleavage stage embryos 
that developed to euploid blastocysts.   
There are a number of mechanisms that would allow an aneuploid cleavage stage embryo 
to develop to a euploid blastocyst: preferential allocation of aneuploid cell lines to the 
trophectoderm (Figure 30), trisomic rescue (Figure 31A), endoreplication leading to UPD 
(Figure 31B), and advantageous growth of euploid cell lines during preimplantation 
development.  In this study, only the latter seems to be prevalent during preimplantation 
development. 
Figure 30: An aneuploidy cleavage stage embryo demonstrating preferential allocation of 











Table 18: SNP results of the same embryo at the cleavage and blastocysts stage.  (0) 
denotes no chromosomes present (i.e., (0)3, indicates no chromosome 3).  Sex 
chromosomes are disomic unless noted. ^ denotes <85% confidence in diagnosis (dx). 
 
Pt Emb. Day 3 Dx Day 5 dx Destiny Outcome 
1 1 +X Euploid Cryo NA 
2 2 +19 +19 Discarded NA 
2 3 -1,-2,-5,-16 Euploid Cryo NA 
2 4 +X Euploid FET Liveborn 
2 5 +21,+22 Euploid Cryo NA 
2 6 +X,-15 -15 Discarded NA 
2 7 +10 Euploid Cryo NA 
3 8 XO,-14,-15,-17,-20 XO Discarded NA 
3 9 +X,+3,+4,+5,+6,+9,+11,+15,+18 +15 Discarded NA 
3 10 69XXX 69XXX Discarded NA 
4 11 Euploid Euploid Cryo NA 
4 12 Euploid (^chromo 22, sex) -7 Discarded NA 
4 13 Euploid (^chromo 22) Euploid Cryo NA 
4 14 (0)1,-2,(0)3,-5,-7,-8,-9,-10,-11,-13,-16,-17,-20,-21,+22 +22 Discarded NA 
4 15 -17 Euploid Cryo NA 
4 16 +X,-13 Euploid Cryo NA 
4 17 Euploid (^chromo 22, sex) Euploid Cryo NA 
5 18 Euploid (^chromo 21) Euploid Cryo NA 
6 19 +20 Euploid FET Liveborn 
7 20 -5,+22 Euploid Cryo NA 
7 21 -16 -16 Discarded NA 
7 22 Euploid Euploid Cryo NA 
8 23 +19 +19 Discarded NA 
8 24 -19 -19 Discarded NA 
8 25 +5 +5 Discarded NA 
8 26 Euploid (^chromo 22) Euploid Cryo NA 
9 27 69XXX Euploid Cryo NA 
9 28 -1,-2,+13,+20 +1,+2,-20 Discarded NA 
10 29 -2 -2 Discarded NA 
10 30 Euploid (^chromo 22) Euploid Cryo NA 
10 31 -15 -15 Discarded NA 
10 32 -9,-22 -22 Discarded NA 
10 33 -10 Euploid Cryo NA 
10 34 Euploid (^chromo 21, sex) Euploid Cryo NA 
10 35 -20 -20 Discarded NA 
11 36 XY, -2,0(4),-8,-9,+10,+13,-17 OY,+2,+8,+9,+17 Discarded NA 
11 37 Euploid* Euploid Cryo NA 
11 38 XO,-1,-3,-9,-13,-14,-16,-17,-20 XO Discarded NA 
11 39 Euploid* +20 Discarded NA 
11 40 +X,+1,+5,+8,+10,+11,+12,+13,+14,+17,+0,+22 Euploid FET#1 Biochem 
11 41 +11 Euploid Discarded NA 
11 42 Euploid (^chromo 21) Euploid FET#1 NA 
11 43 -22 Euploid FET#2 Biochem 
11 44 +15 Euploid FET#1 NA 
11 45 XO XO Discarded NA 
11 46 -2 Euploid FET#2 NA 
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Figure 31: Proposed chromosomal mechanisms of self-correction that can lead to 
uniparental disomy (UPD).  A) Correction of a trisomic cell line by trisomic rescue, leading 
to a proper disomic cell line 2/3 of the time and UPD 1/3 of the time.  B) Correction of a 





Preferential allocation to the trophectoderm describes a process that the aneuploid cell 
line is forced to the trophectoderm of the preimplantation embryo.  If aneuploid cell lines 
were forced to the trophectoderm and euploid cell lines to the ICM, one would expect 
CPM.  This has been shown to exist in 1-2% of all pregnancies (Ledbetter et al., 1992), and 
there are data to suggest that it may be meiotic in origin (Robinson et al., 1997) or 
mitotically derived later in development when the cytotrophoblast invades the uterine 
wall (Weier et al., 2005).  However, current research has indicated that there is a high 
degree of concordance between the chromosomal status of the trophectoderm and ICM 
indicating no preferential allocation of aneuploid cell lines to the trophectoderm (Capalbo 
et al., 2013b; Johnson et al., 2010).  In order to demonstrate preferential allocation of 
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aneuploid cells lines to the trophectoderm, the ICM would have to be biopsied.  
Unfortunately this was not conducted during this particular study.  Nonetheless, some 
valuable observations have been made by Northrop and colleagues (2010).  In this study 
50 aneuploid cleavage stage embryos were biopsied at the blastocyst stage, and only 2 
(4%) of these presented with a euploid ICM and the same error detected at the cleavage 
stage present in the trophectoderm.  However, both of these embryos also presented 
with euploid sections of trophectoderm.  If allocation of aneuploidies to the 
trophectoderm was active, one would expect more abnormalities to be present at the 
blastocyst stage.  However, this is not the case, and aneuploidies are more common at 
the cleavage stage then at the blastocyst stage (Adler et al., 2014).  
This study had two live births and two biochemical pregnancies from diagnosed aneuploid 
cleavage stage embryos.  These embryos had euploid cell lines present in the 
trophectoderm as evident by re-biopsy at the blastocyst stage.  It is possible that the 
aneuploid cell line from the cleavage stage embryo was incorporated into the 
trophectoderm, however it did not propagate and the biopsy at the blastocyst stage did 
not detect the aneuploidies.  Everett and West (1998) demonstrated that mosaicism 
within the blastocyst can have either a checkerboard or scattered pattern.  However, this 
observation was made from a 4N-->2N mouse chimera, and has not been demonstrated 
in human blastocysts or with trisomies.  Nonetheless, it is plausible that the blastocyst 
stage biopsy did not detect the aneuploidies because of the location of the biopsy.  
Alternatively, it is also possible that the aneuploid cell lines along with euploid cell lines 
are present within both the ICM and the trophectoderm.  In the two embryos that 
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resulted in a live born, the euploid cells could have been destined to become the fetus 
while the aneuploid cell lines became extraembryonic tissue.  Likewise, in the two 
biochemical pregnancies, the aneuploid cells could have been destined to become the 
fetus while the euploid cell lines became the extraembryonic tissue.  The two biochemical 
pregnancies occurred in the same patient, at two different transfers; therefore, it cannot 
be ruled out that these biochemical pregnancies were patient related as opposed to 
embryonic. 
A second mechanism that an aneuploid cleavage stage embryo might develop to a euploid 
blastocyst is trisomic rescue.  In this instance, anaphase lag can alter a trisomy cell line by 
reducing the number of chromosomes from 47 to 46 (reviewed in Taylor et al., 2014a).  
This occurs when a chromatid fails to become incorporated during the final stages of 
mitosis.  In this study, a total of 34 trisomies detected at the cleavage stage were not 
present at the blastocyst stage.  If a lag event occurred in a trisomic cell line, it is possible 
that the trisomy would be rectified to a disomy state.  Since a trisomic chromosome 
contains 2 chromatids from one parent and a single chromatid from the other, 2/3 of the 
time the process of reducing a trisomic chromosome should result in a proper disomic cell 
line, while 1/3 of the time the process should result in UPD (Figure 31A).  Similarly, 34 
monosomic events occurred at the cleavage stage and corrected themselves by the 
blastocyst stage.  In order to correct this error, an endoreplication event, the duplication 
of an entire chromosome, resulting in UPD must occur (Figure 31B).  Given these errors, 
one would have expected UPD to occur in approximately 45 of the errors that corrected; 
however, this was not the case, as UPD was not detected in any sample within the 
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trophectoderm.  This finding parallels research demonstrating that UPD occurs in 
approximately 0.06% of blastocysts, indicating that UPD is an extremely rare event (Gueye 
et al., 2014).  The overall suggestion therefore, is that the mechanisms of endoreplication 
and trisomy rescue do not explain the embryos ability to compensate for cleavage stage 
aneuploidy. 
Research has indicated that the cleavage stage is highly prone to chromosomal 
malsegregation, particularly in ambient air as opposed to lower oxygen culture conditions 
(Bean et al. 2001; Bean et al., 2002).  However, more recent studies have shown an 
increase in euploid cells as the embryo progresses (Ruangutilert et al., 2008; Adler et al., 
2014).  For example, Santos and colleagues (2010) demonstrated an increase in euploid 
rates from day 4 (6%), day 5 (37%), and day 8 (58%) while Munne and colleagues (2005) 
cultured aneuploid embryos with fibroblasts and found approximately 50% of the cells 
were normal by day 12.  In this study, 16 embryos that were aneuploid at the cleavage 
stage were euploid at the blastocyst stage.  Moreover, a total of 95 errors occurred at the 
cleavage stage, while only 26 errors occurred at the blastocyst stage.  This supports other 
research showing that blastocyst development favors euploid cell lines (Ruangutilert et 
al., 2008; Adler et al., 2014). 
Of the embryos that resulted in a successful child, one was diagnosed on day 3 as trisomy 
20 and the other as XXX.  Trisomy 20 is one of the more common abnormalities and 
typically leads to miscarriage in the first trimester (Robinson et al., 2005).  Triple XXX 
syndrome is a rare disease that often goes undiagnosed because it presents with little to 
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no clinical manifestations (Ben Hamouda et al., 2009).  It is of course possible that these 
liveborns may be mosaic, however in order to fully eliminate mosaicism as a possibility 
one would have had to examine the placenta (as mosaicism can become isolated to the 
placenta), which was not carried out in this study (Kalousek and Dill, 1983).  Moreover, 
mosaicism in the blastocyst seems to be incredibly low, (approximately 5%; Capalbo et 
al., 2013b) and so even if the blastocysts were mosaic, it may not have been clinically 
significant.  Nonetheless, both babies are currently healthy and present with no 
abnormalities. 
Lastly, one must be careful in interpreting these results, as no test is 100% accurate.  SNP 
microarray has been validated to have a false-positive rate of 3.9% and a false-negative 
rate of 2.1% (Johnson et al., 2010).  However, research suggests that analysis of single 
cells by SNP array is flawed and can lead to the over stating of errors (Handyside et al., 
2010; Bisignano et al., 2011).  Scott and colleagues (2012) demonstrated that both 
cleavage stage and blastocyst stage euploidy is predictive of live birth rate.  In their study, 
only 1/53 (1.9%) embryo that was diagnosed as aneuploid at the cleavage stage 
developed to a live birth, while 3/46 (6.5%) blastocysts diagnosed as aneuploid developed 
to a liveborn.  In this respect, this study contradicts theirs by demonstrating that the 
chromosomal status of the cleavage stage embryo is a poor predictor of the chromosome 
copy number in the child.  
Due to the lack of evidence in support of preferential allocation to the trophectoderm 
and the low incidence of UPD during preimplantation development, I propose that the 
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only active corrective mechanism during preimplantation development is the 
advantageous growth of euploid cell lines.  In this study, the majority of errors at the 
cleavage stage were corrected by the blastocyst stage (71/95. 74.7%), indicating that this 
mechanism is fairly efficient.  Lastly, the dogma that the chromosomal status of the 
cleavage stage embryo is predictive of the chromosome copy number in the blastocyst or 
child should be reconsidered.  
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2.8 Specific Aim 8.  To assess aneuploidy rates between the polar, mid, and 
mural trophectoderm? 
For this specific aim, the following published works are presented: 
Taylor TH, Crain JL, Katz SL, Griffin DK. Preliminary assessment of aneuploidy rates 
between the polar, mid and mural trophectoderm. Submitted JARG 2017. 
Stankewicz-McKinney TL, Taylor TH, Glassner MJ, Orris JJ, Basile DR, Griffin DK. 2015. 
Preliminary assessment of aneuploidy rates between the polar, mid, and mural 
trophectoderm. PGDIS, Chicago. 
 
2.8.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.8.2 Chapter Summary 
It has been suggested that ploidy is consistent throughout the trophectoderm.  Thus, cells 
removed from the mural trophectoderm should mirror the chromosome content of the 
remaining cells.  To test this hypothesis, this projected aimed to compare aneuploidy rates 
between three distinct areas of trophectoderm: mural, polar, and a region in between 
ƚŚĞƐĞƚǁŽůŽĐĂƚŝŽŶƐƚĞƌŵĞĚƚŚĞ “ŵŝĚ ?ƚƌŽƉŚĞĐƚŽĚĞƌŵ ?ůůĨĞƌƚŝůŝǌĞĚŽŽĐǇƚĞƐǁĞƌĞĐƵůƚƵƌĞĚ
to day 3 and AH was performed.  Embryos were placed back into incubator and cultured 
to the blastocyst stage.  Embryos whose trophectoderm was hatching out of the ZP 
underwent the biopsy procedure.  Biopsied blastocysts were divided into three groups 
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depending on which area (polar, mid, or mural) of the trophectoderm was protruding 
from the ZP and was biopsied.  Aneuploidy rates were significantly higher with cells from 
the polar region of the trophectoderm (56.2%) compared to cells removed from the mural 
region of the trophectoderm (30.0%).  Although not significant, this data does show a 
strong trend in decreasing aneuploidy from the polar (56.2%), mid (47.4%), and mural 
trophectoderm (30.0%; Figure 32).  The non-concordance demonstrated between polar 
and mural trophectoderm can be attributed to biological occurrences, differences 
between embryologists in the biopsy procedure, and chromosomal mosaicism. 
 
2.8.3 Introduction 
Aneuploidy refers to the presence of absence of whole chromosomal abnormalities.  In 
order for a euploid live birth to occur, chromosomes must divide equally in the developing 
fetus.  Any abnormal division during development can have disastrous downstream 
effects, leading to poor embryo development, failed implantation, obstetric 
complications, pregnancy loss, stillbirth, neonatal congenital abnormality, and infertility.  
Thus, PGS has been created to tests for aneuploidy prior to implantation thereby allowing 
the transfer of only diagnosed euploid embryos.  The transferring of euploid embryos has 
demonstrated a higher pregnancy rate, lower miscarriage rate, and higher live birth rate 
than the transfer of untested embryos (Scott et al., 2013b). 
Biopsy for PGS occurs the majority of the time at either the cleavage (day 3) or blastocyst 
stage (day 5/6).  For cleavage stage biopsy, a single cell is removed from a 5-8 cell embryo.  
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In contrast, at the blastocyst stage, approximately 5-10 cells are removed from a 
blastocyst that can contain hundreds of cells.  Thus, the removal of one cell from a 
cleavage stage embryo represents a larger proportion of the embryo and has been shown 
to cause a decrease in implantation potential when compared to blastocyst stage biopsy 
(Scott et al., 2013a).  Not only is blastocyst biopsy less detrimental but more cells removed 
ĨŽƌĂŶĂůǇƐŝƐĐĂŶŝŵƉƌŽǀĞĂĐĐƵƌĂĐǇĂŶĚĚĞĐƌĞĂƐĞ “ŶŽƌĞĂĚƐ ?   /ƚ is believed that all cells 
within the trophectoderm have the same karyotype and aneuploidy or euploidy is 
consistent throughout the blastocyst.   
The blastocyst represents the first stage of differentiation in preimplantation 
development.  The blastocyst differentiates into the ICM, which will become the fetus, 
and the trophectoderm that will become the placenta.  The trophectoderm itself is 
subdivided into two areas based on the location of the ICM: the mural trophectoderm, 
the area furthest away from the ICM, and the polar trophectoderm, the area adjacent to 
the ICM.  Typically during PGS, cells are removed from the mural trophectoderm as not 
to expose the ICM to the damage caused by the laser (Taylor et al., 2014b; Taylor et al., 
2014c).  However, blastocyst biopsy is not standardized, which can lead to inter and intra 
differences with embryologists in terms of the area of biopsied. 
It has been suggested that ploidy is consistent throughout the trophectoderm i.e. that all 
cells have the same karyotype.  Thus, cells removed from the mural trophectoderm 
should mirror the chromosome content of the remaining cells.  To test this hypothesis, 
this projected aimed to compare aneuploidy rates between three distinct areas of 
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trophectoderm: mural, polar, and a region in between these two locations termed the 
 “ŵŝĚ ?ƚƌŽƉŚĞĐƚŽĚĞƌŵ ? 
 
2.8.4 Methods 
This study was deemed exempt by Sterling IRB because it only incorporated routine IVF 
procedures.  Only patients undergoing IVF with PGS between January 2012 and April 2013 
at Reproductive Endocrinology Associates of Charlotte (Charlotte, North Carolina, USA) 
were included in this study.  All biopsy specimens were sent to Genesis Genetics (Detroit, 
Michigan, USA) where samples underwent NGS by the Veriseq kit (Illumina, San Diego, 
USA). 
Briefly, all fertilized oocytes were cultured to day 3 and AH was performed.  Embryos were 
placed back into incubator and cultured to the blastocyst stage.  Embryos whose 
trophectoderm was hatching out of the ZP underwent the biopsy procedure.  Biopsied 
blastocysts were divided into three groups depending on which area (polar, mid, or mural) 
of the trophectoderm was protruding from the ZP and was biopsied. 
 
2.8.4.1 Egg Retrieval and Embryo Culture  
All retrieved oocytes were designated for intracytoplasmic sperm injection (ICSI).  Oocytes 
were retrieved, trimmed of blood, and stripped of cumulus cells as described by Taylor 
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and colleagues (2006).  Oocytes were separated based on maturity and placed into a 60 
mm dish (Thermo scientific, Rochester, New York, USA) with approximately 100 µL drops 
of CSC (Irvine Scientific, Santa Ana, California, USA) supplemented with 10% SSS (Irvine 
Scientific, Santa Ana, California, USA) and overlayed with oil (Irvine Scientific, Santa Ana, 
California, USA).  After grading, the dish containing the oocytes was placed into an 
incubator at 37oC, 6% CO2 and 5% O2 for 2-3 hours.  After 2 hours, all oocytes presenting 
ǁŝƚŚĂƉŽůĂƌďŽĚǇǁĞƌĞ/^/ ?ĚĂƐĚĞƐĐƌŝďĞĚďǇEĂŐǇĂŶĚĐŽůůĞĂŐƵĞƐ ? ? ? ? ? ) ?ƉůĂĐĞĚďĂĐŬ
into the same dish, and put back into the incubator. 
The next day, 16-18 hours post ICSI, oocytes were evaluated for proper fertilization.  
Embryos that exhibited two pronuclei were group cultured in a fresh dish of CSC+10%SSS 
overlayed with oil and placed back into the incubator.  Embryos were not viewed on day 
2.   
On day 3, the embryos were removed from the incubator, graded, and AH was performed 
on all cleaving embryos with the aid of a laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, 
USA).  Using a pulse of 610 µs, the ZP was breached with 2-3 shots of the laser (Zilos-tk, 
Hamilton Thorne, Beverly, Maine, USA).  The ZP was breached where there were no 
blastomeres that could be directly affected by the laser pulse.  After breaching the ZP with 
the laser, the embryos were left in the same drop and placed back into the incubator. 
On the morning of day 5 (112-115 hours post insemination) and day 6 (136-139 hours 
post insemination), embryos were removed from the incubator, blastocysts were graded 
based on Schoolcraft and colleagues (1999), and those blastocysts that had a good or fair 
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trophectoderm protruding from the ZP along with good or fair quality ICM were biopsied.  
Blastocysts were only viewed once in the morning and at no other times.  If the blastocysts 
were not suitable for biopsy in the morning of day 5, they were reevaluated on the 
morning of day 6.  Blastocysts were biopsied on day 5 or day 6, which ever day they met 
the biopsy criteria.  If embryos did not meet the criteria for biopsy on day 6, they were 
discarded.  There was no difference between blastocysts that were biopsied on day 5 or 
day 6 other than the embryos needed an extra day to reach the proper stage for biopsy. 
 
2.8.4.2 Trophectoderm biopsy 
Blastocysts that presented with a good or fair quality ICM and trophectoderm were placed 
in a drop of modified human tubal fluid (Irvine scientific, Santa Ana, California, USA) + 
10% SSS (Irvine scientific, Santa Ana, California, USA).  Suction was applied to the 
blastocysts via a holding pipette (Humagen, Charlottesville, Virginia, USA).  A biopsy 
pipette (Humagen, Charlottesville, Virginia, USA) gently aspirated the trophectoderm into 
the biopsy needle.  A laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA), with a pulse 
length of 610 µs ?ǁĂƐƵƐĞĚƚŽ “ĐƵƚ ?ƚŚĞƚƌŽƉhectoderm from the blastocyst, taking care 
not to expose the trophectoderm to unnecessary laser pulses.  The piece of 
ƚƌŽƉŚĞĐƚŽĚĞƌŵ ǁĂƐ ƉƌĞƉƉĞĚ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ƌĞĨĞƌĞŶĐĞ ůĂďƐ ? ƉƌŽĐĞĚƵƌĞƐ ĨŽƌ Ă',
(Genesis Genetics, Detroit, Michigan, USA).  aCGH slides were supplied by Bluegnome 
(Cambridge, United Kingdom) and were validated through FISH reanalysis of embryos 
(Fragouli et al, 2011).  
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2.8.5 Results 
In total, 166 blastocysts were biopsied, 48 from the plural trophectoderm, 78 from the 
mid trophectoderm, and 40 from the mural trophectoderm.  There was no significant 
difference in maternal age between the three groups, i.e. 35.8±4.9 years, 34.9±4.4 years, 
and 35.2±5.1 years, for the plural, mid, and mural trophectoderm, biopsied groups 
respectively (Table 19; P=0.8024).  Aneuploidy rates were 27/48 in polar trophectoderm 
group (56.2%), 37/78 in the mid trophectoderm group (47.4%), and 12/40 in the mural 
trophectoderm group (30.0%; Table 19; P=0.1859).  Interestingly, in a direct comparison 
between mural and polar trophectoderm, aneuploidy rates were significantly higher 
(Table 20; P=0.0243).   
 
2.8.6 Discussion 
The hypothesis that aneuploidy is evenly distributed throughout the trophectoderm 
cannot be supported by this study.  Aneuploidy rates were significantly higher when cells 
were taken from the polar region of the trophectoderm (56.2%) compared to cells 
removed from the mural region of the trophectoderm (30.0%).   
Table 19: A comparison of aneuploidy rates between the polar, mid, and mural 
trophectoderm. 
1 Kruskal-Wallis test                  2 Chi-square test 
 Polar Mid Mural P value 
Avg. Age (years) 35.8±4.9 34.9±4.4 35.2±5.1 0.802411 
No. Blastocyst 48 78 40 
0.185922 
No. Aneuploid 27 (56.2%) 37 (47.4%) 12 (30.0%) 
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Table 20: A comparison of aneuploidy rates between polar and mural trophectoderm. 
 Polar Mural P Value 
Avg. Age (years) 35.8±4.9 35.2±5.1 0.84171 
No. Blastocyst 48 40 
0.024322 
No. Aneuploidy 27 (56.2%) 12 (30.0%) 
1 Kruskal-Wallis test               2 Chi-square test 
Figure 32: Aneuploidy rates between polar, mid, and mural trophectoderm. 
 
Although not significant, this data does show a strong trend in decreasing aneuploidy 
from the polar (56.2%), mid (47.4%), and mural trophectoderm (30.0%; Figure 32).  The 
non-concordance demonstrated between polar and mural trophectoderm can be 
attributed to biological occurrences, differences between embryologists in the biopsy 
procedure, and chromosomal mosaicism. 
Biologically speaking, Hogan and Tilly (1978) dissected mouse ICM from the 
ƚƌŽƉŚĞĐƚŽĚĞƌŵĂŶĚůĞĨƚƚŚĞ/DŝŶĐƵůƚƵƌĞ ?tŝƚŚŝŶ ?ĚĂǇƐ ?ƐŽŵĞŽĨƚŚĞŝŶĚŝǀŝĚƵĂů/D ?Ɛ
had the appearance of a blaƐƚŽĐǇƐƚ ?DŽƌĞŽǀĞƌ ?ƚŚĞŝŶĚŝǀŝĚƵĂů/D ?ƐĚĞƌŝǀĞĚƚƌŽƉŚ ďůĂƐƚ
giant cells.  These studies suggest that cells from the ICM feed the trophectoderm.  It is 





























explain these data.  For example, if the ICM were mosaic and contained equal proportions 
of aneuploid and euploid cells, then aneuploid cells would feed into the trophectoderm 
at the same rate as euploid cells.  However, once in the trophectoderm, the euploid cells 
would proliferate at a faster rate than aneuploid cells (Ruangvutilert et al., 2000).  Thus, 
the blastocyst could have a higher proportion of aneuploid cells in the polar compared to 
the mural trophectoderm, which these data supports.  Conversely, this theory would 
suggest that the blastocyst may be able to allocate aneuploid cells to the trophectoderm 
thereby correcting its chromosome state by the elimination of aneuploid cells from the 
ICM.  Research using FISH and array based techniques have found no evidence of this 
correction mechanism in place for human blastocysts (Johnson et al., 2010; Northrop et 
al., 2010; Evsikov and Verlinsky, 1998; Magli et al., 2000; Derhaag et al., 2003; Fragouli et 
al., 2008). 
Another biological reason for the discrepancy between regions of the trophectoderm 
could be the process of implantation.  During implantation, the blastocyst embeds itself 
with the ICM (polar trophectoderm) against the uterine wall.  In order to invade into the 
uterine wall, the cytotrophoblasts, which are located in the polar region, have been 
shown to induce aneuploidy (Weier et al., 2005).  Aneuploidy in the polar region may be 
a completely normal pathway of cytotrophoblast invasion.  These data suggests that 
aneuploidy is higher in the polar region, possibly because the embryo is undergoing 
chromosomal changes to prepare for implantation.  Unfortunately this study did not 
examine implantation rates between the three different categories, so it is unknown if 
aneuploidy in the polar region is detrimental.  HowevĞƌ ? ƚƌĂŶƐĨĞƌƐ ŽĨ  “ĂŶĞƵƉůŽŝĚ ? Žƌ
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mosaic blastocysts have resulted in euploid live births suggesting that some aneuploidy 
and mosaicism may not be clinically significant (Scott et al., 2013a; Florinto et al., 2015; 
Taylor et al., 2014a). 
Literature is currently lacking in terms of the effects of the biopsy procedure on the 
outcomes of CCS cycles.  For example, in this study, the embryologist has to biopsy from 
the mural trophectoderm.  Because of its proximity to the ICM, it is possible that some 
ICM cells were removed with the trophectoderm during the biopsy.  Unfortunately, the 
level of contamination between the ICM and trophectoderm during the biopsy is 
unknown.  However, this may not affect the CCS result as research has indicated a high 
concordance between the two regions (Rabonowitz et al., 2010; Capalbo et al., 2012).  
Moreover, recent research has suggested a limited effect of the embryologist on the CCS 
results (Capalbo et al., 2015).  Interestingly, with the advent of NGS and its increase in the 
detection of mosaicism, the biopsy procedure has become a variable.  For example, 
ŵŽƐĂŝĐŝƐŵŝƐĚĞƉĞŶĚĞŶƚŽŶƚŚĞŶƵŵďĞƌŽĨĐĞůůƐĂŶĂůǇǌĞĚ ?/ĨĞŵďƌǇŽůŽŐŝƐƚ “ ?ďŝŽƉƐŝĞƐ ?
ĐĞůůƐĨƌŽŵƚŚĞďůĂƐƚŽĐǇƐƚ ?ŵŽƐĂŝĐŝƐŵǁŝůůŶŽƚďĞĚĞƚĞĐƚĞĚ ?,ŽǁĞǀĞƌ ?ŝĨĞŵďƌǇŽůŽŐŝƐƚ “ ?
biopsies 10 cells from the blastocysts, the probability that mosaicism will be detected 
increases due to the increase number of cells biopsied.  Research has also suggested that 
the majority of abnormalities at the blastocyst stage are mitotic in origin, suggesting that 
with enough cells present, CCS results could be altered (Rabonowitz et al., 2015). 
These data also suggests other occurrences during preimplantation development.  Of the 
166 blastocysts, there was no difference between which area (polar, mid, or mural) 
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hatched out of the blastocyst, 37.8%, 30.7%, 31.5%, respectively (P=NS).  Schimmel and 
colleagues (2014) demonstrated a similar trend in mouse embryos that underwent laser 
AH whereby 32%, 33%, and 35% hatched from the polar, mid, and mural trophectoderm, 
respectively.  
One argument to the current data is the phenomena of mosaicism (Taylor et al., 2014a).  
One could biopsy from the polar, mid, and mural trophectoderm from a single blastocyst; 
however, this was not possible because these were patients undergoing IVF and not 
blastocysts donated to research.  Northrop and colleagues (2010) examined three 
separate sections of the trophectoderm and demonstrated a concordance rate of 80% 
(40/50 blastocysts).  Unfortunately this study did not record the location of the 
trophectoderm samples in relation to the ICM.  Most of the research with mosaicism at 
the blastocyst stage deals with the reanalysis of aCGH samples or the mixing of known 
cell lines to determine the percent mosaicism present in the entire blastocyst (Ruttanajit 
et al., 2016).  Using a technique developed by Taylor and colleagues (2016b), it would be 
ƉŽƐƐŝďůĞƚŽĞĨĨĞĐƚŝǀĞůǇ “ŵĂƉ ?ĂŶĞƵƉůŽŝĚŝĞƐŝŶƐŝŶŐůĞĐĞůůƐĨƌŽŵƚŚĞďůĂƐƚŽĐǇƐƚ ?ǁŚŝĐŚŵĂǇ
help in understanding aneuploidy and blastocyst morphology.   
In conclusion, these data does not support the hypothesis that aneuploidy is evenly 
distributed throughout the trophectoderm.  This study adds to the pool of data that may 
ŚĞůƉƉĂƚŝĞŶƚƐĂŶĚĐůŝŶŝĐŝĂŶƐƵŶĚĞƌƐƚĂŶĚǁŚǇƐŽŵĞĞŵďƌǇŽƐĚŝĂŐŶŽƐĞĚĂƐ “ĞƵƉůŽŝĚ ?ĨĂŝůƚŽ
implant.  Further research is needed to better understand aneuploidy at the blastocyst 
stage and its clinical consequences. 
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2.9 Specific aim 9.  To determine if a previously diagnosed aneuploid 
trophectoderm relates to the embryo proper. 
 
For this specific aim, the following published works are presented: 
Taylor TH, Divic N, Katz SL, Gitlin SA, Griffin DK. Reanalysis of blastocysts previously 
diagnosed as aneuploidy demonstrates that one in four are rediagnosed as euploid. 
Submitted 2017. 
 
2.9.1 My Personal Contribution to the Work 
For this study I did the majority of the embryology including setup, biopsies, and tubing.  
I developed the idea, analyzed the data, and wrote the manuscript. 
 
2.9.2 Chapter Summary 
Preimplantation genetic screening is typically performed on a piece of the 
trophectoderm.  The biopsied sample should reflect the whole embryo, however data 
showing the relationship between the chromosome content of the trophectoderm and 
its relationship to the chromosome content of the whole embryo is limited.  Due to 
mosaicism, I hypothesize that the trophectoderm biopsy is not concordant to the whole 
embryo.  Blastocysts with a previously diagnosed aneuploidy trophectoderm sample were 
assessed for chromosomes using aCGH.  A total of 43 blastocysts from 34 patients 
(35.3±2.4 years) were analyzed.  Of these, 24 (55.8%) exhibited full concordance between 
the trophectoderm sample and the blastocyst, six (11.6%) had at least one aneuploid 
chromosome that was concordant between the trophectoderm and blastocyst, two 
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(4.7%) were non concordant but both the trophectoderm and blastocyst were 
aneuploidy.  Remarkably, 11 (25.6%) displayed a euploid result.  Of the 65 aneuploidies 
detected in the trophectoderm, 37 (56.9%) were detected in the whole blastocyst.  In 
approximately one quarter of the blastocysts analyzed, a diagnosis of aneuploidy did not 
reflect the chromosome constitution of the whole embryo.  Possible explanations for this 
are mosaicism, mitotic non-disjunction, post-zygotic errors with sequestering of the 
aneuploid cells to the trophectoderm, and/or technical errors.   
 
2.9.3 Introduction 
Chromosome malsegregation, or aneuploidy, is the leading cause of miscarriages and IVF 
failure (Hassold and Hunt, 2001).  In order to screen for aneuploidy during the course of 
IVF, PGS has been developed.  Previously, PGS was performed on cleavage stage embryos 
using a technique known as FISH that allows for the detection of a limited number of 
chromosomes (Griffin et al., 1994).  Aneuploidy, as demonstrated by FISH, is well 
documented in scientific literature (Baart et al., 2007; Li et al., 2005; Rubio et al., 2005; 
Munne et al., 1995).  More recently however, PGS has transitioned to testing at the 
blastocyst stage and using techniques that can detect aneuploidies across all 
chromosomes, referred to as CCS (Treff et al., 2010, 2012; Gutierrez-Mateo et al., 2011). 
When PGS utilizes trophectoderm biopsy and an aneuploidy is diagnosed, the assumption 
is that this aneuploidy is present throughout the embryo as well.  One study 
demonstrated a high concordance between the trophectoderm and ICM (Capalbo et al., 
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2012).  However this study was conducted using FISH which does not detect all errors 
(Treff et al., 2010).  Using CCS, Johnson and colleagues (2010) examined all the 
chromosomes from the ICM and trophectoderm and found a 96% concordance rate 
between the two sections.  Subtle differences may be reflective of biological errors or 
technical errors.  Mosaicism, or the presence of two distinct cell lines, is common at the 
blastocyst stage; therefore, a small piece of the trophectoderm may not be representative 
of the entire embryo (Taylor et al., 2014a).  Chromosomal mosaicism within the 
trophectoderm has been demonstrated in approximately 20% of embryos (Northrop et 
al., 2010).  However, the chromosome constitution of the whole embryo in regards to the 
biopsied trophectoderm is sparse. 
Theoretically, the biopsied sample should reflect the embryo as a whole; however 
karyotype data showing the relationship between the chromosome content of the 
trophectoderm and its relationship to the average chromosome content of the blastocyst 
is sparse.  Moreover, mosaicism may cause a non-concordant result between the 
trophectoderm and the remaining embryo.  The objective of this study is to examine the 
chromosome constitution of trophectoderm biopsies and test the hypothesis that the 
corresponding blastocyst yields a contradictory result. 
 
2.9.4 Methods 
This is an observational study and was approved by an institutional review board (WIRB 
#1138244).  The University of Kent Research Ethics Advisory Group also approved this 
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study.  Only previously diagnosed aneuploid blastocysts that were donated to research 
were used in this study.  Ovarian hyperstimulation, IVF, ICSI, extended culture, and 
vitrification are discussed in detail elsewhere (Taylor et al., 2014b, 2014c).  
Briefly, embryos from patients requesting PGS were cultured to the blastocyst stage.  Only 
blastocysts presenting with a good or fair quality ICM and trophectoderm were biopsied 
on day 5 or day 6.  Blastocysts chosen for biopsy were placed in modified human tubal 
fluid (Irvine Scientific, Santa Ana, California, USA) + 10% SSS (Irvine Scientific, Santa Ana, 
California, USA) overlayed with oil (Irvine Scientific, Santa Ana, California, USA).  The 
blastocyst was held in place with a holding pipette (Humagen, Charlottesville, Virginia, 
USA).  Using a laser (Zilos-tk, Hamilton Thorne, Beverly, Maine, USA) and a biopsy pipette 
(Humagen, Charlottesville, Virginia, USA), care was taken to remove approximately 5-10 
cells of the trophectoderm.  Immediately after biopsy, the piece of the trophectoderm 
was prepped for aCGH while the biopsied blastocysts were individually vitrified on a 
Cryolock ® (Biodiseno, Atlanta, Georgia, USA) as previously described (Taylor et al., 
2014b).   
ŽŶĂƚĞĚ ĂŶĞƵƉůŽŝĚ ďůĂƐƚŽĐǇƐƚƐ ǁĞƌĞ  “ŬŶŽĐŬĞĚ ŽĨĨ ? ƚŚĞƌǇŽůŽĐŬ ŝŶƚŽ  ? ?0C thawing 
solution (Irvine Scientific, Santa Ana, California, USA).  The protocol for aCGH requires that 
the cells be lysed for analysis.  For this reason, it was decided that the blastocysts did not 
have to undergo the complete warming procedure.  Upon visualization of the blastocyst 
in the thawing solution, a 150 um stripper tip was used to pipette the blastocyst up and 
down until the ZP was separated from the blastocyst.  The entire blastocyst was prepped 
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for aCGH by sending it through a series of rinses with wash buffer and placed into the PCR 
tube for analysis.  The reference laboratory was blinded to the previous analysis. 
 
2.9.4.1 Array Comparative Genomic Hybridization 
The cells in the PCR tubes underwent whole genome amplification (WGA; Sureplex, 
Rubicon Genomics/Bluegnome; CPC4, Capital Park).  Cy3 dye and Cy5 dye was used for 
the sample and reference DNA, respectively.  The sample DNA and reference DNA were 
denatured at 740C.  Both sets of DNA were mixed, placed on the microarray slide, and 
hybridized overnight at 470C.  Afterwards, the microarray slides were washed at room 
temperature for 10 minutes with 2x saline sodium citrate (SSC) and 0.05% Tween-20, 10 
minutes with 1x SSC, 5 minutes with 0.5 SSC at 600C, and lastly in 0.1x SSC.  Microarray 
slides with DNA were scanned and analyzed by Bluefuse software (Harton et al., 2013). 
 
2.9.5 Results 
A total of 43 whole blastocysts from 34 patients (35.3±2.4 years) were analyzed by aCGH.  
Of these, 24 (55.8%; Table 21) exhibited full concordance between the trophectoderm 
sample and the whole blastocyst, six (11.6%; Table 21) had at least one aneuploid 
chromosome that was concordant between the trophectoderm and blastocyst, two 
(4.7%; Table 21) were non concordant but both the trophectoderm and blastocyst were 
aneuploidy.  Remarkably, 11 (25.6%; Table 21) displayed a euploid result. 
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In the original biopsied trophectoderm samples, a total of 65 whole aneuploidies were 
diagnosed and two segmental aneuploidies.  Of the 65 aneuploidies, 37 (56.9%) were 
detected in the whole embryo consisting of 19 (51.4%) gains and 18 (48.6%) losses.  There 
were 28 aneuploidies detected in the trophectoderm sample that were not in the 
blastocyst, composing of 16 (57.1%) gains and 12 (42.9%) loses. 
Two trophectoderm samples presented with segmental aneuploidies (#22 and #31).  
Trophectoderm sample #22 presented with a deletion on the p arm on chromosome 6, 
the same deletion was seen throughout the entire embryo.  Trophectoderm sample #31 
presented with a deletion on the q arm on chromosome 1.  This deletion was not present 
in the entire blastocyst.  Although this blastocyst did not present with the segmental 
aneuploidy seen in the original trophectoderm sample, the blastocyst still presented with 
a monosomy 19 error. 
From the 31 whole aneuploid blastocysts, a total of 42 aneuploid chromosomes were 
determined.  Of these, 37 (88.1%) had been initially detected in the trophectoderm, 
composing of 18 (48.7%) gains and 19 (51.3%) losses.  Five (11.6%) aneuploidies in the 
whole blastocyst were not detected by the trophectoderm biopsy, composing of three 
(60.0%) gains and two (40.0%) loses.   
 
2.9.6 Discussion 
These results indicate that the trophectoderm yielded full concordance with the whole 
blastocyst approximately 56% of the time.  Interestingly, at the chromosomal level, 88.1% 
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of aneuploidies detected in the trophectoderm were detected in the whole embryo.  
Biological reasons for discrepancies include chromosomal mosaicism (Figure 33A), mitotic 
non-disjunction with equivalent number of trisomy and monosomy cells (Figure 33B), 
preferential sequestering of the aneuploid cells to the trophectoderm (Figure 33C) and 
technical errors in the CCS test.  
As previously discussed, chromosomal mosaicism refers to the presence of two or more 
distinct cell lines and is a well-documented phenomenon during human preimplantation 
development.  In these data, 19 of 43 (44.2%) could be classified as mosaics.  Reports 
have demonstrated a mosaicism rate of 69%, 33%, and 16% in the blastocyst (Liu et al., 
2012; Fragouli et al., 2011; Northrop et al., 2010).  Conflicting results on the rate of 
mosaicism could be due to the tests utilized, number of cells examined, and patient 
populations.  Regardless, mosaicism is present in the blastocyst; what is unknown is when 
mosaicism becomes clinical significant.  Approximately 59% of all mosaic embryos are 
diploid-aneuploid mosaics, composed of both diploid and aneuploid cell lines (Echten-
Arends et al., 2011).  In this study, 11 of 43 (25.6%) of the blastocysts could be classified 
as a diploid-aneuploid mosaic. 
Mitotic non-disjunction occurs when sister chromatids fail to separate during mitosis.  
Instead of separating equally, one cell receives 3 copies of a chromosome (trisomy) and 
the other cell receives a single copy of the reciprocal chromosome (monosomy; Taylor 
et al., 2014a).   
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Table 21: Trophectoderm samples and their corresponding whole embryo aCGH analysis. 
 
Nonconcordant but aneuploid whole embryo 
25 XO, -15 XO; -5 
26 -10, -13, XY -10, -13, +15, XY 
27 -6, -16, +20, XY -6, -16, XY 
28 +5, -6, +7, +9, -10, +15, -16, +18, XX -16, XX 
29 -9, +15, +19, XX -9, +15, +19, +22, XX 
30 -22, XY +19, XY 
31 +1q, XY -19, XY 
32 -5, +14, +21, XY +14, +21, XY 
Nonconcordant but euploid whole embryo 
33 +4, XY Euploid, XY 
34 +22, XX Euploid, XX 
35 +2, XX Euploid, XX 
36 +11, +17, +20, XX Euploid, XX 
37 -7, -8, XY Euploid, XY 
38 +8, +14, XY Euploid, XY 
39 +14, XX Euploid, XX 
40 -6, -10, -18, XY Euploid, XY 
41 +21, XY Euploid, XY 
42 -14, XX Euploid, XX 
43 -14, XX Euploid, XX 
 
Full concordance 
Sample Trophectoderm Whole Embryo 
1 -8, XX -8, XX 
2 +21, XY +21, XY 
3 +22, XY +22, XY 
4 -21, XY -21, XY 
5 -21, XY -21, XY 
6 +22, XY +22, XY 
7 -7, XX -7, XX 
8 -16, XX -16, XX 
9 -16, XX -16, XX 
10 +13, XX +13, XX 
11 +16, XX +16, XX 
12 +9, +22, XX +9, +22, XX 
13 -13, XX -13, XX 
14 XYY XYY 
15 +19, XX +19, XX 
16 -14, XY -14, XY 
17 +22, XX +22, XX 
18 +16, XX +16, XX 
19 +15, XX +15, XX 
20 +19, -22, XY +19, -22, XY 
21 +20, XX +20, XX 
22 -6p, XY -6p, XY 
23 +16, XY +16, XY 
24 -11,-18, XX -11,-18, XX 
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Although this is an error, it might not be identified by aCGH because the cells are pooled 
together, creating the same amount of DNA that is present in euploid cells (Harton et al., 
2013).  However, it depends on when and where the non-disjunction occurs as to how it 
will influence the aCGH results.  For example, if the non-disjunction occurs in the zygote, 
then the two cell lines can propagate throughout the embryo.  Depending on the number 
of cells biopsied from the trophectoderm, this particular scenario could yield an aneuploid 
trophectoderm and euploid whole embryo result.  If the non-disjunction event occurred 
in the trophectoderm, then the number of aneuploid cells may be outnumbered by the 
euploid cells in the ICM, causing a euploid result.  However, research has shown as high 
as a 96% concordance between the two tissues (Johnson et al., 2010).   
Another possibility for the euploid result is that the majority of the embryo is in fact 
euploid while the trophectoderm piece was aneuploid.  Research has indicated that 
mouse 4N-AN ?EĐŚŝŵĞƌĂƐŚĂǀĞƚŚĞĂďŝůŝƚǇƚŽĞǆĐůƵĚĞ ?E ?ƐĨƌŽŵƚŚĞĞƉŝďůĂƐƚ ?dĂƌŬŽǁƐŬŝet 
al., 1977; Nagy et al., 1990; James et al., 1995).  This demonstrates that a mechanism is 
in place to force abnormal cell lines out of the ICM and into the trophectoderm.  This 
mechanism has not been demonstrated in humans or trisomies, although CPM has been 
documented (Kalousek and Dill, 1983).  Research in the mouse has shown that as little as 
three cells from the ICM are destined to be the fetus (Markert and Peters, 1978).  This 
suggests that even if aneuploidy exists in the ICM, a euploid fetus is possible.  The only 
way to fully detect preferential allocation of aneuploidy cell lines is to individually screen 
each cell of the blastocyst and be able to reconstruct a virtual image of the blastocyst 
(Taylor et al., 2016a). 
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Figure 33: Possible biological explanations for discrepancies between the aCGH results of 
the trophectoderm and whole embryo.  (A)  Two or more aneuploid cell lines are 
presented throughout the embryo resulting in an aneuploid trophectoderm biopsy and 
possible euploid whole embryo diagnosis.  (B) The biopsied trophectoderm results in a 
trisomy diagnosis; however the whole embryo is diagnosed as euploid due to equal 
numbers of trisomy and monosomy cells.  (C) An aneuploid cell in the day 3 embryo is 









Scott and colleagues (2010) biopsied a piece of trophectoderm but transferred the 
blastocyst without testing.  After a live birth was obtained they retrospectively analyzed 
the piece of trophectoderm.  They found that of the 46 blastocysts that were biopsied 
and transferred, 3 (6.5%) live births derived from a subsequently diagnosed aneuploidy 
210 
in the trophectoderm.  It is unknown however if this aneuploid result in the 
trophectoderm was due to an error in the test.  Given that the test performed by Scott 
and colleagues (2010) has shown an extremely low error rate against known cell lines 
(97.6%), it seems as if their results, and in combination with ours, supports the theory 
that human preimplantation embryos may be able allocate aneuploid cell lines to the 
trophectoderm (Treff and Scott, 2013).  To fully identify this mechanism, isolation and 
testing of the ICM is needed, which was not performed in this study.  Further research is 
needed to determine if this mechanism is purposeful, accidental, or just a product of 
mosaicism. 
Segmental aneuploidies, or aneuploidies that only involve a piece of the embryo, are 
detectable by aCGH or SNP.  Although detectable, the clinical significance of segmental 
aneuploidies during preimplantation development has yet to be established.  In this 
study, two of the blastocysts contained segmental aneuploidies in the trophectoderm.  
One of these segmental aneuploidies was present when analyzing the whole embryo 
(#40) and one was not (#42).  Therefore, some segmental aneuploidies may not have any 
clinical significance and may result in a euploid live birth, while others may result in 
miscarriages and affected live births.  Segmental aneuploidy can be biological or technical 
in nature.  For example, it is possible that the WGA procedure does not cover the area 
with the segmental error.  Thus, the result will return a euploid result, even though there 
is segmental error.  Further studies in regards to segmental aneuploidies are warranted. 
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This study does have limitations.  Research has described conflicting results against 
known cell lines using different WGA protocols (Treff et al., 2010).  In a recent study, 
Capalbo and colleagues (2014) demonstrated a 7% error rate with aCGH, which requires 
t' ?ĐŽŵƉĂƌĞĚƚŽƋWZ ?ƋƵĂŶƚŝƚĂƚŝǀĞƉŽůǇŵĞƌĂƐĞĐŚĂŝŶƌĞĂĐƚŝŽŶ ) ?ǁŚŝĐŚĚŽĞƐŶ ?ƚƌĞƋƵŝƌĞ
WGA, and SNP, which does require WGA.  In this study, of the 43 whole aneuploidies in 
the entire blastocyst, 37 (88.1%) were detected in the trophectoderm.  Therefore, 11.9% 
of the aneuploidies in the whole blastocysts were not detected by trophectoderm biopsy, 
which is similar to the 7% error rate as determined by Capalbo and colleagues (2014).  
Another limitation is the number of cells removed or the quality of these cells removed 
for testing.  However, the initial blastocyst biopsy was performed by a knowledgeable 
technician and were biopsied according to laboratory procedures that have resulted in 
high pregnancy rates.  Thus, the biopsy or laboratory procedures could not have 
attributed to these errors and these errors are either biological or a failure in the test as 
previously mentioned (Taylor et al., 2014a; Taylor et al., 2014b) 
In conclusion, these data support the theory that the biopsied piece of the trophectoderm 
does not always coincide with the remaining chromosome content of the embryo; 
however, 88.1% of single aneuploidies in the trophectoderm were detected in the whole 
embryo.  These discrepancies could be due to mosaicism, the inability of aCGH to 
distinguish between mitotic non-disjunction and euploidy, preferential allocation of 
aneuploid cell lines to the trophectoderm, or an error in the test.  Further studies are 
needed to distinguish between these scenarios. 
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3.0 General Discussion 
This work has identified some of the limitations surrounding PGS testing.  Given the 
shortcomings of PGS, certain questions still need to be answered in order to determine 
who may benefit from this technology.  Thus, PGS at the blastocysts stage requires the 
understanding of a few questions.  
1) Can an embryo diagnosed as aneuploidy lead to a euploid individual? 
2) Is the chromosomal status of preimplantation embryos stagnant? 
3) What is the chromosomal relationship between the trophectoderm and ICM? 
4) Are all preimplantation aneuploidies equal? 
5) What is the success rate of poor quality embryos? 
3.1 Can an embryo diagnosed as aneuploidy lead to a euploid individual? 
Scott and colleagues (2012) addressed this question in a well-designed study that 
determined the reproductive potential of CCS diagnosed cleavage stage embryos and 
blastocysts.  Scott and colleagues biopsied both cleavage stage and blastocyst stage 
embryos prior to transfer.  CCS results were not available until after the transfer was 
conducted and a fetus obtained.  They found that of the 53 cleavage stage embryos that 
resulted in a live birth, 52 were diagnosed as euploid while only 1 (1.9%) was diagnosed 
as aneuploid.  Of the 46 blastocysts that resulted in a live birth, 43 were diagnosed as 
euploid and 3 (6.5%) were diagnosed as aneuploid.  This leads the authors to correctly 
state that those embryos diagnosed as euploid have an incredibly high reproductive 
213 
potential.  Unfortunately, DNA was not obtainable in those embryos that failed to implant 
or miscarried; therefore, it is unknown if the diagnosis was correct.  Thus, the diagnostic 
value of the CCS can only loosely be determined from this study. 
In my study, approximately a quarter of the embryos that were diagnosed as aneuploid 
were, in fact, euploid.  The reason for an aneuploid diagnosis leading to a euploid 
individual is either due to an error in the test (as no test is accurate 100% of the time), 
modification of the embryo by the removal of aneuploid cell(s), or mosaicism that is the 
presence of two or more cell lines within an individual.  In my study, it is possible that the 
day 3 analysis was incorrect due to the complications of WGA on an individual cell.  When 
the rebiopsy occurred at the blastocyst stage, the multiple cells present in the blastocyst 
biopsy allowed for a more accurate WGA procedure and the embryo was diagnosed 
correctly as euploid.   
The phenomenon of mosaicism would lead one to believe that more aneuploid cleavage 
and blastocyst stage embryos could result in a euploid individual.  What is unknown is 
that if any of those embryos that were diagnosed as euploid were mosaic, and if the 
researchers had biopsied different cell(s), would they have had a different CCS result.  
Obviously this type of approach cannot be undertaken with current technology; however, 
one can estimate using the current understanding of diploid-aneuploid mosaicism.  
Diploid-aneuploidy mosaicism is the presence of both aneuploid and diploid cell lines 
within the same individual and is believed to occur in approximately 59% of all cleavage 
stage embryos and 14% of blastocysts (van Ecten-Arends et al., 2011; Northrop et al., 
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2010).  If those rates of diploid-aneuploid mosaicism are applied to the Scott et al. (2012) 
study, then of the 52 cleavage stage embryos that were diagnosed as euploid that lead to 
a live birth, approximately 30 (57.7%) contained aneuploid cells.  Of the 43 euploid 
blastocysts that lead to a live birth, approximately 6 (14.0%) blastocysts diagnosed as 
euploid could have also been diagnosed as aneuploid had a different piece of the 
trophectoderm been biopsied.  Therefore, those diagnosed as euploid may not be entirely 
euploid and those diagnosed as aneuploidy, may not be entirely aneuploid.  This analysis 
is purely hypothetical and generalized.  The rate of diploid-aneuploid mosaicism may 
differ upon test utilized, embryo quality, number of cells analyzed, and patient 
characteristics. 
Mosaicism at the blastocyst stage can present in many different forms.  According to 
research in the mouse, mosaicism in the trophectoderm may be either a checkerboard 
pattern or in isolated clumps (Everett and West, 1996).  Whether these patterns are true 
of human preimplantation development is currently unknown, however the way 
mosaicism presents itself during the blastocyst stage can influence CCS results.  For 
example, if aneuploid cells lines are clumped within the trophectoderm, it is entirely 
possible that the biopsy portion will remove a section of the abnormal cell line, thereby 
giving an aneuploid result while the blastocyst is truly euploid (Figure 34).  The opposite 
also holds true in that the blastocyst could be diagnosed euploid but actually contain a 
large portion of aneuploid cells (Figure 35).  If mosaicism presents in a checkerboard 
pattern, the test utilized could yield both a euploid (Figure 36) or aneuploid (Figure 37) 
results, depending on the number of aneuploid cells within the biopsied sample.  Lastly, 
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it is also possible that the trophectoderm is completely euploid but the ICM is mosaic 
(Figure 38).   
Figure 34: Mosaic blastocyst with an aneuploid cell line isolated to the trophectoderm.  
The section biopsied is represented with broken, black lines.  If these cells were biopsied, 
the results would be aneuploid but the embryo would be euploid. 
 
Figure 35: Mosaic blastocyst with an aneuploid cell line isolated in the trophectoderm.  
The section biopsied is represented with broken, black lines.  If these cells were biopsied 






Figure 36: A mosaic blastocyst with an aneuploid cell line isolated to the trophectoderm 
and presenting in a checkerboard fashion.  The section biopsied is represented with 
broken, black lines.  If these cells were biopsied, the result would be euploid but the 
embryo would be mosaic. 
 
 
Figure 37: A mosaic blastocyst with an aneuploidy cell line isolated to the trophectoderm 
and presenting in a checkerboard fashion.  The section biopsied is represented with 
broken, black lines.  If these cells were biopsied, the result would be aneuploidy but the 






Figure 38: A mosaic blastocyst with a euploid cell line in the trophectoderm but mosaic 
inner cell mass.  The section biopsied is represented with broken, black lines.  If these cells 
were biopsied, the result would be euploid but the embryo would be mosaic. 
 
Mosaicism is common and routine during both pre and post implantation development.  
In essence all of us are mosaic, as we all contain at least one cell that is aneuploid.  For 
example, it is entirely possible that during cleavage stage biopsy the cell removed and 
diagnosed is the only cell that is aneuploid.  If only one cell is aneuploid while the others 
are euploid, it may be possible for the embryo to develop to a euploid individual.  
Likewise, at the blastocyst stage, if 10 cells are removed from the trophectoderm and two 
of the cells are aneuploid and eight are euploid, the diagnosis is euploid; however, the 
blastocyst is truly an undiagnosed mosaic because two distinct cell lines are present.  
Although mosaic, the clinical relevance of this mosaicism at these stages is unknown and 
the number of cells affected, along with those aneuploidies involved, may have different 
influences during development. 
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3.2 Is the chromosomal status of preimplantation embryos stagnant? 
Not only can aneuploidy occur at a single point during preimplantation and/or post 
implantation development but aneuploidy is also fluid, occurring at many different points 
and under many different conditions.  An error earlier during development gives the 
aneuploid cell line more time to propagate and outnumber the euploid cells.  Conversely, 
confined mosaicism involves an aneuploidy that typically occurs post implantation, 
thereby containing that aneuploidy within a particular area.  Confined mosaicism has 
been reported in the brain, skin, and gonads, amongst other organs (Yurov et al., 2007; 
Happle, 1993).  For these particular cases, the fetus (pre and post implantation) could be 
euploid; however, an error occurs post implantation: an error that would not be 
diagnosed by PGS (Kalousek and Dill, 1983).   
Numerous reports have re-examined blastocysts from diagnosed aneuploid cleavage 
stage embryos, providing evidence that cleavage stage embryos with at least one 
aneuploid cell can be diagnosed as a euploid blastocyst (Norhtrop et al., 2010; Magli et 
al., 2000; Fragouli et al., 2008).  My study contained in this thesis demonstrated that 
approx. 50% of diagnosed aneuploid cleavage stage embryos can develop to euploid 
blastocysts.  Although interesting, there are multiple problems with these studies.  First, 
these studies only examined a limited number of chromosomes at the cleavage stage or 
blastocyst stage, or both.  Secondly, the data can be interpreted a multitude of ways.  For 
example, Magli and colleagues (2000), examined multiple cells from the ICM of 
ďůĂƐƚŽĐǇƐƚƐĚĞƌŝǀĞĚĨƌŽŵĂŶĞƵƉůŽŝĚĐůĞĂǀĂŐĞƐƚĂŐĞĞŵďƌǇŽƐ ?Ɛŝǆ /D ?ƐŚĂĚĂƚ ůĞĂƐƚŽŶĞ
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ĞƵƉůŽŝĚĐĞůůǁŚŝůĞŽŶůǇŽŶĞŚĂĚA? ? ?A?Ğuploid cells present in the ICM.  This leads the 
ĂƵƚŚŽƌƐ ƚŽ ĐŽŶĐůƵĚĞ ƚŚĂƚ ďĞĐĂƵƐĞ A? ? ?A? ŽĨ ƚŚĞ /D ǁĂƐ ĞƵƉůŽŝĚ ? ƚŚŝƐ ĞŵďƌǇŽ ŚĂĚ
successfully corrected itself.  Lastly, none of these studies ascertain the reproductive 
potential of the aneuploid cleavage stage embryos that are diagnosed as euploid at the 
blastocyst stage.  The study presented in this thesis using SNP on day 3 and day 5 
blastocysts demonstrated that diagnosed day 3 aneuploid embryos can develop into a 
euploid blastocyst and can achieve a live birth.  These data, along with others indicates 
that the chromosomal constitution of the embryo is not stagnant. 
Aneuploidies can occur on every chromosome and at any time.  It is possible that one 
aneuploidy may not propagate whilst another may become established.  Moreover, the 
clinical significance of each aneuploidy can be examined at the individual chromosome 
level or preimplantation embryo as a whole.  Capalbo and colleagues (2013a) examined 
correction at a chromosomal level.  Of 62 meiotic derived aneuploidies, 12 (19.4%) were 
not present at the blastocyst stage, while only 5 (20.0%) of 25 mitotic errors at the 
cleavage stage were not present at the blastocyst stage.  Lastly, Northrop and colleagues 
(2010) examined multiple pieces of the trophectoderm and the whole ICM after embryos 
were diagnosed as aneuploid at the cleavage stage.  If one includes any blastocysts that 
had a euploid section of the trophectoderm or ICM, then 37 (74.0%) of the aneuploid 
cleavage stage embryos contained euploid cell lines at the blastocyst stage.  However, 
only 29 (58.0%) embryos were completely euploid by the blastocyst stage.  Using FISH, 
Munne and colleagues (2005) examined 24 embryos on day 12 that were diagnosed as 
aneuploid on day 3.  They demonstrated that 7 (29.2%) were completely euploid and 11 
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(45.8%) were partially euploid.  All of these studies suggest that aneuploidy can occur at 
any given moment and cleavage stage errors may not be predictive of further 
chromosomal status in the embryo. 
It has also been shown that euploid cells proliferate at a higher rate than aneuploid cells, 
at least during preimplantation development (Ruangvutilert et al., 2000).  Moreover, it is 
possible that the higher rate of proliferation of euploid cell lines may be a product of 
natural selection, i.e., a mechanism developed by nature to combat the faulty 
chromosome segregation during preimplantation development.  In yeast, aneuploidy has 
been shown to be induced under stressful conditions.  The aneuploidy allows for the 
survival of the yeast by increasing the rate of cellular division, thereby allowing the yeast 
to propagate (Chen et al., 2012).  In mouse embryos, aneuploidy rates differ between low 
oxygen and atmospheric oxygen culture conditions, which supports the idea that 
aneuploidy is a mechanism induced by stress (Adler et al, 2014).  If this is the case, then 
perhaps the presence of aneuploidy in a human embryo is a mechanism to compensate 
for stressful conditions.  The aneuploidy is induced to overcome a conditional stress, and 
then once that stress dissipates, the aneuploidy is weaned out by the more aggressive 
growth of euploid cell lines.  For example, in humans, the cleavage divisions are known to 
have more aneuploidies than the blastocyst stage (Braude et al., 1988).  It may be that 
the first cellular divisions are extremely stressful and aneuploidy results.  Once the 
embryonic genome activates at the six to eight cell stage, stress is reduced and the growth 
of euploid cells lines is favored over aneuploid cell lines (Lejeune et al., 1959).  Therefore, 
aneuploidy maybe a correction mechanism, and although the embryo may be under 
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stress, the embryo could potentially be viable.  Nonetheless, chromosomes are not 
stagnant, and each stage of development may be more or less prone to aneuploidy. 
 
3.3 Are all preimplantation aneuploidies equal? 
This is perhaps one of the largest misconceptions within IVF.  For example, it is known 
that trisomy 21, or Downs Syndrome, can result in a live born, whereas a monosomy 
(except 45 XO) is lethal shortly after implantation, and triple X syndrome or 47, XXX is 
fairly benign and often goes undiagnosed (Lejeune et al., 1959; Ford et al., 1959; 
Gustavson, 1999).  There are others, but these examples demonstrate that individual 
aneuploidies have different outcomes.  It may be that certain preimplantation 
aneuploidies are benign and impact little during the course of development, while other 
aneuploidies have extreme clinical consequences.  However, when PGS is conducted, all 
aneuploid embryos are diagnosed as abnormal and discarded; thereby treating all 
aneuploidies equally, even those that may present with little to no clinical significance. 
Every chromosome acts differently and is influenced by different factors at each stage of 
development (Griffin, 1996).  Precocious separation of sister chromatids is the most 
common error during meiosis while non-disjunction is more prominent in the sex 
chromosomes during the first cleavage divisions (Bean et al., 2002, 2001; Handyside et 
al., 2012; Forman et al., 2013a).  Alternatively, the autosomes are more prone to 
anaphase lag during preimplantation development (Capalbo et al., 2013a; Ioannou et al., 
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2012; Coonen et al., 2004).  Lastly, rates of aneuploidy differ between each chromosome 
during preimplantation development. 
Blastocyst biopsy in conjunction with PGS determines the chromosomal constitution of 
the trophectoderm, which is destined to become the placenta, along with other 
extraembryonic tissue.  The placenta is biopsied during CVS to determine the 
chromosomal constitution of the fetus.  It is known that certain aneuploidies that present 
within the placenta are not present in the fetus.  For example, trisomy 13, 18, or sex 
chromosome aneuploidies are present in CVS and will typically present in the fetus 
(Cytogenetic, 1994).  On the other hand, trisomies 2, 3, 7, and 8 typically do not present 
with adverse effects and the fetus is typically euploid (Wolstenholme, 1996; Kalousek et 
al., 1996).  It is unknown if these relationships are merely a product of post-implantation 
development or are also relevant during preimplantation development. 
Similarly, there are differences between aneuploidies seen in the extraembryonic 
mesoderm (derived from the ICM) and the cytotrophoblast (derived from the 
trophectoderm).  For example, trisomy 2 and 17 typically present themselves within the 
EEM while trisomy 3, 6, 7, 12, 13, 14, 16, 18, 20, 21, and 22 typically are associated with 
the cytotrophoblast (Ledbetter et al., 1992).  It is evident that aneuploidies act and are 
influenced by different factors at every stage of development.  Thus, treating all 
aneuploidies as equal during preimplantation development should be reconsidered.  
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3.4 What is the Chromosomal Relationship between the Trophectoderm 
and ICM? 
CPM occurs in roughly 1-2% of all pregnancies indicating that discrepancies between the 
ICM and trophectoderm exist (Ledbetter et al., 1992).  However, when IVF utilizes 
blastocyst biopsy and an aneuploidy is diagnosed, it is assumed that this aneuploidy is 
present throughout the embryo as well.  Research has shown a high concordance 
between the trophectoderm and ICM (Capalbo et al., 2013b).  However this research was 
conducted using FISH, which may not be accurate (Treff et al., 2010).  Johnson and 
colleagues (2010) examined all the chromosomes from the ICM and trophectoderm and 
found a 96% concordance rate between the two tissues.  These differences in mosaicism 
could be attributed to patient characteristics, as patients with different diagnosis tend to 
have different rates of aneuploidy.  Research has also shown that mosaicism is common 
at the blastocyst stage; therefore, a small piece of the trophectoderm may not be 
representative of the entire embryo (Liu et al., 2012).  Indeed, mosaic trophectoderm has 
been shown in approximately 20% of embryos (Northrop et al., 2010; Fragouli et al., 
2011).  
This study examined individual cells from the blastocyst and determined that mitotic 
errors are common.  In fact, all of the blastocysts presented with at least two different 
cell lines meaning that every blastocyst was mosaic.  
As previously discussed, the fetus is derived from the ICM.  However, not all of the cells 
from ICM become the fetus.  In fact, it is believed as little as three cells are needed to 
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become the fetus, while the reminder of the ICM is destined to become extraembryonic 
tissue (Markert and Peters, 1978).  This poses a potential problem, as one is unable to 
determine, which cells within the ICM will become the fetus and those that are destined 
for extraembryonic tissue.  It may very well be possible that only three euploid cells are 
needed to be present in the ICM to develop into a euploid individual.  The chromosomal 
status of the remaining ICM cells may be irrelevant.   
The goal of genetic testing is to determine the chromosome composition of the fetus.  
This is done via CVS, amniocentesis, or PGS.  Ironically, the majority of genetic sampling 
is not conducted on the fetus; therefore, understanding the relationship between tested 
material and the fetus is essential.  For example, CVS sampling is known to have roughly 
a 6% rate of maternal contamination (Grifo et al., 2013).  Consequently, if CVS sampling 
demonstrates an aneuploid result, amniocentesis is typically recommend as a follow up.  
This demonstrates that aneuploidies can present within extraembryonic material that do 
not present within the fetus proper.  In a way, amniocentesis acts as a double check for 
CVS results, no such double check exists for PGS.  It may be plausible to suggest that 
embrǇŽůŽŐŝƐƚ ?ƐƌĞďŝŽƉƐǇĂůůĞŵďƌǇŽƐƚŚĂƚŚĂǀĞďĞĞŶĚŝĂŐŶŽƐĞĚĂƐĂŶĞƵƉůŽŝĚƚŽĐŽŶĨŝƌŵ





3.5 What is the Success Rate of Poor Quality Embryos? 
CCS at the blastocyst stage provides pregnancy rates comparable to anonymous oocyte 
donation (Handyside, 2013b).  Unfortunately, studies have been conducted on patients 
that generate a fair amount of blastocysts; therefore, these patients are typically not poor 
responders.  An increase in pregnancy rates with blastocyst biopsy theoretically makes 
sense considering there are two selection mechanisms, morphology and chromosomal 
constitution, as opposed to just standard morphology (Handyside, 2013b).  With 
blastocyst biopsy, embryos are given until day 6 to develop.  If they fail to progress to a 
blastocyst by day 6, they are discarded.  Research has shown that live births have occurred 
from day 7 blastocysts; therefore, the discarding of non-biopsiable blastocysts on day 6 
may be disposing of viable embryos (Kovalevsky et al, 2013).    
ůĂƐƚŽĐǇƐƚƐƚŚĂƚƵŶĚĞƌŐŽW'^ǁŽƵůĚŚĂǀĞĞǀĞŶƚƵĂůůǇďĞĞŶƚƌĂŶƐĨĞƌƌĞĚ ?ŝ ?Ğ ? ?ŝĨƚŚĞǇĚŝĚŶ ?ƚ
undergo genetic testing they would be transferred or cryopreserved without biopsy 
because they were of optimal quality).  Therefore, PGS at the blastocyst stage does not 
increase pregnancy rates, it decreases time to pregnancy.  One could even argue that if 
there is only one or two blastocyst available, the time to pregnancy is actually increased.  
For example, results are typically not available same day, so if there are only one or two 
blastocysts (which would have been transferred anyway), then delaying the transfer until 
a FET would only delay the time to pregnancy.  Not to mention the added cost and 
potential harm caused by the biopsy and vitrification/warming procedure.  Therefore, one 
could make an argument that PGS on poor responders actually lengthens time to 
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pregnancy and increases the risk of embryo death, thereby having no beneficial effect to 
the patient.  So, what should we do with patients that are not producing any blastocysts 
in culture?  As a field, do we discard embryos because they are not blastocysts?  The data 
generated in this thesis concludes that the reproductive potential of these poor quality 
embryos is minimal, around 1.5% and thus I believe that the utilization of only good and 
fair quality blastocysts is justifiable. 
 
4.0 Conclusion 
It is not just blastocyst biopsy and PGS that may be discarding viable embryos.  For 
example, zygotes displaying one pronuclei (as opposed to two) may contain a Y 
chromosome, indicating that these embryos may be viable (Staessen and Van 
Steirteghem, 1997).  Furthermore, the vitrifying and warming (even if they are optimal 
quality), could potentially result in the loss of viable embryos.  Lastly and as previously 
discussed, live births have occurred from day 7 blastocysts (Kovalevsky et al., 2013).  
Although a blastocyst has to form in order for implantation to occur and given that day 7 
blastocysts have been shown to implant and produce liveborns, perhaps we should 
rethink day 6 as the final day of culture.    
One of the benefits of blastocyst biopsy with CCS is the effectiveness of this technique at 
limiting multiple births.  However, this is simply because it adds another selection criteria 
in addition to extended culture (Forman et al., 2013b).  However, the application of this 
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technology may also be preventing patients from achieving pregnancy and potential live 
born.  The more blastocysts that are tested, the more likely the patient will meet the 
assumptions described and could benefit from blastocyst biopsy with CCS.  Some patients, 
especially poor responders, who produce a single blastocyst or no blastocysts during IVF 
treatment, may not benefit from blastocyst biopsy and CCS.  However, it should be noted 
that female age is the main determinant of aneuploidy and thus, aneuploidy screening 
may be warranted in an older patient population.  Moreover, there are a multitude of 
factors that are not discussed that could influence these data, including embryo quality, 
sperm quality, maternal age, paternal age, PGS methodology, site of biopsy, etc.  It is 
imperative that we continue to research these areas in an attempt to perfect IVF and PGS. 
Given the inability of this field to determine which embryo is viable and which is not, it is 
important to discuss the limitations of CCS with anyone considering PGS.  The goal of IVF 
is to give every patient that undergoes retrieval a chance at pregnancy, not just those that 
produce blastocysts in culture.  
 
4.1 Future Work 
Although the technologies of PGS have advanced radically in the previous years, the 
application of this technology still remains as controversial as ever.  The attractiveness of 
a test that can predict those embryos which will implant and those that cannot is the 
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testing. 
Technical limitations of PGS testing include the biopsy site and technique.  As described 
in this work, perhaps the location of the biopsy influences results; thus, embryologists 
should be more aware of what piece of the trophectoderm they are removing.  Moreover, 
it seems logical to suggest that during the biopsy procedure, chromosomes may be loss 
in the media due to the excessive laser heat or from the ripping and tearing that is 
required to remove a piece of the trophectoderm.  If a chromosome is damaged during 
the biopsy procedure or lost in the culture media, then false aneuploidy readings are to 
be expected.  This begs the question, how much of our understanding of preimplantation 
genetics is wrong simply due to technical error?  It is entirely possible that we are not as 
mosaic as we believe and that the presence of mosaicism is merely a technical artifact 
created during the biopsy procedure.  Non-invasive biopsy procedures should also be 
pursued.  Currently, removing a piece of the trophectoderm has not demonstrated a 
reduction in implantation potential; however, the process is still invasive.  The ability to 
correctly determine the chromosome content of the embryo without biopsy could be 
extremely beneficial.  Small studies have been performed which have demonstrated the 
ability to obtain the chromosomal content of embryo by testing the surrounding culture 
media and should be pursued further (Shamonki et al., 2016; Feichtinger et al., 2017).  
Further studies are warranted to understand the contributions of the biopsy procedure 
to the detection of aneuploidy.   
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Biologically, aneuploidy is induced in the cytotrophoblast during implantation; thus, the 
aneuploidy detected may be a biologically normal event (Weier et al., 2005).  Also,   CPM 
occurs in approximately 6% of all pregnancies (Kalousek et al., 1991; Griffin et al., 1997).  
Both of these signify a difference between the fetus and placenta.  To overcome these 
biological pitfalls perhaps a different biopsy technique needs to be developed.  In the 
mouse, biopsies of the ICM have resulted in live births.  Perhaps future research needs to 
develop a technique that can determine the chromosomal constitution of the actual fetus 
as opposed to the placenta (Dittrich et al., 2011).  In fact, I have already started to conduct 
these studies.  Using a small gauge ICSI needle, a small portion of the ICM is aspirated into 
the needle, expelled, and placed in a PCR tube for PGS testing.  Pilot studies have yielded 
PGS results that are similar to the trophectoderm.  Many more samples need to be taken 
and results analyzed before any conclusions can be drawn, but the direct sampling of cell 
lines that will become the actual fetus is an important aspect that should be explored. 
Finally, future research needs to focus on the clinical significance of aneuploidy.  For 
example, some aneuploidies may present with clinical consequences and some may not.  
What if the presence of trisomy 10 or monosomy 12 in the trophectoderm has no clinical 
implications? Obviously, there are differences between a blastocyst diagnosed with 
trisomy 21 as opposed to monosomy 4, for example.  Instead of discarding embryos 
because they are aneuploid, what if we ranked them based on the severity of the clinical 
consequences of that corresponding aneuploidy?  This way, a patient can still opt for 
transfer knowing the limitations and consequences of those aneuploidies.  With this 
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viewpoint, almost every embryo can be deemed viable and the discarding of potential 
babies can be limited. 
 
4.2 Personal Perspective  
I have found that this field is divided into two camps.  The first is the geneticists who feels 
that everything must be perfect and euploid to deliver a healthy baby.  The second camp, 
and likely the one I fall into, is the embryologist who is on the front lines, biopsing and 
discarding embryos, and perhaps most importantly seeing and feeling the emotions 
patients have when you tell them that we have to discard their embryos because they are 
abnormal.  I have seen numerous patients consulted to pursue egg donation because they 
produced all aneuploid embryos.  What if my biopsy technique contributed to that 
decision?  What if something I did caused this patient not to get pregnant?  What if the 
PGS testing was inaccurate and those embryos could have resulted in a live birth?  We 
will never know. 
Due to the lack of studies surrounding good quality/euploid embryos and the plethora of 
retrospective data, I feel larger well controlled, randomized controlled trial would benefit 
not only me but the field, in better understanding preimplantation aneuploidy and its 
clinical consequences.  
/ĨĞĞů/ŚĂǀĞĂďĞƚƚĞƌŐƌĂƐƉŽŶƉƌĞŝŵƉůĂŶƚĂƚŝŽŶŐĞŶĞƚŝĐƐďƵƚ/ ?ŵŶŽĐůŽƐĞƌƚŽĂŶĂŶƐǁĞƌ
than I was before this research started.  Understanding the limitations of PGS testing 
231 
makes me more of a critic than a believer.  The deeper I dig, the more confused I 
become.  How is it possible that an embryo produces this much aneuploidy?  Are we 
really that horrible at reproducing, or is our knowledge flawed because we are 
examining preimplantation outside of its natural environment?  There is research to 
suggest that aneuploidy is induced to overcome stress and once that stress is overcome, 
the aneuploidy is phased out (Chen et al., 2009).  So is aneuploidy a phenomena 
induced by our culture system used during IVF?  Are the techniques employed in the IVF 
lab influencing aneuploidy (Swain et al., 2016)?  Is aneuploidy a corrective measure by 
the embryo to overcome stress?  I guess it boils down to one question, is aneuploidy all 
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